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SUMMARY: 
Essential hypertension and familial intracranial aneurysm (FIA) are complex 
disorders which may have, in common, features such as gene-gene and gene- 
environment interactions, small individual gene effects, genetic heterogeneity, 
incomplete penetrance and pleiotropy. Such features hamper efforts to discover 
disease genes and have resulted in continuous evolution of complex genetic 
strategies. Appropriate strategies and current thinking were applied to genetic 
dissection of essential hypertension and familial intracranial aneurysms. 
Essential hypertension is a complex oligogenic or polygenic disorder with 30% 
to 60% of inter-individual differences determined by genes. Much is known 
from studies in Mendelian disorders, rat and mouse models, and human 
populations. The genetic basis of Mendelian disorders has been dissected, but 
susceptibility genes have yet to be confirmed for essential hypertension. 
The studies of hypertension, described herein, combined complementary 
strategies to examine the relevance of human chromosome 5q31.1-qter to blood 
pressure as a quantitative trait, and hypertension as a qualitative trait. This distal 
region of chromosome 5 was focused upon due to its implication by other human 
and animal model studies and the cluster of cardiovascular candidate genes 
located there. 
Eleven microsatellites across 55 cM of 5q3l. I to qter were genotyped in 212 
hypertensive nuclear families of the Silesian Hypertension Study. Two-point and 
XVI 
multipoint analyses showed linkage of a7 cM region to both hypertensive status 
and blood pressure phenotypes. A maximal multipoint Z-score of 2.2 for systolic 
blood pressure (SBP) was obtained proximal to the marker D5s1480. In light of 
the debate regarding significance in linkage studies, this quantitative trait locus 
(QTL) was confirmed in a second sample derived from the Scottish population. 
Genotyping of the same markers was done for 1,469 individuals from sibships of 
the MIDSPAN Family Study. Two-point and multipoint analyses confirmed a 
reproducible 7 cM QTL with a maximum multipoint logarithm of odds (LOD) 
score of 1.8 obtained for mean arterial pressure. 
Several putative candidate genes were located within the QTL including the P2- 
adrenergic receptor gene, ADRB2, which is known to have a major role in 
cardiovascular physiology. Three functional loci, Argl6GIy, Gln27GIu and 
Thr16411e, were genotyped within the ADRB2 gene using the Silesian sample. 
Single locus and haplotype analyses using transmission disequilibrium tests and 
family-based association methods showed no association to hypertension status 
(P>0.05), effectively excluding this gene in the Silesian sample. 
The fibroblast growth factor I gene, FGF I, is located at the centre of the QTL. 
This gene had previously been cited as a putative blood pressure candidate gene 
in the 5q region but not studied in humans. With roles in endothelial cell 
proliferation, possible oxidative stress defence and proven direct effects on blood 
pressure in rodent models, we considered it a possible novel candidate. Coding 
regions and 3' UTR were sequenced and family-based association analyses 
performed for three polymorphisms which were discovered in the 3' UTR. 
xvil 
Association of SBP (P=0.045), pulse pressure (P=0.019) and hypertension status 
(P=0.038) was demonstrated to the most proximal locus. Association of 
hypertension to a three-locus haplotype was also shown (P=0.020). 
The work on essential hypertension demonstrated the merit of confirming linkage 
in independent populations, implicating a7 cM region of 5q3l. l-q33 linked to 
blood pressure. Subsequent candidate gene studies utilised the added value of 
haplotype analyses, excluding the ADRB2 locus but showing interesting data to 
implicate the novel FGH locus as a putative positional candidate. Further fine 
mapping strategies are now underway to define, more clearly, the haplotype tag 
across the FGF I locus. Combination of genetic approaches with expression and 
functional profiling will be required to determine the importance of FGF I. 
The work on candidate genes of familial intracranial aneurysm (FIA) considers a 
complex disorder which has not benefited from the detailed study directed at 
essential hypertension. Genetic and physiological studies of this disorder are in 
their infancy. However, rupture of these lesions is often fatal, leading to 
subarachnoid haemorrhage, and contribution to all-stroke mortality and 
morbidity is disproportionate. 
Four candidate genes were investigated in a small pilot study of 80 individuals 
from 21 Scottish families with a history of FIA. These genes were collagen type 
III (COUAI), fibrillin I (FBNI), polycystin I (PKD1) and serine protease 
inhibitor I (SERPINAI). They were selected based on their importance to 
arterial wall integrity and remodelling; knowledge from Mendelian connective 
xviii 
tissue disorders; and studies in humans and animal models. A single intragenic 
or proximal microsatellite marker was genotyped for each gene and analysed 
with intracranial aneurysm status by linkage and association methods. A very 
small case-control paradigm comprising 18 cases and carefully matched controls 
suggested association of the marker proximal to SERPINAI (P=0.028). Using a 
family-based association test (FBAT), aP value of 0.062 was obtained for the 
same marker. There was no suggestion that markers at the CODAI, FBNI or 
PKDl loci were linked or associated (P>>0.05). 
To increase sample size, the SERPINAI marker was genotyped in 12 FIA 
families from the south of England. The combined dataset was analysed. 
Multiallelic FBAT and empirical variance-FBAT bordered on point-wise 
significance with P=0.054 and 0.071, respectively. This was supported by results 
from biallelic TDT analyses which implicated a 157 bp allele. Biallelic FBAT 
analyses implicated the same allele. 
This pilot study is very small and a much larger study will be required to 
determine whether these preliminary data are robust. However, the results are 
interesting, being the first known study of this locus in FIA families. The 
SERPINAl gene fits neatly with pathophysiological knowledge of FIA and 
further study of this- gene is considered worthwhile to clarify its relevance to FIA 
aetiology. However, to fully take advantage of developing complex genetic 
strategies, considerable work is required on FIA to clarify 
important 
pathophysiOlOgical mechanisms. 
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CHAPTER I 
INTRODUCTION 
1.1: HUMAN ESSENTIAL HYPERTENSION: 
Blood pressure is a classic example of a complex polygenic or oligogenic trait 
under the multifactorial control of genes and environment (Dominiczak et al, 
2000) (Fig. 1.1.1). The primary determinants of blood pressure (BP) in humans 
are cardiac output and peripheral resistance (Brown & Haydock, 2000). 
However, output and resistance are affected by many complex systems including 
the central nervous system; vasoconstrictor or vasodilator factors; vascular 
anatomy; body fluid volume and renal function (Carretero & Oparil, 2000b). 
1.1.1: DEFINITION AND EPIDEMIOLOGY OF HYPERTENSION: 
Debate raged in the 1960's regarding the population distribution of blood 
pressure and the mode of inheritance of hypertension (Pickering, 1967; Platt, 
1967). Large population studies have since confirmed the opinion of Pickering, 
showing that blood pressure is normally distributed with a slight skew to the 
right. The continuous unimodal distribution implicates an oligogenic or 
polygenic regulation (Carretero & Oparil, 2000b). 
At the individual level, blood pressure has a characteristic profile through life. 
Systolic blood pressure (SBP) increases progressively with age as the arterial tree 
loses its elasticity. Women's SBP increases more steeply. After 70 years 
women have as high or higher SBP than men (Burt et al, 1995). Diastolic 
blood 
pressure (DBP) increases until age 55 - 60 years (Carretero & Oparil, 
2000b). 
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Fig. 1-1-1: Multifactorial model of hypertensive disease demonstrating the 
potential influence of genes, environmental factors, and demographic factors. 
Interactions are represented by arrows. Adapted from Lifton, 1995. 
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There is a graded and continuous increase in cardiovascular disease mortality and 
morbidity as blood pressure increases (Stamler et al, 1993). Hypertension is thus 
defined with regard to disease risk. The World Health Organisation (WHO) 
currently describes hypertension as "SBP of 140 mmHg or greater andlor DBP 
of 90 mmHg or greater in subjects who are not taking antihypertensive 
medication" (Chalmers et al, 1999). By these criteria, approximately one quarter 
to one third of adults in the Western economies are hypertensive (Burt et al, 
1995; Mancia et al, 1997). The third National Health and Nutrition Examination 
Study (NHANES III) in the US showed that significant differences in prevalence 
exist between racial groups (Burt et al, 1995). However, population blood 
pressures and prevalence of hypertension are decreasing as treatment and 
awareness improve (Burt et al, 1995). There is also a concomitant reduction in 
stroke and coronary heart disease (CHD). Despite the improvements it is 
generally the case, in Western economies, that about half of hypertensives are 
treated and a quarter adequately controlled (Burt et al, 1995; Mancia et al, 1997). 
Some suggest that this may be an overestimate. Treatment of hypertension 
therefore remains a major public health challenge (Brown, 1997). 
A minority of hypertensive cases are due to secondary causes, for example 
renovascular disorders, phaeochromocytorna or aldosteronism or rare single gene 
disorders. The vast majority of hypertensive disease is due to primary or 
essential hypertension in the absence of secondary causes and simple genetic 
disorders (Brown & Haydock, 2000; Carretero & Oparil, 2000b). 
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1.1.2: BLOOD PRESSURE AND DISEASE RISK: 
Studies as early as the 1930s demonstrated that blood pressures greater than 
140/90 mmHg were associated with excess mortality and a blood pressure of 
110/70 mmHg was optimal for longevity (Lew, 1973). This was confirmed by 
large studies, for example the Multiple Risk Factor Intervention (MRFIT) study 
which included 300,000 US middle-aged men. Table 1.1.1 shows the increasing 
risk of CHD as SBP and/or DBP increase in the MRFIT cohort. Table 1.1.2 
shows the striking relationship between adjusted stroke risk and SBP (Stamler et 
al, 1993). Current evidence suggests disease risk increases above 115/75 mmHg, 
doubling for every 20/10 mmHg increment thereafter (Chobanian et al, 2003). 
In the 1970s the Framingham study showed that SBP rather than DBP was the 
primary risk factor for both CHD and stroke (Kannel et al, 1970; Kannel, 2000). 
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These results were later upheld in the 5,000-strong Framingham offspring cohort 
(Wilson et al, 1991) and studies such as MRFIT (Stamler et al, 1993) and the 
Chicago Heart Association Detection in Industry (CHA) study (Miura et al, 
2001). Such studies confirmed that this is true of all age/ sex classes and 
ethnicities (Stamler et al, 1993). Other studies showed that the risk was 
reversible and that lowering of blood pressure was beneficial even in the elderly. 
Studies in patients over 60 years of age recorded reductions of one third for 
stroke (Probstfield, 1991), and one quarter for myocardial infarction (Staessen et 
al, 1997) as a result of anti -hypertensive treatment. 
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TABLE 1.1.1: Effect of baseline SBP and DBP on adjusted coronary heart 
disease death in the MR-FIT study. 
Systolic Blood 
Pressure, mmHg <80 
Diastolic Blood Pressure, mmHg 
80-84 85-89 90-99 >-100 
<120 1.00 1.35t 1.361 0.98 3.23 
120-129 1.19§ 1.30t 1.49t 1.49t 1.84 
130-139 1.67t 1.61t 1.67t 1.91 t 2.64-t 
140-159 2.52t 2.22t 2.67t 2.56t 2.99t 
ý! 160 4.19t 3.20t 3.41 t 3.41 t 4.57t 
Adjusted for age, race, serum cholesterol, cigarettes per day, medication and income. 
tP<0.001 §P<0.01 JP<0.05. Taken from Stamler et al, 1993. 
TABLE 1.1.2: Deciles of SBP and adjusted stroke mortality in the MRFIT 
study. 
SBPý No. of Rate* Relative 
Decile of SBP mmHg deaths risk 
I <1 12 19 0.59 1.00 
2 112-117 28 0.77 1.33 
3 118-120 30 0.89 1.56 
4 121-124 59 1.44 2.621 
5 125-128 39 0.97 1.67 
6 129-131 44 1.30 2.251 
7 132-136 78 1.74 3.06§ 
8 137-141 82 2.04 3.60§ 
9 142-150 116 2.53 4.44§ 
10 ý! 151 238 4.76 8.21 § 
*Rate per 10,000 person-years adjusted for age, sex, race, serum cholesterol, cigarettes per 
day, diabetes medication, and income. Average follow-up of 11.6 yrs. TP<0.01; §P<0.001. 
Taken from Stamler et al, 1993. 
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The Framingham study noted that hypertension must be considered in the context 
of other cardiovascular disease risk factors since the effects were cumulative as 
shown in Fig. 1.1.2. This has been confinned by others who show that low risk 
groups have only 25% the mortality of high-risk groups (Stamler et al, 1999). 
The Framingham study also noted that such additional risk factors tended to 
occur in hypertensives more than twice as often as expected (Kannel, 2000). 
1.1.3: PATHOPHYSIOLOGY OF HYPERTENSION: 
The variety of physiological, enviromnental and genetic factors affecting 
regulation of blood pressure and, potentially, development of hypertension is 
immense (Fig. 1.1.3). Pathophysiology, acquired factors and the evidence for 
genetic factors will now be discussed. 
1.1.3.1. - SYMPA THETIC NER VO US SYSTEM 
Increased sympathetic nervous system activation increases blood pressure and 
maintains hypertension via stimulation of heart, peripheral vasculature and 
kidneys. Population-based studies show positive correlation between increased 
heart rate and development of hypertension (Oparil et al, 2003) and studies 
demonstrate that sympathetic cardiac stimulation is greater in young 
hypertensives than controls (Esler, 2000). Renal stimulation, on infusion of the 
a-adrenergic antagonist phentolamine, is also increased in hypertensives 
(Hollenberg et al, 1975; Esler et al, 1990). 
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Arterial baroceptors, which feed back to decrease sympathetic outflow, are reset 
at a higher pressure in hypertensive patients and this offset can be reversed by 
normalisation of arterial pressure (Guo et al, 1983; Chapleau et al, 1988; Me et 
al, 1990). Such resetting of the baroreflex function appears to be at least partly 
mediated by the central activity of angiotensin 11 (Guo & Abboud, 1984). Small 
molecular species such as reactive oxygen species and endothelin suppress 
baroceptor activity and contribute to exaggerated sympathetic drive of 
hypertension (Chapleau et al, 1992; Li et al, 1996). Chronic sympathetic 
stimulation induces release of various trophic factors such as transforming 
growth factor P, insulin-like growth factor I and fibroblast growth factors (Brook 
& Julius, 2000). These contribute to vascular remodelling and left ventricular 
hypertrophy. 
1.1.3.2: VASCULAR REACTIVITY AND REMODELLING. 
Hypertensive patients show greater vasoconstriction to noradrenaline than 
normotensive controls (Ziegler et al, 1991) as do normotensive offspring of 
hypertensive individuals. This suggests a genetic mechanism rather than simply 
an adaptive response. They also have impaired downregulation of adrenergic 
receptors (Oparil et al, 2003). Antagonists of oc and P-adrenergic receptors are 
effective anti-hypertensive treatments providing evidence of the role of 
sympathetic systems in the maintenance of hypertension (Oparil et al, 
2003). 
Peripheral resistance, determined at the level of arterioles and small arteries') is 
generally elevated in hypertension due to structural and mechanical changes 
in 
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the vessels (Oparil et al, 2003). Vascular remodelling contributes to high blood 
pressure and the associated target organ damage (Folkow, 1982; Mulvany & 
Aalkjaer, 1990). Gluteal skin biopsies from untreated hypertensives show 
increased media-lumen ratios due to decreased lumen area (Oparil et al, 2003). 
Several classes of antihypertensive treatment normalise vessel structure, 
including ACE inhibitors, angiotensin-receptor blockers (ARB) and calcium- 
channel blockers (Schiffrin, 2001). P-blocker therapy lowers blood pressure but 
does not improve vessel remodelling. Also, hypertension in animal models can 
be reversed by acute manipulation (for example, by unclipping the renal artery in 
the Goldblatt model), again without affecting vascular hypertrophy. This 
suggests that resistance vessel structure may not be strictly secondary to 
hypertension (Oparil et al, 2003). 
1.1.3.3. - ARTERIAL STIFFNESS: 
Collagen deposition, muscle cell hypertrophy and decreased integrity of elastic 
fibres are observed in aging arteries. These contribute to arteriosclerosis. In 
conjunction with these structural abnormalities, endothelial dysfunction develops 
due to aging and hypertension in both rodent models and humans (Hamilton et 
al, 2001). Thus arteries become stiffer through life (Berry et al, 2001). Reduced 
nitric oxide (NO) synthesis or release, in this setting, contributes to increased 
wall thickness of conduit vessels. Such deficiency appears to be important. NO 
donors, such as nitrates, increase arterial compliance and distensibility, reducing 
systolic blood pressure without affecting diastolic pressures (Oparil et al, 2003). 
Stiffness of arteries results in increased velocity of reflected pulse waves. This, 
in turn, increases SBP because reflected pulse waves reach the aortic valve 
before closure, and may result in decreased DBP and coronary perfusion 
pressure. This phenomenon explains the predictive value of the SBP-DBP 
derivative, pulse pressure, on cardiovascular disease risk (Oparil et al, 2003). 
1.1.3.4. - RENIN-ANGIOTENSIN SYSTEM 
Angiotensin 11 (Ang II) increases blood pressure by mechanisms including 
vasoconstriction, alclosterone synthesis, renal salt handling, stimulation of thirst 
and sympathetic outflow from the brain (Oparil et al, 2003). Constriction to Ang 
II is increased in hypertensive individuals. It signals through two angiotensin 
receptors, type I (ATIR) and type 11 (AT2R). Via the ATIR, Ang 11 induces 
cardiac and vascular hypertrophy and hyperplasia. It also stimulates release of 
several growth factors and cytokines (McConnaughey et al, 1999). AT2R 
inactivates the signalling pathway downstream of ATIR, opposing the biological 
effects and leading to vasodilatation, growth inhibition and cell differentiation. 
This is thought to be important under stress conditions (Oparil et al, 2003). 
Local renin-angiotensin systems are now recognised. These may make an 
important contribution to remodelling of resistance vessels and the development 
of target organ damage in hypertensives (McConnaughey et al, 1999). 
1.1.3.5. - ANGIOTENSIN HAND OXIDATIVE STRESS: 
Hypertension associated with long-term infusion of Ang 11 is linked to 
upregulation of vascular p22phox mRNA, a component of the oxidative enzyine 
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NAD(P)H oxidase (Fukui et al, 1997). This results in increased production of 
superoxide (02-) which oxidises nitric oxide to peroxynitrite (ONOO-). 
Blockade of ATIR has beneficial effects on superoxide levels in rat models of 
hypertension and stroke (Brosnan et al, 2002). This reduced NO bioavailability 
may be part of the reason for the increased vasoconstriction to Ang Il in 
hypertensive individuals. NAD(P)H oxiclase may also mediate the hypertrophic 
response to Ang 11 since antisense p22phox inhibition in cultured vascular 
smooth muscle cells (VSMCs) inhibits Ang II-induced protein synthesis (Zafari 
et al, 1999). 
1.1.3.6. - ENDOTHELIAL DYSFUNCTION: 
Nitric oxide is a potent vasodilator, inhibitor of platelet adhesion and 
aggregation, and suppressor of VSMC migration and proliferation (Oparil et al, 
2003). The cardiovascular system in healthy individuals is exposed to 
continuous NO-dependent vasodilator tone, but NO-related vasodilatation is 
reduced in hypertensive individuals (Berry et al, 2001; Oparil et al, 2003). 
Superoxide dismutase (SOD) reduces superoxide and in vivo delivery of SODs 
have been shown to reduce blood pressure and increase NO bioavailability in 
hypertensive models (Nakazono et al, 1991; Laursen et al, 1997; Fennell et al, 
2002). This provides further evidence that oxidative stress contributes to the 
reduction of NO bioavai lability, and development of endothelial dysfunction in 
hypertensive models. 
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1.1.4: ACQUIRED RISK FACTORS FOR ESSENTIAL HYPERTENSION: 
The most important modifiable environmental risk factors are salt intake, alcohol 
consumption and obesity (Kornitzer et al, 1999). 
1.1.4.1. - SALT INTAKE 
In the 1960's, Dahl showed a heterogeneous blood pressure response to salt in 
rats. The trait was captured by inbreeding, developing salt-sensitive and resistant 
strains (Dahl et al, 1962a; Dahl et al, 1962b). This confirmed the influence of 
both salt and genes on blood pressure. Effect of salt has also been demonstrated 
in chimpanzees (Denton et al, 1995) and humans. 
The Intersalt study showed correlation of SBP with salt excretion and blood 
pressure increase over life with salt intake in more than 10,000 individuals from 
32 countries (Stamler et al, 1989). Meta-analyses have confirmed this between 
populations (Law et al, 1991) and within populations (Frost et al, 1991). There 
is also an ethnic component as shown by 73% prevalence of salt- sensitivity in 
black hypertensives versus 56% in white hypertensives (Komitzer et al, 1999). 
Moderate salt reduction decreases blood pressure in both hypertensive and, to a 
lesser extent, normotensive individuals and the effect is dose dependent (Law et 
al, 1991; Cutler et al, 1997). This applies to all ages from new born (Geleijnse et 
al, 1997) to elderly (Whelton et al, 1998). Thus, many advocate a population- 
wide reduction in salt intake (Komitzer et al, 1999). 
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Salt's effect on blood pressure could involve several mechanisms. Salt intake 
has been observed to increase sympathetic activity (Koolen & Vanbrummelen, 
1984) and hyperinsulinaemia has been noted in salt-sensitive individuals 
(Bigazzi et al, 1996). Interaction with factors such as stress has been proposed 
(Staessen et al, 1994). Reduced nitric oxide bioavailability, as observed in 
animal models, may enhance the pressor effect of sodium (Weinberger, 1996). 
1.1.4.2. - POTASSIUM INTAKE. - 
Data from NHANES I showed that increased blood pressure in the black 
population was partly attributable to a relatively low potassium intake (Frisancho 
et al, 1984). The MRFIT study showed an inverse relationship of potassium 
intake and SBP, and to a lesser extent DBP, in men (Stamler et al, 1997). This 
correlation was not observed in women of the Nurses Health Study (Komitzer et 
al, 1999) but a substudy did observe a significant 2 mmHg decrease in SBP with 
potassium supplementation for 16 weeks (Sacks et al, 1998). High potassium 
diets were reported to reduce SBP and DBP by 5.5 mmHg and 3.0 mmHg in US 
adults (Appel et al, 1997). Meta-analysis of 33 potassium supplementation trials 
indicated a significant reduction in pressures, again of the order of 3 mmHg 
(Whelton et al, 1997). 
1.1.4.3. - ALCOHOL CONSUMPTION: 
Studies in US, European and Asian populations show a J-shaped correlation 
between alcohol intake and blood pressure (MacMahon et al, 1990). The 
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correlation of alcohol use and BP is also dependent on age and sex (Fortmann et 
al, 1983). The Intersalt study showed that high alcohol consumption was 
independently related to the prevalence of hypertension (Stamler et al, 1989) and 
reduction of alcohol in hypertensives has been associated with decreases in SBP 
and DBP (Kornitzer et al, 1999). Complete withdrawal of alcohol in 
normotensive persons also causes a reduction in blood pressures (MacMahon et 
al, 1990). 7% to I I% of male hypertension prevalence may be due to alcohol 
(MacMahon et al, 1990). Thus, a population-wide limit of alcohol is advocated. 
Current recommendations suggest daily limits of 30 ml of alcohol for men and 
15 ml for women (Chobanian et al, 2003). Mechanisms for this relationship may 
involve several pathways, not least increased catecholarnine secretion, disruption 
of normal Na+-Li+ countertransport in erythrocytes or a decrease in insulin 
sensitivity (Kornitzer et al, 1999). 
1.1.4.4. - METABOLIC SYNDROME: 
The metabolic syndrome is a clustering of disease risk factors, including 
abdominal obesity, glucose intolerance, dyslipidaemia and often hypertension 
(Isomaa, 2003). The link between these features is not clear, but it is clear that 
patients with hypertension are at greater risk of having other features of the 
metabolic syndrome (Reaven, 2003). For example, insulin resistance is found in 
45% of hypertensives versus 10% of normotensives (Reaven et al, 1996). 
Features of the metabolic syndrome are, themselves, risk factors for the 
development of hypertension. Body mass is related to blood pressure and the 
16 
Framingham study showed that changes in weight were accompanied by changes 
in blood pressure (Kannel et al, 1967; Stamler et al, 1975). Weight loss in 
middle-aged, borderline hypertensives has been shown to reduce BP by 3.7/2.7 
mmHg (Whelton et al, 1997). Intervention in the elderly also indicates a 
beneficial effect from weight loss (Whelton et al, 1998). Distribution of fat is 
important. Abdominal, visceral fat is metabolically more active and insulin 
resistant than subcutaneous fat (Amer, 1995) and correlates with hypertension 
(Bjomtorp, 1990). 
Insulin sensitivity has been reported to be inversely correlated with blood 
pressure in both sexes (Ferrannini et al, 1997). Baseline fasting plasma insulin 
levels were shown to predict hypertension status a decade later in 2,322 middle- 
aged men (Skarfors et al, 1991). Similar results have been reported in women 
with 12 years follow-up with a threefold prevalence of hypertension in the top 
quartile compared with the bottom (Lissner et al, 1992). 
Insulin resistance is not increased in patients with secondary hypertension, but 
there is a higher prevalence in normotensive relatives of hypertensive individuals 
(Reaven, 2003). This suggests that hypertension does not cause the metabolic 
anomalies. Some suggest that insulin resistance and hyperinsulinaemia are 
causally linked to essential hypertension (Reaven, 2003). There is evidence that 
endothelial damage may occur in conditions of insulin resistance and 
hyperglycaemia (Tooke & Hannemann, 2000). Sympathetic nervous system 
stimulation by high plasma levels of insulin (Julius & Jamerson, 1994) or 
insulin's action on sodium retention by the kidney may also be potential 
mechanisms (Sechi & Bartoli, 1997). 
1.1.4.5. - OTHER FA CTORS. - 
Many studies show an inverse relationship between exercise and both blood 
pressure and hypertension risk (Komitzer et al, 1999). The benefit of exercise 
and improved fitness in lowering blood pressure has been demonstrated in 
African American men (Kokkinos et al, 1995), and Caucasian men (Paffenbarger 
et al, 1983) and women (Kornitzer et al, 1999). Psychosocial stress has also 
been shown to contribute to risk. Work-related stress correlates with ambulatory 
blood pressures in men and women (Van Egeren, 1992; Theorell et al, 1993). 
1.1.5: EVIDENCE FOR A GENETIC COMPONENT IN ESSENTIAL 
HYPERTENSION: 
Evidence from human population studies, rat model studies and Mendelian blood 
pressure disorders demonstrate a genetic component in essential hypertension 
(Rapp & Deng, 1995). 
1.1.5.1. - EVIDENCE FROMHUAIMN POPULATION STUDIES: 
An early study used longitudinal blood pressures over 9 years to assess 
aggregation of blood pressure in families in Wales (Miall et al, 1967). It showed 
a correlation of BP in probands and first-degree relatives which was absent in 
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spouses, despite their shared environment. Similarly, the Framingham study 
showed correlation between the BPs of parents and offspring but no correlation 
between spouses. Like Miall et al, above, the conclusion was that genetic factors 
could explain this (Havlik et al, 1979). Studies in Evans County in the US 
showed that blood pressure aggregation was present in both black and white 
populations and an individual's BP correlated with the number of hypertensive 
parents (Hayes et al, 1971). Examination of related and unrelated individuals 
living together or apart in Michigan was used to quantify the genetic effect. 
Heritability of SBP was 0.42 and DBP was 0.30. Genetic factors accounted for 
25% of SBP variance (Longini et al, 1984). Comparable results have been 
published in populations lacking some of the Western risk factors, such as urban 
Nigerian families with low BMI and hypertension prevalence. Heritability 
estimates of 0.34 and 0.29 were obtained for SBP and DBP (Adeyemo et al, 
2002). 
Twin studies support population studies. A significant genetic effect on BP was 
demonstrated in 500 monozygotic (MZ) and dizygotic (DZ) middle-aged twin 
pairs by the National Heart, Lung and Blood Institute (NHLBI) (Feinleib et al, 
1977). Resting blood pressures and response to stress, tested by the cold pressor 
test, demonstrated that a genetic component was involved in both cases in young 
to middle-aged German twins (Busjahn et al, 1996). Adoption studies support 
the findings of other study designs. One of the most informative studies in 
French-Canadian families compared BP correlation between adoptees, or natural 
children, and parents. It concluded that most of BP correlation was explained 
by 
heredity (Biron ef al, 1976). Subsequently the same group estimated that up to 
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61% and 58% of the SBP and DBP correlation could be explained by shared 
genes. About a third of the phenotypic variance in the population was attributed 
to genes. 
Overall, different study designs have confirmed that blood pressure is highly 
heritable. This also applies, as one might expect, to hypertension (Williams et al, 
1989). The precise contribution of inherited genes has been more difficult to 
define. At best one can say that between 30% and 60% of interindividual 
variation is attributable to genes (Ward, 1990). 
1.1.5.2. - EVIDENCE FROM RAT MODELS: 
In rodent models, it has been shown very clearly that blood pressure must be 
influenced by genetic variation. The 20th century saw the development of a 
number of inbred rat strains. These were produced by selectively breeding rats 
that showed a propensity for high blood pressure. Some were developed from 
outbred rats, being brother-sister mated to fix the phenotype and the genomic 
complement (Smirk & Hall, 1958). Others were derived from normotensive 
inbred strains using animals which displayed unusually high blood pressures. 
Thus the widely used spontaneously hypertensive rat (SHR) was derived from 
atypical Wistar rats (Okamoto & Aoki, 1963). Dahl developed partially inbred 
salt sensitive and resistant strains (Dahl et al, 1962a). From these initial strains, 
fully inbred strains were created later (Rapp & Dene, 1985). Sabra H and Sabra 
N rats were developed by Ben-Ishay, having a marked BP response to DOCA- 
salt administration or negligible response, respectively (Ben-Ishay et al, 1972). 
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These rat strains develop spontaneous hypertension which is relatively 
consistent, within a strain, in terms of its severity and age of onset (Lee et al, 
2000). 
Mating of normotensive and hypertensive rats to produce an F2 generation 
results in continuously distributed blood pressures in the progeny. This suggests 
that, as in humans, the rats develop polygenic forms of hypertension 
(Dominiczak et al, 1998). This has been confirmed by the finding that multiple 
genetic loci contribute to the hypertension in each model (Rapp, 2000). Rodent 
models elegantly demonstrate that high blood pressure levels are inherited from 
generation to generation and this phenotype can be captured by inbreeding. Use 
of congenic strain production provides definitive proof for the effect of a 
chromosomal segment on blood pressure (Rapp & Deng, 1995; Dominiczak et 
al, 1998). As far as possible environment is a constant so inbred rat strains allow 
us to directly observe the effects of genes on blood pressure. 
1.1.5.3. - EVIDENCE FROM MENDELIAN HYPERTENSIVE DISORDERS: 
Whilst contributing very little to the overall burden of hypertensive disease, 
Mendelian hypertensive disorders have confirmed not only the crucial role of 
genes in human blood pressure control, but also indicated mechanisms by which 
this control is achieved and disrupted. 
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1.1.5.3.1: Glucocorticoid-remediable aldosteronism: 
Glucocorticoid-remediable aldosteronism (GRA) is characterised by early onset 
of hypertension with normal or elevated aldosterone levels with suppressed, or 
undetectable, plasma renin activity (PRA) (Sutherland et al, 1966). 
Hypokalaemia and metabolic alkalosis may also feature (Rich et al, 1992). 
Exogenous glucocorticoids relieve symptoms (Sutherland et al, 1966). 
Linkage analysis in multiple GRA pedigrees showed the cause to be unequal 
crossing over between two highly homologous genes on chromosome 8q (Lifton 
et al, 1992a; Lifton et al, 1992b). CYPIIBI, normally regulated by 
adrenocorticotrophic hormone (ACTH), expresses steroid II P-hydroxylase, an 
enzyme involved in cortisol synthesis in the adrenal fasciculata. CYP II B2, 
normally regulated by angiotensin 11 (AngII), expresses aldosterone synthase, the 
rate-limiting enzyme in alclosterone synthesis in the adrenal glomerulosa. The 
resulting chimaeric gene expresses a protein with aldosterone synthase activity 
under the control of ACTH. Thus, efforts to maintain normal levels of cortisol 
result in ectopic and constitutive production of aldosterone from the adrenal 
fasciculata. 
The hyperaldosteronism causes hyperactivation of the mineralocorticoid receptor 
leading to increased Na+ reabsorption via the epithelial sodium channel (ENaQ 
(Fig. 1.1.4). Plasma volume expansion and hypertension result (Lifton et al, 
2001). Increased secretion of K' and H+ is driven by the lumen-negative 
potential from the low Na 
2+ concentration. 
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Fig 1. IA: Mendelian hypertensive disorders in humans. A schematic kidney nephron is 
shown in yellow. NaCl reabsorption pathways are shown with hypertensive disorders in 
red. PT = proximal tubule; TAL = thick ascending limb; DCT = distal convoluted tubule; 
CCT = cortical collecting tubule. Ang I= angiotensinogen 1; Ang 11 = angiotensinogen 11. 
PHA 11 = pseudohypoaldosteronism type 11. Adapted from Lifton et al, 2001. 
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Conversely, loss-of-function mutations in the CYP 11 B2 gene (Mitsuuchi et al, 
1992; Pascoe et al, 1992) and the steroid 21-hydroxylase gene, CYP21B, 
(Bongiovanni & Root, 1963) are known which cause salt-wasting and 
hypotension. 
1.1.5.3.2: Syndrome of apparent mineralocorticoid excess: 
Syndrome of apparent mineralocorticoid excess (AME) is an autosomal recessive 
early onset hypertensive disorder associated with hypokalaemia and metabolic 
alkalosis, accompanied by low PRA but virtual absence of circulating 
aldosterone (New et al, 1977). Administration of spironolactone, a 
mineralocorticoid receptor (MR) antagonist, or a low sodium diet alleviates the 
symptoms (New et al, 1977; Mune et al, 1995). 
AME is caused by homozygous loss-of-function mutations in the HSDIIB2 
gene, encoding the II P-hydroxysteroid dehydrogenase type 2 kidney isozyme 
(I I PHSD2) (Mune et al, 1995; Stewart et al, 1996). Cortisol is a potent agonist 
of the MR (Arriza et al, 1987) which is converted to inactive cortisone by 
II PHSD and so that the MR is selective for aldosterone (Fudner et al, 1988). 
Removal of this protection by mutation of the HSD II B2 gene results in a greater 
half life of cortisol which activates the MR (Ulick et al, 1979). This causes 
hypertension due to increased sodium reabsorption via the ENaC (Fig. 1.1.4). 
Antagonism of the MR blocks this. 
High cortisol levels associated with heritable mutations of the glucocorticold 
receptor or pituitary or adrenal adenomas also result in hypertension (Hurley et 
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al, 1991). Deficiencies in steroid Ilp-hydroxylase and 17a-hydroxylase can 
result in low renin hypertension due to the accumulation of MR-agonist 
precursors of cortisol synthesis (Kagimoto et al, 1988; White et al, 1991). 
1.1.5.3.3: Pregnancy-accelerated hypertension: 
Mutation of the mineral ocorticoid receptor causes an autosomal dominant form 
of hypertension which worsens during pregnancy (Geller et al, 2000) (Fig. 1.1.4). 
The mutations disrupt the receptor's specificity such that progesterone will 
activate it. Progesterone increases 100-fold in pregnancy, and exacerbates the 
hypertension during this time (Lifton et al, 2001). 
Conversely, loss-of-function mutations in the MR cause autosomal dominant 
pseudohypoaldosteronism type I (AD PHA I) which is a form of neonatal salt 
wasting associated with hypotension in the presence of elevated aldosterone 
levels and metabolic acidosis (Lifton et al, 2001). 
1.1.5.3.4: Liddle syndrome: 
Liddle syndrome is characterised by autosomal dominant transmission of early 
onset hypertension associated with hypokalaemic alkalosis, suppressed plasma 
renin activity and low Plasma aldosterone levels (Lifton et al, 2001). 
The disease is caused by mutations in either the P or y subunit of the epithelial 
sodium channel (ENaC). ENaC is a heterotrimeric protein consisting of a, P and 
y subunits (Fig. 1.1.4). Mutations result in loss of the C terminus of the affected 
subunit (Shimkets et al, 1994: Hansson et al, 1995). The effect of mutations in 
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either subunit is increased channel activity due to increased numbers of ENaC 
molecules at the cell surface (Schild et al, 1995; Snyder et al, 1995). All 
mutations described affect a highly conserved PPPXY motif in the C terminus 
(Hansson et al, 1995; Inoue et al, 1998). Studies showed that mutation of any 
conserved PPPXY residues resulted in increased amiloride-sensitive Na+ 
conductance in X laevis oocytes (Schild et al, 1996). The PPPXY motif was 
subsequently implicated in internalisation of channels or subsequent degradation 
hence the increased channel numbers at the membrane (Shimkets et al, 1997). 
Nedd4-1 (Staub et al, 1996), and Nedd4-2 (Kamynina et al, 2001) interact with 
the PPPXY motif, ubiquinating the channel and targeting it for degradation. 
Loss-of-function mutations in ENaC cause recessive pseudohypoaldosteronism 
type I (Chang et al, 1996) which results in neonatal salt wasting with 
hypotension, elevated aldosterone and metabolic acidosis. It is more severe than 
the dominant form (Strautnieks et al, 1996). 
1.1.5.3.5: Pseudohypoaldosteronism type 11: 
Pseudohypoaldosteronism type 11 (PHA 11), or Gordon's syndrome, is an 
autosomal dominant form of hypertension with hyperkalaemia, possible 
metabolic acidosis and suppressed renin activity, despite otherwise normal renal 
function. It is particularly sensitive to thiazide diuretics (Lifton et al, 2001). 
Genome wide scans identified linkage on chromosomes I q3l-42,17p I1 -q21 and 
12p 13 (Mansfield et al, 1997, Disse-Nicoderne et al, 2000). Subsequently, two 
serine-threonine kinases were shown to underlie the linkage results on 
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chromosomes 12 and 17. Large deletions in the first intron of lysine-deficient 
protein kinase I (VVNKI) caused increased expression whilst missense mutations 
caused loss-of-function of lysine-deficient protein kinase 4 (IANK4) in PHA 11 
pedigrees. Both proteins co-localise to the distal convoluted tubule (DCT) and 
cortical collecting duct (CCD) of the distal nephron (Wilson et al, 2001). The 
renal downstream target of )NNKI is not known but may be the Na-K-2CI 
channel, which is known to be regulated by a kinase dependent mechanism 
(Choate et al, 2003). WNK4 limits cell surface expression of the diazide- 
sensitive Na-CI cotransporter expressed in the DCT (Wilson et al, 2003). 
Mutations in the Na-K-2CI channel cause the hypotensive Bartter syndrome type 
I (Simon et al, 1996) whilst a mutant Na-CI cotransporter causes Gitelman 
syndrome (Bettinelli et al, 1992). Both feature hypotension with hypokalaemia 
and alkalosis (Simon et al, 1996). 
1.1.5.3.6 Hypertension with brachydactyly: 
Hypertension with brachydactyly is an autosomal dominant disorder showing 
complete cosegregation of severe early-onset hypertension with abnormal 
skeletal development of the hand and wrist (Lifton et al, 2001). The syndrome 
was mapped to 12pl2.2-11.2 in a Turkish pedigree (Schuster et al, 1996). 
Deletions in this same interval can result in brachydactyly in the absence of 
hypertension and so the possibility that contiguous genes are altered has been 
raised (Bahring et al, 1997). 
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1.1.6: THE ROLE OF GENETICS IN TREATMENT OF HYPERTENSION: 
As discussed, despite advances in the understanding of pathophysiology of 
essential hypertension, health education and development of novel medicines, 
essential hypertension is still not adequately controlled in the majority of patients 
(Chobanian et al, 2003). Essential hypertension has a multifactorial aetiology, a 
combination of environmental and genetic influences (Lifton et al, 2001). 
Therefore, lifestyle modifications have been promoted as an important non- 
pharmacological approach to treatment. They effectively lower blood pressure 
and disease risk (Carretero & Oparil, 2000a). However, in reality lifestyle 
targets are difficult to achieve and harder to maintain. Alone they cannot solve 
the problem (Chobanian et al, 2003). 
What, then, can genetic studies contribute to the situation and how would this 
benefit patients? Recent opinion dichotomises the role of genetics. Essentially, 
there are two distinct questions. The first concerns the genetic basis of essential 
hypertension - answered by disease genetics. The second concerns the role of 
genes in determining individual response to therapy - answered by 
pharm aco genetics (Roses, 2000a). 
Disease genetics studies, the focus of this thesis, may lead to new insights into 
hypertensive disease and could potentially inform future drug development 
(Roses, 2000a). However, Roses notes that, in reality, disease genes and drug 
targets are not the same thing. Most susceptibility genes will not be tractable 
targets or amenable to high-throughput screening methods to identify active 
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compounds (Roses, 2000a). Despite this, understanding of individual aetiologies 
at the genetic level would allow mechanism-based drug discovery (McLeod & 
Evans, 2001). This should ultimately enable a more customised treatment 
regimen based on an individual's subtype of hypertensive disease. Another 
possibility, once disease genes are known, would be genetic-testing. However, 
whilst it might be useful to determine an individual's risk, in practice there is a 
minefield of social, ethical and legal issues (Roses, 2000b). 
From the pharmacogenetics standpoint, an understanding of why a given patient 
fails to respond well to a drug may be of more immediate use in treating the 
individual. One of the greatest obstacles in treating patients is non-compliance 
with medication or change in medication. Between 50 and 70% of hypertensive 
patients will change their medication within 6 months of commencing treatment 
(Carretero & Oparil, 2000a). Unpleasant side effects may result in complete 
non-compliance, and at least will reduce the treatment options available. Even in 
patients tolerating their medication it is poorly understood why response to drugs 
is so variable. The standard deviation of response to medication is as great as the 
mean response. Ranges of response are greater than the mean response. Ten to 
twenty percent of patients have no response at all or a paradoxical increase in BP 
(Turner & Boerwinkle, 2003). Pharmaco genetics could be used to predict if an 
individual patient is likely to benefit from a medicine and be free of serious side- 
effects (Roses, 2000a). 
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1.2: FAMILIAL INTRACRANIAL ANEURYSM AND SUBARACHNOID 
HAEMORRHAGE: 
Formation of intracranial saccular aneurysms (IA) is a complex process 
involving genetic and acquired risk factors. Focal dilatation of intracranial 
arterial walls results in the formation of an extruded pouch - the aneurysm - 
which compromises the integrity of the vessel and may lead to rupture (Zhang et 
al, 2003). Within the cranium, rupture of aneurysms on the surface of the brain 
results in bleeding into the subarachnoid space, between the pia mater and 
arachnoid membrane. This is termed 'subarachnoid haemorrhage' (SAH). Both 
IA and aneurysmal SAH exist as sporadic and familial disorders (Zhang et al. 
2003). 
1.2.1: DEFINITION & EPIDEMIOLOGY OF FAMILIAL INTRACRANIAL 
ANEURYSM & SUBARACHNOID HAEMORRHAGE: 
The suggestion that IA formation may involve a heritable component was first 
raised by Chambers et al when they described lAs in a father and son (Chambers 
et al,, 1954). Many families have since been described in the literature (Lozano 
& Leblanc, 1987; Elshunnar & Whittle, 1990; Schievink et al, 1991; Schievink et 
al, 1994; Bromberg et al, 1995) and the familial aggregation of lAs is now 
accepted. The term 'familial intracranial aneurysm' (FIA) describes the disorder 
in families having two or more affected first to third-degree relatives, this being 
distinct from 'sporadic' aneurysms which have no accompanying family history 
(Schievink et al, 1994; Bromberg et al, 1995). 
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The majority of aneurysms remain asymptomatic (Schievink et al, 1994) and, as 
such, calculation of the population prevalence of sporadic and familial 
intracranial aneurysms is very difficult. Autopsy studies have been used to 
address this question. A meta-analysis by Rinkel et al (Rinkel et al, 1998) of 19 
studies suggested a total population prevalence of 4.3%. The proportion that are 
familial aneurysms is estimated to be from 4% in a Scottish population 
(Elshunnar & Whittle, 1990) and 6.7% in a Swedish study (Norrgard et al, 1987) 
to 29% in French-Canadians (Mathieu et al, 1997). However, the latter 
population may be atypical since it is a geographically isolated population and 
may include founder effects (Mathieu et al, 1997). 
Whilst asymptornatic intracranial aneurysms are not detrimental in themselves, 
should they rupture the prognosis for the patient is very poor. About 80% to 
90% of non-traumatic subarachnoid haemorrhage cases are attributable to a 
ruptured so-called saccular or 'berry' intracranial aneurysm (Alberts, 1999). 
Mortality is about 50% and more than 35% of those admitted to hospital die 
within one month. One third of survivors have serious neurological deficits 
(Gaist et al, 2000). Of SAH due to saccular aneurysmal rupture, about 5 to 10% 
are thought to be familial cases (Bromberg et al, 1995) although some authors 
report as high as 20% having a family history (Schievink et al, 1995). 
1.2.2: EVIDENCE FOR A FAMILIAL DISORDER: 
Most reported FIA families have only two affected members raising the 
possibility that the observed aggregation is purely fortuitous. This has been 
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addressed by several studies. US studies comParing SAH incidence in first- 
degree relatives of SAH cases with the population prevalence demonstrated 
between twofold (Wang et al, 1995) and fourfold risk (Schievink et al, 1995). 
Alberts et al (Alberts et al, 1994) showed fourfold risk of IA or SAH in siblings 
of cases from large sibships in the literature. Comparable recurrence risks of 4 
for IA in Finnish first-degree relatives (Ronkainen et al, 1997) and 3 to 5 for 
SAH in Danish first-degree relatives (Gaist et al, 2000) have been reported. 
Apparent differences between sporadic and familial IA or SAH also suggest two 
separate entities. Dutch, Finnish, Northern Irish and Canadian populations 
consistently show that familial aneurysms rupture, on average, about 5 years 
earlier than sporadic cases (Andrews, 1977; Lozano & Leblanc, 1987; Bailey, 
1993; Ronkainen et al, 1995; Bromberg et al, 1995; Leblanc et al, 1995). Some 
report that ruptures peak in the 4 th decade of life in familial cases but in the 6th 
decade for sporadic (Leblanc et al, 1995). Aneurysms of the anterior 
communicating artery are consistently twice as common in sporadic cases 
(Andrews, 1977; Lozano & Leblanc, 1987; Bailey, 1993; Ronkainen et al, 1995; 
Bromberg et al, 1995; Leblanc et al, 1995). 
FlAs occur at the same or contralateral site in siblings twice as often as random 
sporadic cases (Andrews, 1977), (Lozano & Leblanc, 1987; Leblanc et al, 1995). 
Of 8 published monozygotic twin pairs, reviewed by Lozano and Leblanc, all had 
aneurysms at the same or contralateral site. SAH also occurs in the same decade 
of life more than twice as often (Andrews, 1977; Lozano & Leblanc, 1987; 
Leblanc et al, 1995). 
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Some studies suggest that familial aneurysms may rupture at a smaller size 
(Lozano & Leblanc, 1987; Ronkainen et al, 1995). Some studies also suggest an 
increased prevalence of multiple aneurysms in familial cases (Lozano & Leblanc, 
1987; Bailey, 1993; Bromberg et al, 1995) although perhaps as many find no 
difference (Schievink et al, 1995; Leblanc et al, 1995; Mathieu et al, 1997). 
Prognosis for familial SAH cases may be worse. A Dutch outcome study 
showed that 48% of familial cases were able to continue an independent life 
following SAH compared with 68% of sporadic cases at time of discharge. FIA 
mortality was also higher (Bromberg et al, 1995). Conversely, a Finnish study 
showed no difference in outcome, one year after discharge (Ronkainen et al, 
1999). However, Finland is exceptional in terms of its prevalence of IA and the 
predominance of affected males. This may indicate different aetiology. 
1.2.3: PATHOLOGY AND PATHOPHYSIOLOGY OF INTRACRANIAL 
ANEURYSMS: 
A saccular intracranial aneurysm is a berry-shaped or multi-lobed extrusion of an 
artery wall, usually associated with the circle of Willis at the base of the brain. 
Such aneurysms are distinct in their shape and pathogenesis from atherosclerotic 
fusiform aneurysms; infection-derived mycotic aneurysms; and dissecting 
arteries, often caused by trauma (Alberts, 1999). 
discussed below, are characteristic of saccular lAs 
formation of lAs (Fig. 1.2.1). 
number of features, 
These may play a role in 
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Fig 1.2.1: A schematic representation of processes which may influence arterial 
integrity and the formation of intracranial aneurysms. The complex aetiology may 
involve normal aging and stress effects exacerbated by an underlying vessel weakness. 
Genetic susceptibility may underlie aberrant vessel remodelling, artery wall turnover 
or inflammatory processes. Acquired risk factors interact with some or all 
components. ECM = extracellular matrix 
Aging 
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Too 
Fig. 1.2.2: Schematic of the circle of Willis and the commonly associated sites of 
saccular aneurysm formation. Taken from Zhang et al, 2003. 
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1.2.3.1. - SITE OF ANEURYSM FORMATION., 
Saccular aneurysms often form at the circle of Willis because of the increased 
haemodynamic forces in this region (Zhang et al, 2003), particularly at arterial 
bifurcations (Leblanc, 1997) (Fig. 1.2-2). Haemodynamic stress by carotid 
ligation causes slow formation of experimental aneurysms, and the process is 
accelerated by induced hypertension (Kondo et al, 1997). Mathematical 
modelling confirms the increased stresses at bifurcations and the outside of 
curves (Foutrakis et al, 1999). Previously, haemodynamic stress was thought by 
some to completely account for IA formation (Stehbens, 1989). However, this 
fails to explain why IAs are still relatively rare in hypertensive groups, and why 
aggregation occurs in families and twins. Twins, for example, do not have 
identical vasculature at the circle of Willis (Stehbens, 1989). 
1.2.3.2. - FEATURES OF ANEURYSMAL VESSEL WALLS: 
With aging, and probably due to haemodynamic stress, layers of fibrous tissue 
develop between the endothelium and internal elastic lamina of the cerebral 
vessel wall. This decreases vessel elasticity and causes further deposition of 
fibrous tissue. At arterial bifurcations this further increases haernodynamic stress 
(Zhang et al, 2003). Disruption of the internal elastic lamina (IEL) is a common 
feature in both human (Stehbens, 1972) and experimental aneurysmal vessels 
(Yamazoe et al, 1990). IEL fenestrations are known to exist normally, but are 
larger at aneurysm sites (Campbell & Roach, 198 1). In the developed aneurysm, 
the IEL and medial layer terminate abruptly at the neck of the aneurysm 
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(Abruzzo et al, 1998; Zhang et al, 2003). The wall of the aneurysm shows 
evidence of depleted cellular elements, being little more than a fibrous layer with 
remnants of IEL (Stehbens, 1972). Some authors suggest a lack of fibromuscular 
proliferation and neointimal thickening is characteristic of such aneurysms 
(Abruzzo et al, 1998). These structural changes are more advanced in ruptured 
aneurysms compared with unruptured aneurysms (Kataoka et al, 1999). 
1.2.3.3. - EXTRA CELL ULAR MA TRIX REMODELLING: 
Gross architectural remodelling of extracellular matrix (ECM) has been reported 
in intracranial aneurysms. ECM is seen to be disorganised (Skirgaudas et al, 
1996). Quantitatively and qualitatively abnormal reticular fibres have been 
reported in both aneurysm tissue specimens (Chyatte et al, 1990; Chyatte & 
Lewis, 1997) and normal cerebral arteries of affected patients (Ostergaard et al, 
1987). Skin biopsies taken from some IA patients indicate abnormal collagen 
and elastic fibre morphology (Grond-Ginsbach et al, 2002). Some have reported 
reduced collagen type III content in patients' fibroblasts (van den Berg et al, 
1997; Gaetani et al, 1997) or reduced collagen fibre cross-linking (Gaetani et al, 
1996). 
Expression profiling suggests that intracranial aneurysms are dynamic lesions 
undergoing remodelling. Peters et al examined an IA from a 3-year old girl and 
showed increased expression of several collagen subtypes, elastin, and the matrix 
metal loproteinase inhibitor TIMP3 (Peters et al, 2001). Increased expression of 
growth factors such as vascular endothelial growth factor (VEGF) and basic 
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fibroblast growth factor (bFGF) has been reported in adult lesions (Skirgaudas et 
al, 1996). A recent study reported decreased expression of bFGF, TIMP I and 
components of the local renin-angiotensin system. It was suggested that a lack of 
vascular remodelling may prevent arterial wall thickening, in response to 
increased haemodynamic stress, leading to IA formation (Ohkuma et al, 2003). 
Increased expression of matrix metalloproteinases (MMP) 1,2 and 9 and plasmin 
has been reported in unruptured aneurysms (Bruno et al, 1998). Increased 
MMP2 activity and reduced procollagens in serum from IA patients suggest a 
systemic anomaly (Chyatte & Lewis, 1997). Such observations have led to the 
suggestion that an imbalance in ECM turnover may be a factor in intracranial 
aneurysm formation. 
1.2.3.4. - INFLAMMATORY PROCESSES: 
Some studies have shown a link between atherosclerotic profile and ruptured 
aneurysms (Adamson et al, 1994). Others have shown no increased risk 
(Schievink, 1997). However, there is evidence to suggest that inflammatory 
processes, homologous to those resulting in atherosclerotic plaques, may be 
involved in aneurysm development and/or rupture (Laursen et al, 1997). Neither 
atherosclerotic plaques nor intramural inflammation are necessary features of lAs 
(Abruzzo et al, 1998). However, increased infiltration of macrophages and 
leukocytes has been observed in ruptured compared with unruptured lAs. It has 
been suggested that endothelial damage encourages macrophage invasion leading 
to rupture (Kataoka et al, 1999). A study to assess markers of inflammation in 
unruptured lAs noted increased macrophage and T lymphocyte levels compared 
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with control arteries obtained at autopsy. Levels of vascular cell adhesion 
molecule I (VCAM 1) and immunoglobulins IgG and IgM were also increased 
(Chyatte et al, 1999). These cells and molecules are also involved in 
atherosclerosis and the macrophages are a source of MMPs. 
1.2.4: ACQUIRED RISK FACTORS OF INTRACRANIAL ANEURYSMS 
AND SUBARACHNOID HAEMORRHAGE: 
Familial IA and SAH are complex disorders; it is expected that both acquired 
factors and inherited genetic susceptibility underlie the increased risk in FIA/ 
SAH families. The majority of risk factor studies concentrate on SAH, rather 
than formation of IA, as an endpoint, partly due to the fact that SAH patients are 
more easily identified than asymptomatic IA carriers. Many studies now suggest 
that the primary acquired risk factors for FIA and SAH are smoking and female 
sex. Hypertension and alcohol consumption have been shown to be risk factors 
for SAH only. 
1.2.4.1. - SMOKING: 
Smoking has been associated with increased risk of IA formation and IA growth 
in heterogeneous series of patients consisting of SAH survivors with additional 
unruptured lAs and individuals with unruptured lAs only (Juvela et al, 2001b). 
Smoking is also a risk factor for formation of multiple aneurysms, with a 
smoking history twice as likely in such cases (Qureshi et al, 1998; Ellamushi et 
al, 2001). 
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Many more studies have examined risk associated with SAH. Smoking has been 
addressed in over 20 case-control and cohort studies alone and none has yielded 
a non-significant association (Juvela, 2001). The association has been confirmed 
in Finnish, US, Australian and UK populations (Adamson et al, 1994; Teunissen 
et al, 1996; Weir et al, 1998; Leppala et al, 1999; Qureshi et al, 2001; Mhurchu 
et al, 2001; Pobereskin, 2001; Kissela et al, 2002). Thus, smokers are up to 5 
times more common in SAH cohorts compared with the general population 
(Weir et al, 1998; Qureshi et al, 2001); the risk of SAH amongst smokers is 
increased between 3 and 9 fold (Adamson et al, 1994; Teunissen et al. 1996; 
Leppala et al, 1999; Qureshi et al, 2001; Kissela et al, 2002) and smokers, both 
male and female, suffer SAH perhaps as much as 10 years earlier than non- 
smokers (Weir et al, 1998; Pobereskin, 2001). The relationship is dose- 
dependent (Leppala et al, 1999; Juvela, 2001) and cessation reduces risk. 
However, any history of smoking increases risk (Teunissen et al, 1996; Qureshi 
et al, 200 1; Kissela et al, 2002). 
Smoking may promote elastin degradation by inhibition of degradation inhibitors 
such as serine protease inhibitor I which regulates extracellular matrix 
degradation (Qureshi et al, 2001). Smoking also lowers oestrogen levels which 
may impact collagen levels in arterial walls (Kongable et al, 1996). 
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1.2.4.2: HYPERTENSION: 
Hypertension is considered neither sufficient nor necessary for formation of lAs 
(Alberts, 1999). Indeed, its status as a risk factor for IA fonnation is also in 
doubt. Smaller studies numbering hundreds of individuals find no increased risk 
of IA formation in hypertensives (McCormick & Schmalsteig, 1977; Juvela et al, 
2001b). However, a study in 20,767 individuals with unruptured lAs found that 
elderly unruptured IA patients had a slightly higher prevalence of hypertension 
compared with the control population (Taylor et al, 1995). A UK study showed 
that hypertension increased risk of multiple aneurysms and that hypertension 
prevalence increased across groups having from one to five aneurysms 
(Ellamushi et al, 2001). Conversely, a similarly sized and designed US study 
showed no association (Qureshi et al, 1998). Work in animal models supports an 
effect since experimental aneurysm formation is accelerated if hypertension is 
induced by renal artery ligation and salt administration (Kondo et al, 1997; 
Morimoto et al, 2002). However, available evidence suggest that any increase in 
IA risk from hypertension is small. 
A history of hypertension is an independent risk factor for SAH and indicates a 
poorer prognosis following SAH in both sporadic and familial cases 
(Ronkainen 
et al, 1999). First degree relatives of SAH patients are three times more 
likely to 
have hypertension than second degree relatives (Bromberg et al, 1996). There is 
a graded increase in risk with increase in blood pressure 
(Leppala et al, 1999). 
Hypertension and its sequelae are two to threefold more common in SAH cohorts 
than controls (Teunissen et al, 1996, Kissela el al, 2002). Blood pressure spikes, 
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related to normal circadian rhythm and physical exertion, coincide with rupture 
of cerebral aneurysms (Kleinpeter et al, 1995; Vermeer et al, 1997). 
1.2.4.3: ALCOHOL CONSUMPTION: 
Alcohol consumption is not described as a risk factor for IA formation 
(Schievink, 1997). Indeed, alcohol has also been reported to have no significant 
effect on risk of multiple aneurysms (Qureshi et al, 1998; Ellamushi et al, 2001) 
although confounding of such studies by smoking is always a problem. 
With regard to risk of SAH, however, increased risk from alcohol consumption is 
dose-dependent like risk from smoking and hypertension. Meta-analysis 
estimates relative risk between 2.8 and 4.7 from longitudinal studies and odds 
ratio up to 1.5 for case-control studies, based on alcohol consumption of < 150 
g/week and ý! 150 g/week (Teunissen et al, 1996). Kissela et al (Kissela et al, 
2002) reported that 2 or more drinks per day resulted in an SAH OR of 8.5 in 
their US case-control study. 
1.2.4.4: FEMA LE SEX. - 
Female sex is a prominent risk factor for both IA and SAH. Nearly all reported 
case series show an approximate 2: 1 female to male ratio. This applies whether 
ruptured or unruptured lAs are considered (Kongable et al, 1996). Female sex is 
also a risk factor for multiple aneurysms (Qureshi et al, 1998; Ellamushi et al, 
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2001) independent of increased longevity (Kongable et al, 1996) and risk factors 
such as smoking, hypertension and alcohol (Teunissen et al, 1996). 
Hormonal factors have been investigated to explain this marked and highly 
consistent sexual dimorphism but the case in favour is not clear-cut. Most SAH 
in women occurs post-menopause. Premenopausal women were reported to have 
an OR of 0.24 compared with age-matched postmenopausal women (Longstreth 
et al, 1994) but other studies have not found this (Mhurchu et al, 2001). 
Hormone replacement therapy (HRT) following menopause lowers SAH risk by 
perhaps a third or a half (Longstreth et al, 1994; Mhurchu et al, 2001) although 
this may be dependent on smoking history (Longstreth et al, 1994). Decreased 
oestrogen in the absence of HRT is linked to decreased collagen in skin and 
bone; it might be that this also affects collagen levels in arterial walls (Kongable 
et al, 1996). 
Other studies suggest oestrogens are detrimental rather than protective based on 
their ability to stiffen blood vessels and cause hypertension (Okamoto et al, 
2001). Results from a Japanese case-control study suggest that conditions 
associated with high oestrogens, such as lower gravidity or parity and greater age 
during first pregnancy, increased risk of SAH (Okamoto et al, 2001). Contrary 
to this, greater age at first pregnancy has also been reported to lower risk 
(Mhurchu et al, 2001). A meta-analysis concluded that use of high oestrogen 
content oral contraceptive pills (OCPs) was associated with a slight 
increase in 
risk (Johnston et al, 1998). Others have not found an effect (Teunissen et al, 
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1996; Mhurchu et al, 2001) even when oestrogen dosage and duration of use are 
examined (Schwartz et al, 1998). 
1.2.5: EVIDENCE FOR A GENETIC COMPONENT IN INTRACRANIAL 
ANEURYSM FORMATION: 
The nature of the genetic component of familial intracranial aneurysm is, at 
present, unknown. However, its existence is supported by a number of threads of 
evidence. Reviewers often cite three: aggregation in families has been discussed. 
Prevalence in monozygotic twins and the association of lAs with Mendelian 
disorders are also often noted. A fourth, which receives little attention, is the 
evidence from animal studies. 
1.2.5.1. - EVIDENCE FROM TWIN CASES: 
A high degree of phenotypic concordance in monozygotic twins is accepted as an 
indicator of genetic predisposition, particularly in the presence of aggregation in 
other relatives (Hrubec & Robinette, 1984). No large FIA twin studies have been 
published but a number of individual cases have now been described (Brisman & 
Abassioun, 1971; Fairburn, 1973; Wilson & Cast, 1973; Schon & Marshall, 
1984; Lozano & Leblanc, 1987; Hagen et al, 1997; Nakajima et al, 1998; Sharma 
& Brown, 2001). These are notable for the similarity of age at rupture and site of 
IA. These features were first described by Fairburn, who concluded that genetic 
factors should be considered (Fairburn, 1973). Reports of discordant twin pairs 
also exist, but authors suggest this may indicate reduced penetrance or a twin 
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who will later develop lAs (Puchner et al, 1994; Astradsson & Astrup, 2001). 
The concordance in monozygotic twins is accepted to indicate a genetic risk 
factor (Leblanc, 1997). 
1.2.5.2. - EVIDENCE FROMANIA14L STUDIES: 
Animals very rarely develop IAs and there is a lack of spontaneous animal 
models (Dobrin, 1999). Only a single spontaneous aneurysm in a Sprague 
Dawley rat, with comparable histopathology to human aneurysms, has been 
reported (Kim & Cervosnavarro, 1991). Thus, IA work in animals relies on 
intervention to induce aneurysms. Coutard and colleagues have attempted to 
address this deficit. They reported age and hypertension-dependent spontaneous 
formation of aneurysmal-like structures (ALS) in the rat testicular artery. These 
were regions of widened lumen lacking internal elastic lamina and medial 
smooth muscle cells. They showed that formation of ALS was strain-dependent 
and not entirely explained by blood pressure (Coutard & OsbornePellegrin, 1992; 
Coutard & OsbornePellegrin, 1996). Later work demonstrated strain effects on 
formation of induced aneurysms in Brown Norway (BN), Long Evans (LE) and 
Wistar Kyoto rats. The authors implicated a genetic predisposition as the 
underlying cause (Coutard & OsbornePellegrin, 1997). More recently, the same 
group showed that, on induction of hypertension, LE rats were more susceptible 
to lAs at the Circle of Willis. BN rats were prone to intracerebral haemorrhagic 
lesions. They crossbred these strains showing that FI animals did not form lAs. 
However, FI rats backcrossed to the LE strain and rats of the F2 generation 
developed aneurysms and more ruptured than in the parental LE strain. The 
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authors suggested that recessive genetic factors from the LE strain determined 
formation of the aneurysms, whilst arterial fragility genes from the BN strain 
conferred greater risk of aneurysm rupture (Coutard et al, 2000). 
1.2.5.3: EVIDENCE FROM MENDELIAN DISORDERS: 
The most widely discussed evidence for a genetic component in IA aetiology is 
the association of monogenic connective tissue disorders with occurrence of IA. 
Case reports describe cosegregation of lAs and several connective tissue 
disorders in individuals (Schievink, 1997). For most, there is a shortage of 
detailed epidemiological study. However, study has been made of autosomal 
dominant polycystic kidney disease, Marfan syndrome and Ehlers-Danlos 
syndrome type IV. 
1.2.5.3.1: Autosomal Dominant Polycystic Kidney Disease: 
ADPKD is characterised by the development of renal cysts on nephrons and 
collecting ducts, typically leading to end-stage renal failure by late middle age 
(Peral et al, 1997; Parnell et al, 1998). It also affects the liver, spleen, pancreas 
and seminal vesicles or ovaries, and features systemic arterial dissections and 
aneurysms. Thus, it is considered a connective tissue disorder (Schievink, 1997; 
Schievink, 1998). ADPKD is the only connective tissue disorder which has been 
conclusively linked to lAs, to date (Leblanc, 1997). Intracranial aneurysms are 
found in approximately one quarter of ADPKD patients at autopsy and 
aneurysmal rupture is the cause of death in the majority of these patients. 
46 
Conversely, ADPKD accounts for only 2% to 7% of intracranial aneurysms 
(Schievink, 1998). 
The vast majority of ADPKD cases, perhaps 85-90%, are due to mutations in the 
polycystin-I (PKDI) gene on l6pI3.3 (Parnell et al, 1998; Torra et al, 1999). 
Most remaining cases are due to the PKD2 locus on chromosome 4q2l -q22 
(Torra et al, 1999). Nonsense and frameshift mutations have been described 
throughout the PKD I (Roelfsema et al, 1997) and PKD2 genes (Peral et al, 
1997; Aguiari et al, 1999). PKDI encodes polycystin-I which is a membrane- 
associated glycoprotein thought to act as a G-protein coupled receptor (Pamell et 
al, 1998). The product of PKD2 is polycystin-2. It is thought to be a cation 
channel subunit, based on sequence homology with a family of voltage-gated 
cation channels (Parnell et al, 1998) including the PCL gene, which is a channel 
for Ca 2+ 5 K+ and Na+ when expressed 
in oocytes (Chen et al, 1999). 
Polycystin-I and polycystin-2 interact via coiled-coil domains and PKDI may 
regulate PKD2 function (Qian et al, 1997). Studies of the C. elegans 
homologues, lov-1 andpkd-2, show that they are involved in the same signalling 
events during mating (Barr & Sternberg, 1999). This implies interactions 
between them but how this leads to cyst and aneurysm formation is not clear. 
1.2.5.3.2: Marfan syndrome: 
Marfan. syndrome is an autosomal dominant disorder characterised by 
abnormalities of the skeleton, cardiovascular system, eye and spinal meninges 
(Schievink, 1997). Spontaneous aortic rupture and dissection are the most 
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common causes of mortality in adults (Schievink, 1997). Marfan syndrome is, 
clinically, highly variable (Pereira et al, 1994). 
Marfan syndrome's association with intracranial aneurysms is a vigorously 
contested issue. More than 10 case reports describe Marfan syndrome patients 
with lAs (for example: (Higashida et al, 1988; Hainsworth & Mendelow, 1991; 
Rose & Pretorius, 1991). Association has been suggested based on lAs in two of 
seven patients with Marfan syndrome at autopsy (Schievink, 1997). However, 
no evidence of symptomatic lAs was found in 135 Dutch patients with Marfan 
syndrome after 4.5 year follow-up (van den Berg et al, 1996) and a US review of 
25 Marfan autopsies found no evidence of associated lAs (Conway et al, 1999). 
In addition, no cases of Marfan syndrome were found in case series of 826 (van 
den Berg et al, 1996) and 710 individuals undergoing surgery for lAs (Conway et 
al. 1999). 
Marfan is caused, possibly exclusively, by mutations in the FBNI gene on 
chromosome 15q21.1 encoding the extracellular matrix protein fibrillin. Fibrillin 
is an integral component of microfibrils in both elastic and non-elastic tissues 
(Alberts, 1999). Missense mutations were first described by Dietz et al (Dietz et 
al, 1991) and it is now known that mutations tend to be specific to one family 
(Nijbroek et al, 1995). 
Site of mutation within the FBNI gene may explain some of the clinical 
heterogeneity since a number of studies have noted that neonatal and severe 
cases arise from mutation of the central domains of the gene (Kainulainen et al, 
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1994), (Nijbroek et al, 1995). This determines whether variant fibrillin- I fibres 
incorporate into a microfibril and exert a dominant-negative effect. Until the 
relationship between mutation and phenotype is fully understood, it will be 
difficult to clarify the involvement of IAs in Marfan syndrome. 
1.2.5.3.3: Ehlers-Danlos Syndrome type IV: 
Ehlers-Danlos Syndrome type IV (EDS IV) is an autosomal dominant connective 
tissue disorder characterised by the spontaneous dissection, rupture or aneurysm 
formation of large and medium-sized arteries. The association of EDS IV with 
intracranial aneurysms is controversial. Case reports of cosegregation do exist 
(Dewazieres et al, 1995; DeWitte et al, 1997) although these are rare (Leblanc et 
al, 1990). Carotid-cavernous fistulae, derived from aneurysms, are described as 
common complications of EDS IV by some (Schievink et al, 1994) but should be 
considered as distinct from saccular aneurysms according to others (Leblanc et 
al, 1990). There appears to be no debate, however, that EDS IV does result in 
fragile cerebral arteries (Pope et al, 1991). However, a study in the US of 202 
patients with EDS IV showed no increase in IAs compared with the general 
population (North et al, 1995). 
Ehlers-Danlos syndrome type IV arises from mutations in the COUAI gene 
encoding collagen type III which is a structural protein widely distributed in 
blood vessels (Pope et al, 1996). Much of the CODAI gene encodes a triple 
helix consisting of an uninterrupted sequence of Gly-X-Y amino acid cassettes. 
'X' and 'Y' are frequently proline or lysine (Pope et al, 1996). Mutations 
include point mutations, which alter Gly residues, small deletions, mutations 
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activating cryptic splice sites and exon-skipping mutations (Chiodo et al, 1995; 
Byers, 1995; Schwarze et al, 1997). 
Mutations disrupting the triple helix affect folding and secretion of the protein 
(Narcisi et al, 1993). Those closest to the C terminal have the greatest effect 
(Mackay et al, 1996) and correlation between site of mutation and clinical 
features has been noted. For example, the region between amino acids 910 and 
1021 is implicated in lethal arterial complications (Pope et al, 1996). It is the 
opinion of many that rarer type III collagen genetic mutants are associated with 
cerebrovascular abnormalities (Pope et al, 1990). Whether there is a firm link to 
lAs remains to be answered. 
1.2.6: ROLE OF GENETICS IN TREATMENT OF INTRACRANIAL 
ANEURYSMS: 
Overall, detection and elective surgery of lAs is preferable to emergency surgery 
after SAH. Meta-analysis of case series from around the world showed mortality 
of I% and morbidity of about 4% for elective surgery (King et al, 1994). The 
international ISUIA study, considering the outcome of over 1,400 IA patients, 
estimated combined surgical morbidity and mortality at 13 to 17%. However, 
this still compares well with 50% and 35% respectively, post-SAH (Gaist et al, 
2000). However, as already stated, many lAs remain asymptomatic (Schievink 
et al, 1994) and only a minority rupture. It is important to establish whether 
subgroups of high-risk patients are identifiable, and what the rupture risk of a 
particular aneurysm is (White & Wardlaw, 2003). Identifying candidates 
for 
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surgery is not trivial, requiring expensive screening which itself may carry a risk 
of complications. For example, conventional catheter angiography may be 
complicated in 1.8% and fatal in 1% of cases (van Gijn & Rinkel, 2001). 
Current management guidelines of FIA families issued by the American Heart 
Association Stroke Council suggest screening on an 'individual basis' (Bederson 
et al, 2000). This essentially admits that no cohesive strategy exists. Several 
studies have attempted to model the benefits and risks of screening. Findings 
have suggested that screening can extend life expectancy (Leblanc et al, 1994), 
but is not beneficial in families with less than three affected individuals 
(Crawley et al, 1999). Modelling of various incidences and rupture rates led 
Obuchowski et al to recommend a compromise of one screening at age 30 or 
younger. However, it was noted that any screening protocol is ineffective in 
cases where lAs form and rupture rapidly, or form then stabilise. This will only 
identify low risk cases (Obuchowski et al, 1995). Wiebers et al observed that 
lAs over 10 mm ruptured in a series of 160 IA patients, but the average size at 
rupture at their institution was 7.5 mm. They concluded that lAs form and 
rupture at small sizes or stabilise depending on vessel wall elasticity. If they 
stabilise, they rupture when larger than 10 mm (Wiebers et al, 1987). The size 
dependency of rupture has been noted by others (Rinkel et al, 1998; Raaymakers 
et al, 1999; Wiebers et al, 2003). 
Many authors recommended screening in families with a strong history, based on 
their clinical experience (Schievink et al, 1991; Alberts et al, 1994; Ronkainen et 
al. 1994). Ronkainen et al advocated a 
dynamic individual approach based on 
ýI 
the history of the family, for example screening at the same age as a patient's 
sibling or relative ruptured (Ronkainen et al, 1996). However, retrospective data 
from the ISUIA study suggested that annual rupture rates of lAs are lower than 
was previously believed; 0.05% for lAs less than 10 mm and 0.5% for lAs over 
10 mm. Risk of rupture was dependent on personal history of SAH, location and 
size of IA (Wiebers et al, 1998). The same study recently published the first 
prospective data on lAs which supported the retrospective findings (Wiebers et 
al, 2003). Overall, many now argue that there is a strong case against screening 
for IAs (Kirkpatrick & McConnell, 1999; Crawley et al, 1999; White et al, 
1999). This is based on low rupture rates, the fact that screening is expensive 
and will identify low-risk lesions, and that risks of surgical intervention in such 
low-risk cases outweigh the reduction of rupture risk. 
One way forward from this conundrum is to identify which individuals are most 
at risk. More information is needed on the genetic basis and inheritance patterns 
of IA and SAH (White et al, 1999). An understanding of the genetics of FIA 
formation and rupture may open the door to cheap and simple testing, and 
prophylactic treatment. This would reduce the risk and expense of screening 
and, importantly, surgical intervention. The knowledge might also 
be 
extrapolated to sporadic IA and SAH treatment. 
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1.3: STRATEGIES FOR THE DISSECTION OF COMPLEX TRAITS: 
The challenge of dissecting complex disorders is immense due to small 
individual gene effects, gene-gene interactions and gene-environment 
interactions, genetic heterogeneity, phenocopy and incomplete penetrance 
(Lander & Schork, 1994; Tabor et al, 2002). The underlying gene variants may 
be common - the 'common disease, common variant' hypothesis - as seen for 
the ApoE4 allele in Alzheimer's disease and the insulin gene minisatellite in type 
I diabetes. Others argue a larger pool of less common variants may be more 
likely. The truth may lie somewhere between these extremes (Johnson & Todd, 
2000). Genetic strategies evolve continually in the face of this challenge. In 
humans, these include study of rare Mendelian disorders, genome-wide scanning 
strategies and candidate gene approaches (O'Shaughnessy, 2001). In animal 
models, genome-wide scans have been confirmed by congenic strain production 
leading to target genomic regions (Stoll et al, 1999; Dominiczak et al, 2000). 
Mendelian disorders relevant to hypertension and intracranial aneurysms are 
described in Sections 1.1 and 1.2. The other strategies will now be discussed. 
1.3.1: GENOME-WIDE SCANS: 
Genome-wide scans (GWS) allow screening of the entire genome in the absence 
of any a priori hypothesis regarding location or function of causative genes. 
Traditionally, GWS studies have involved linkage analysis which detects 
cosegregation of a marker and phenotype in relatives. Such studies reveal 
regions of linkage which provide targets for ffirther detailed study (Dominiczak 
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et al, 1998). In studies examining continuous traits, these regions of linkage are 
known as quantitative trait loci (QTL). Linkage studies originally used single 
restriction fragment length polymorphisms (RFLPs) in Mendelian diseases 
(Botstein et al, 1980). This expanded to encompass heterogeneous disorders. 
then the entire human genome (Lander & Botstein, 1986), before adaptation to 
experimental models (Lander & Botstein, 1989). RFLPs were soon replaced by 
microsatellite markers which are more common and more suitable to high 
throughput systems. 
There are now many reported genome-wide scans of complex traits (Altmuller et 
al, 2001) and it is well recognised that agreement between them is limited. Their 
widespread use has resulted in great debate regarding interpretation of results and 
issues of statistical significance. Lander and Kruglyak were the first to suggest 
guidelines for reporting linkage (Lander & Kruglyak, 1995). They set stringent 
thresholds of significance, dependent on study design. For sib pair studies, for 
example, these were logarithm of odds (LOD) ý! 3.6; Z ý! 4.1; P :! ý 2xl 0-55 
equating to a corrected 95% confidence level. Others argued for lower 
stringency, used a less demanding model to reduce false negatives, and suggested 
P:! ý 0.0023 as significant (Rao & Province, 2000). What has become clear is that 
reproduction in different studies is key (Krushkal et al, 1999). 
1.3.1.1. - GENOME- WIDE SCANS FOR ESSENTIAL HYPER TENSION: 
At present, there are more than 25 genome-wide scan studies relating to blood 
pressure (Table 1.3.1). Most report nominal or suggestive linkages with only 
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(Levy et al, 2000; Allayee et al, 2001; Kristjansson et al, 2002; Angius et al, 
2002) reaching the stringent genome-wide significance levels of Lander and 
Kruglyak (Lander & Kruglyak, 1995). It is notable that two of these studies were 
in relatively isolated populations (Kristjansson et al, 2002; Angius et al, 2002), 
although Angius et al only reached genome-wide significance on increasing 
marker density across a suggestive locus. The Framingham study is unique in its 
use of a longitudinal blood pressure phenotype (Levy et al, 2000). 
The diversity of the studies is emphasised by Table 1.3.1. The first reported 
GWS (Krushkal et al, 1999) analysed SBP using a discordant sib pair design, 
sampling individuals from the top and bottom quintiles of blood pressure 
distribution in the US. Since then, studies in unselected sib pairs, affected sib 
pairs, nuclear families, extended families and large single pedigrees have also 
been reported. These have been selected from families ascertained by blood 
pressure alone, or with diabetes (Hsueh et al, 2000), obesity (Rice et al, 2000),, 
familial hyperlipidaernia (Allayee et al, 2001), early-onset hypertension (von 
Wowern et al, 2003) or early-onset cardiovascular disease (Camp et al, 2003). 
South East Asian, Northern European, Southern European, African, and Hispanic 
ethnic groups are represented. Outbred populations predominate, but isolated 
communities such as the Old Order Amish (Hsueh et al, 2000), Sardinian 
villagers (Angius et al, 2002) and rural Chinese individuals (Gong et al, 
2003) 
have been studied. Phenotypes tested encompass hypertension status and 
quantitative phenotypes for SBP, postural SBP, DBP and pulse pressure 
(PP) 
Some studies also examined effects of fitness training (Rankinen et al, 
2001; 
Rice et al, 2002). 
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The major QTL from each study are shown in Figure 1.3.1. There is clearly no 
single, major locus across all populations. Areas of linkage have been found on 
the majority of human chromosomes. This probably reflects genetic 
heterogeneity of blood pressure control and hypertension (Samani, 2003), the 
propensity for false positives in genome-wide scans (Lander & Kruglyak, 1995) 
and/or the variability of study design (Munroe & Caulfield, 2000). 
Some QTL have been detected in multiple studies. Primary among these is the 
locus on 2pI 1.2 which has been linked to SBP in Canadian whites (Rice et al, 
2000) and DBP in Mexican Americans (Atwood et al, 2001) and Nigerians 
(Cooper et al, 2002). In all three studies, linkage peaked at the same marker, 
D2s 1790. Proximal QTL on 2p have also been reported for SBP in US blacks 
(Rice et al, 2002; Rao et al, 2003) and whites (Krushkal et al, 1999), whilst 
genome scans for preeclampsia, a pregnancy-associated hypertensive disorder, 
have reported linkage to 2p13 (Amgrimsson et al, 1999; Moses et al, 2000). 
Recent work has suggested the sodium bicarbonate gene, SLC4A5, as a 
positional candidate in the 2p QTL following analysis of multiple, intragenic 
single nucleotide polymorphisms (Barkley et al, 2004). Other QTL seen in 
multiple independent studies also exist on lp, lq, 3p, 6q, 7q, 8q, 1 lq, l5q, 18q 
and 19p (Fig. 1.3.1). 
Some QTL have been reproduced, in independent samples, by the reporting 
authors thus strengthening the case for their existence. Linkage of DBP to 15q25 
was shown in Chinese siblings (Xu et al, 1999). Confirmation was shown 
in a 
second independent cohort of low DBP siblings, with the 
LOD score increasing 
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from 2.7 to 3.2 at the same marker, D15s657. Increasing the marker density in 
this locus from an average spacing of 10 cM to 2 cM resulted in a LOD score of 
3.77 (Xu et al, 1999). Zhu et al (Zhu et al, 2001) also used a fine mapping 
approach in an independent sample of Han Chinese. A marker spacing of 2 cM 
resulted in a multipoint Z score of 3, confirming linkage of hypertension to 2q2l. 
The heterogeneity of hypertension and blood pressure control is a major hurdle 
for GWS studies. The lack of agreement between studies has led some to 
suggest, retrospectively, that analysis of subgroups may improve this. It is 
argued that a more homogeneous study sample may improve power, where 
simply increasing numbers of subjects has failed (Samani, 2003; Lalouel, 2003; 
Harrap, 2003). This notion is strengthened by data from the Family Blood 
Pressure Program (FBPP) meta-analysis (Province et al, 2003). Analysis of over 
6,000 individuals pooled from black, white, Hispanic and Asian cohorts failed to 
improve on LOD scores obtained in the individual groups (Province et al, 2003; 
Lalouel, 2003). 
Some studies have already attempted to address the issue of heterogeneity by 
stringent recruitment policies. The best example is the BRIGHT Study from the 
UK which is also the largest single hypertension GWS to date (Caulfield et al. 
2003). BRIGHT recruited phenotypically-extreme affected sib pairs in the top 
5% of blood pressure distribution from the Caucasian population. Thus, subjects 
had blood pressures over 1501100 mmHg as determined at a single screening. In 
addition, age at onset of hypertension was below 60 years. The study aimed to 
-2 
recruit individuals with BMI less than 30 kg M, and was 80% successful in this. 
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Those with high alcohol consumption, diabetes or renal disease were excluded. 
This stringent recruitment enriched the sample for linkage information to 
hypertension loci, reduced heterogeneity and maximised power for the 2,010 sib 
pairs analysed. With this rigorous design and large size, the maximum LOD 
score obtained was 3.21 at 6q27 (Caulfield et al, 2003). 
1.3.1.2. - GENOME-WIDE SCANS FOR FAMILIAL INTRACRANIAL 
ANEURYSMAND SUBARACHNOID HAEMORRHAGE. - 
There are inherent problems in performing GWS studies of familial IA or SAH 
due to the high mortality, difficulties of determining affection status and potential 
for misclassification. Thus, any GWS in FIA or SAH is a major undertaking and 
must rely on an affected patient strategy. At present two GWS have been 
reported. Onda et al (Onda et al, 2001) used a suitably focused strategy in an, 
inevitably, small study of 104 Japanese affected sib pairs, most of whom had 
suffered IA ruptures. Two-point linkage highlighted three regions on 5q22,7ql I 
and 14q22 for fine mapping. Multipoint analysis gave LOD scores of 2.24,3.22 
and 2.31 respectively. Yamada et al aimed, but failed, to reproduce the results of 
Onda (Yamada et al, 2003). However, with mostly unruptured cases and 
different markers this is difficult to interpret. A recent US study showed linkage 
to 7ql I in 13 extended Utah families with 39 IA cases. Multipoint analysis of 
three markers across the region gave LOD = 2.34 (Farnham et al, 2004). 
Olson et al (Olson et al, 2002) used 48 Finnish affected sib pairs for their GWS. 
They also focused fine mapping efforts by initial linkage analyses. Of seven 
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regions, which were fine mapped, the most promising multipoint LOD score of 
2.6 was obtained for chromosome l9q. No QTL overlay those of the Japanese 
study. However, the two studies were performed in distinct ethnic groups and 
Finnish IA cases may be particularly atypical. SAH history in the Finnish 
patients was also disregarded. 
1.3.2: CANDIDATE GENE STUDIES: 
1.3.2.1. - EVIDENCE-BASED CANDIDATE GENE SELECTION: 
In contrast to the genome-wide approach, candidate genes studies are entirely 
based on a priori hypotheses. Lack of reproducibility of candidate gene studies 
in complex traits has led to recommendations for a multifaceted selection 
strategy. Thus, type of phenotype and risk factors; heritability; mode of 
inheritance; penetrance; tissue-specific expression studies and animal model 
evidence may be used when assessing the potential pathophysiological role of a 
gene (Tabor et al, 2002). 
Useful leads can be derived from many sources. Study of Mendelian disease 
suggests physiological pathways involved in the regulation of complex traits 
(Dominiczak et al,, 1998). Study of complex traits and intermediate phenotypes 
increases knowledge of interacting systems and possible pathophysiological 
processes (Dominiczak et al, 1998). Genome-wide scans implicate genomic 
regions and the positional candidate genes within them. QTL may be large (Lee 
et al, 2000), and contain many genes, but narrow the field considerably. 
Rodent 
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QTL can be transferred to the equivalent 'syntenic' chromosomal region(s) in 
humans - so-called 'comparative mapping' (Gauguier et al, 1999; Stoll et al, 
2000). Candidate gene and biochemical studies in animals, and knock-out or 
knock-in mouse models, implicate homologous genes in humans (Dominiczak et 
al, 1998). Increasingly, microarray technology is being used to provide genome- 
wide gene expression data (Aitman et al, 1999; McBride et al, 2003). 
1.3.2.2. - ASSOCIATION, LlNK, 4GE DISEQUILIBRIUM & HAPLOTYPE TAGS: 
A candidate gene study most often tests for association of polymorphic markers 
with trait, although linkage analysis may also be used. Association to a trait is 
demonstrated by allele-specific frequency differences between affected and 
unaffected samples. This is distinct from linkage which compares the inheritance 
of a marker and a trait amongst relatives and is not allele-specific. Association is 
strongest when the polymorphism being tested is the causative locus underlying 
the trait (Risch & Merikangas, 1996). Otherwise, any marker tested is a 
surrogate for the disease locus and must be in linkage disequilibrium (LD) with 
the disease locus. 
LD is a short-range effect compared to linkage (Kruglyak, 1999). It is a non- 
random association of alleles at adjacent loci (Ardlie et al, 2002), for example a 
marker locus, M, and a disease mutation locus, D. LD is proportional to distance 
between loci at distances over 60kb; below this the relationship is non-linear 
(Wright ei al, 1999; Drysdale et al, 2000). LD is said to be high if the allele at M 
predicts the allele at D. If there is little or no relationship between M and D, LD 
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is low (Remm & Metspalu, 2002). LD is affected by recombination, the number 
of original founder mutations, natural selection, population structure and allele 
frequency (Weiss & Clark, 2001; Zondervan & Cardon, 2004). 
Simulations by Risch and Merikangas showed that the power of association to 
detect small gene effects exceeds that of linkage (Risch & Merikangas, 1996). 
Therefore, association methods have been applied to microsatellite markers and, 
more commonly, single nucleotide polymorphisms (SNPs) to interrogate 
candidate genes. SNPs are now more commonly used because they are the most 
common genomic variation in species (Jordan et al, 2002; Gabriel et al, 2002), 
may affect gene function and are well suited to high-throughput genotyping 
(Syvanen, 2001). 
As a rule, SNPs within candidate genes have been studied as individual loci 
(Sharma & Jeunemaitre, 2000). However, haplotype tagging approaches have 
recently been developed (Johnson et al, 2001). These make use of the fact that 
small blocks of the genome appear to undergo relatively little recombination, and 
SNPs within these regions segregate into distinct haplotypes. These 'haplotype 
blocks' of I Kb to 100 Kb have been reported by a number of studies (Daly et al, 
2001; Dawson et al, 2002; Gabriel et al, 2002) and are separated by 'hot spots' 
of recombination (Maniatis et al, 2002). Common haplotypes can be 
determined 
by genotyping specific haplotype tag SNPs and can allow interrogation of 
regions with the minimum of genotYPing. However, this requires prior 
knowledge of LD within the local region (Johnson et al, 2001) and detailed 
haplotype and LD map construction is underway (Gibbs et al, 2003). Such 
65 
haplotype tagging methods have been used recently in common disorders to 
investigate small regions and specific candidate genes (Drysdale et al, 2000; 
Rioux et al, 2001; Gretarsdottir et al, 2003). 
1.3.2.3: CANDIDATE GENE STUDIES FOR ESSENTIAL HYPERTENSION 
AND BLOOD PRESSURE PHENOTYPES: 
Many genes, to a greater or lesser extent, have been investigated as hypertension 
candidates. In general, lack of reproducible evidence means that most are still 
candidates but no more. Some examples are discussed below. 
1.3.2.3.1: Angiotensinogen: 
Angiotensinogen (AGT) is the precursor of angiotensin I and, ultimately, 
angiotensin Il (Ang II). Ang 11 regulates aldosterone production by aldosterone 
synthase which determines sodium reabsorption via ENaC in the distal tubule 
(Morgan et al, 1996) (See Fig. 1.1.4). Jeunemaitre et al (Jeunemaitre et al, 
1992b) demonstrated linkage of a microsatellite in the 3' region of the AGT gene 
to hypertension, association of the M235T polymorphism to hypertension, and 
variation of circulating AGT levels with M235T genotype in French and US 
sibling pairs. Caulfield et al (Caulfield et al, 1994) examined a proximal 
dinucleotide repeat and the intragenic M235T and T174M polymorphisms in 63 
white, European families. Linkage and association of hypertension to the 
dinucleotide repeat, but not the other polymorphisms, was shown. Later work in 
African Caribbean sib pairs similarly showed linkage and association to the 
dinucleotide repeat only (Caulfield et al, 1995). 
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Subsequent studies of AGT polymorphisms have found no association with 
hypertension (Corvol et al, 1999), nor linkage to hypertension even in the 
phenotypically extreme resource of the BRIGHT Study (Munroe et al, 2000). 
However, meta-analyses of the M235T polymorphism across multiple ethnicities 
(Staessen et al, 1999), Japanese studies (Kato et al, 1999) and Caucasian studies 
(Kunz et al, 1997) all demonstrate a weak, but significant, association of the T 
allele with hypertension. It is possible that the effect of the AGT locus is more 
pronounced in white and younger individuals (Staessen et al, 1999). The M235T 
locus is in linkage disequilibrium with a promoter substitution, A(-6)G, known to 
enhance gene transcription (Inoue et al, 1997). Elegant observations in mice 
show that blood pressure increases as AGT gene copy number, and expression, 
increase (Kim et al, 1995). 
1.3.2.3.2: Angiotensin converting enzyme: 
The angiotensin converting enzyme (ACE) locus has been the target of intense 
study. It catalyses the conversion of Ang I to Ang 11 (Morgan et al, 1996) (See 
Fig. 1.1.4), affects vascular reactivity and morphology (Lee et al, 2000), and is 
the target of ACE inhibitor anti-hypertensive therapy (Black et al, 1997). Studies 
in Europeans initially suggested no linkage of the ACE locus to essential 
hypertension (Jeunemaitre et al, 1992a). However, the Rochester Family Heart 
study later showed linkage (Fomage et al, 1998) and the Framingham study 
showed linkage and association to blood pressure (O'Donnell et al, 
1998) in 
white, male US population samples. Framingham found that the 
D allele of the 
I/D polymorphism in intron 16 of the ACE gene increased hypertension risk 
in 
men only (O'Donnell et al, 1998). The D allele also associated with 
hypertension 
67 
in Japanese men (Higaki et al, 2000). These significant results contrast with an 
earlier meta-analysis of 23 I/D studies which comprised nearly 7,000 pooled 
subjects for hypertension (Staessen et al, 1997) and showed no association to the 
D allele. Meta-analysis of quantitative BP traits in over 12,000 individuals from 
46 studies also showed no association (Staessen et al, 1997). The variability of 
results from studies of the AGT and ACE loci suggests, then, that any effect on 
hypertension risk and blood pressure variation is probably small, and in the case 
of ACE, may be more influential in men. 
1.3.2.3.3: Epithelial sodium channel subunits: 
AGT and ACE have been studied ad infinitum, but systematic assessment of 
Mendelian blood pressure genes, for example the epithelial sodium channel 
subunits, is less common (Lifton et al, 200 1). Linkage analyses of P and y-ENaC 
subunit loci, implicated by their role in Liddle syndrome (Hansson et al, 1995; 
Hansson et al, 1995), have proved non-significant in Chinese hypertensive sib 
pairs (Niu et al, 1999), but positive in white Australian families (Wong et al. 
1999). A case-control study of 206 hypertensives and 142 controls suggested 
association of a T594M variant in the P-subunit with hypertension in UK blacks 
(Baker et al, 1998) who are also more prone to salt-sensitive hypertension 
(Komitzer et al, 1999). However, coding regions of the P subunit gene were 
sequenced in whites and blacks but functional effects of the seven 
polymorphisms found were small and non-significant in Xenopus oocytes. There 
was also no evidence of association of a G589S variant, which had the greatest 
effect on ENaC activity, and hypertension in a single large 
family (Persu et al, 
1998). 
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1.3.2.3.4: Lysine -deficient protein kinase 4: 
Another direct consequence of findings in Mendelian disorders is the recent 
interest in the role of lysine-deficient protein kinase 4 (WNK4) in essential 
hypertension. This follows its implication in PHA II (Wilson et al, 2001) (See 
Section 1.1). Recently, a case-control study showed association of hypertension 
with a single SNP in intron 10 of WNK4 in whites but not blacks (Erlich et al, 
2003). Linkage studies of the genomic region have also been positive in whites 
but not blacks (Julier et al, 1997; Baima et al, 1999). The primary finding of the 
Framingham GWS study was a QTL for longitudinal SBP on chromosome 
17q2 1, the location of WNK4 (Levy et al, 2000). To complete the picture, 
linkage in the stroke-prone spontaneously hypertensive rat model to chromosome 
10 has also been demonstrated (Jacob et al, 1991), although recent sequencing 
and transcription studies of rat Wnk4 have not supported its role (Monti et al, 
2003). 
1.3.2.4: CANDIDATE GENE STUDIES FOR FAMILIAL INTRACRANIAL 
ANE UR YSMS AND SUBARA CHNOID HAEMORRHA GE. - 
The cosegregation of lAs and connective tissue disorders, and expression 
profiling in IA patients, have concentrated candidate gene studies on components 
of vessel structure and remodelling. 
1.3.2.4.1: Elastin: 
Elastin and its primary protease, elastase, are key to the elastic properties of the 
artery. Reduced elastin in aortic aneurysms has 
been reported (Minion et al. 
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1994). Aortic or intracranial aneurysms develop in transgenic mice with 
compromised elastin genes or lysyl oxidase, the latter being required for correct 
elastin synthesis (Sechler et al, 1995; Coutard, 1999). Inhibition of elastin 
crosslinking by P-aminopropionitrile leads to experimental IA formation 
(Yamazoe et al, 1990). 
The Japanese GWS by Onda et al implicated the elastin locus at 7ql I (Onda et 
al, 2001). They followed this with haplotype analysis of SNPs in the gene, 
finding a strong association of a 2-locus haplotype with intracranial aneurysms. 
This equated to an odds ratio of 4.39 for homozygous carriers of this haplotype. 
A European study was unable to demonstrate a similar association in a case- 
control study using IA patients with mostly unknown family history (Hofer et al, 
2003). Further clarification of the role of elastin in aneurysm development is 
needed (Zhang et al, 2003). 
1.3.2.4.2: Collagen type 1 u2: 
The COLIA2 gene is located on 7q22.1 and encodes collagen type I a2, one of 
the most abundant structural proteins in vertebrate connective tissue. 
Overexpression in IA tissue has been reported (Peters et al, 2001). On the 
strength of this and its location, the COLIA2 gene was investigated 
by the 
Japanese GWS group as a second positional candidate near 7ql 1 (Yoneyama et 
al, 2004). Association was seen to an Ala --+ Pro polymorphism 
in exon 28 in 
260 cases and 293 controls. Functional studies suggested that this affected 
the 
melting temperature of the triple helix. 
However, with an 8% frequency in 
familial IA cases it may only account for a proportion of IA (Yoneyama et al, 
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2004). Confirmation of this is needed but there is, at present, no other study for 
IA and only one in aortic aneurysmal disease which showed no linkage to the 
locus in sib pairs (van Vlijmen-van Keulen et al, 2003). 
1.3.2.4.3: Matrix metalloproteinases and their inhibitors: 
Matrix metal loproteinase s (MMPs) have wide-ranging roles in protease 
activation, structural protein degradation and tissue remodelling (Nagase, 1997). 
Their increased expression in IAs has been shown in several studies (Chyatte & 
Lewis, 1997). Peters et al (Peters et al, 1999) showed association of a 
dinucleotide repeat in the promoter of MMP9 in a US case-control study. 
Interestingly, the polymorphism affected gene expression in fibroblasts. 
However, only 10% of cases had a confirmed family history of IA. A Finnish 
study using 57 familial cases (Yoon et al, 1999), and a UK study with 92 mixed 
cases (Zhang et al, 2001), were also negative. Promoter polymorphisms of 
MMP 1,3 and 12 also showed no association in the latter study. 
Tissue inhibitors of metalloproteinases (TIMPs) regulate the activity of MMPs 
(Nagase, 1997). Their elevated expression has also been demonstrated in IA 
tissue (Kim et al, 1997). Krex et al (Krex et al, 2003) studied TIMPS 1,2 and 3 
in 44 cases and controls. Polymorphisms were discovered by sequencing of the 
coding and promoter regions of the three genes, but there was no association to 
any of the loci. This agreed with earlier work on TIMP I and 2. A SNP in each 
gene, discovered by sequencing, showed no association in a small number of IA 
patients, although an nt573 polymorphism in TIMP2 was more common 
in aortic 
aneurysm patients (Wang et al. 1999). 
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1.3.3: REDUCING THE COMPLEXITY: USE OF EXPERIMENTAL 
MODELS: 
Use of animal models in complex disease genetics allows tight control of 
environmental factors, rapid breeding and large litters. Late onset disorders, 
taking decades in humans, present within weeks in animal models. Mating pairs 
can be selected for informativeness and inbred strains simplify the genetics of the 
experimental trait under investigation (Dominiczak et al, 2000). 
1.3.3.1. - RA T MODELS OF GENETIC HYPER TENSION: 
Traditionally, the rat has been the model of choice in essential hypertension 
research. Multiple inbred strains now exist which were selectively bred for 
blood pressure phenotypes (Table 1.3.2). It is important to note that these 
experimental strains develop a continuously distributed, complex hypertensive 
trait under Oli9O- or polygenic control (Rapp, 2000). 
1.3.3.1.1: Genome-wide scans in rat models of hypertension: 
Genome-wide scans have been widely published in rat models (Jacob et al, 1991; 
Schork et al, 1995; Clark et al, 1996; Kovacs et al, 1997). The concept is very 
similar to that in human populations. Essentially, two inbred strains discordant 
for the trait of interest are bred together to generate an F1 population which is 
then brother x sister mated to produce an F2 population. In the case of a 
quantitative trait, like blood pressure, this F2 population will represent the full 
distribution of that trait between the normotensive and hypertensive rat strains 
72 
used (Lee et al, 2000). Linkage analysis of microsatellites across the genome 
leads to the identification of QTL as in the human paradigm. QTL for blood 
pressure phenotypes of 20-30 cM (Dominiczak et al, 2000) have been reported 
on the majority of rat chromosomes through use of different inbred crosses (Lee 
et al, 2000) (Table 1.3.3). Since all rats of an inbred strain are, by definition, 
genetic clones, modelling of the genetic heterogeneity inherent in human 
populations is achieved by use of various crosses. 
1.3.3.1.2: Congenic rat strains: 
It is once the GWS has been completed and thus when QTL need to be 
confirmed, and genes positionally cloned, that rat models come into their own. 
The effect of a QTL can be directly proved by the production of congenic strains 
achieved by breeding parental strains together and then selectively back-crossing 
the offspring to one or other of the parental strains. The resultant congenic 
strains are homozygous for a specified chromosomal segment from strain A in a 
genome otherwise derived from strain B. Two lines can be made, one in which 
the QTL from the hypertensive strain is introgressed into the normotensive 
background and a reciprocal strain in which the converse is true. If the QTL is 
genuine, BPs of these two congenic strains should be higher than the 
normotensive strain and lower than the hypertensive strain, respectively. This 
provides proof-positive of the existence of relevant genes in the QTL (Rapp, 
2000), an option not available in human studies. 
By breeding of substrains, congenic regions can be narrowed, ultimately 
allowing more precise positioning of causative genes. 
Theoretically, the 
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Table 1.3.3: Quantitative trait loci for blood pressure in rat genome-wide scans 
Chr 
2 
3 
4 
5 
10 
13 
16 
17 
18 
19 
20 
x 
y 
WKY = Wistar-Kyoto; SHRSP = stroke-prone spontaneously hypertensive; izm = Izumo; 
Hd = Heidelberg; gla = Glasgow; Dahl SS = Dahl salt-sensitive; Sabra HR = Sabra 
hype rtens i on-res i stant; Sabra HP = Sabra hypertension-prone, Lyon-N = Lyon normotensive, 
Lyon-H = Lyon hypertensive; BN = Brown Norway; MNS = Milan normotensive: 
RI(BNxSHR) = recombinant inbred strain from BN x spontaneously hypertensive. N/A 
LOD score not quoted. Taken from Lee et al, 2000. 
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Rat strains 
WKYHdx SHRSPHd 
Lewis x Dahl SS 
Lewis x Dahl SS 
WKY x SHR 
WKY x SHR 
Sabra HR x Sabra HP 
Sabra FIR x Sabra HP 
WKYgIa XSHRSPgIa 
WKY x Dahl SS 
MNS x Dahl SS 
Lyon Nx Lyon H 
BN x SHR 
BN x SHR 
BN x SHR 
WKYgIa XSHRSPg]a 
WKYi,, 
n x 
SHRSPi,.,, 
RI(BN x SHR) 
WKY x SHR 
LEW x Dahl SS 
WKY x SHR 
WKY x SHRSP 
WKY x SHRSPHd 
MNS x Dahl SS 
MNS x Dahl SS 
Lyon-N x Lyon-H 
WKY x SHR 
BN x SHR 
Sabra HR x Sabra HP 
WKY x SHRSPHd 
RI(BNxSHR) 
RI(BNxSHR) 
WKY x SHRSPHd 
WKY x SHR 
Phenotype 
SBP after salt 
SBP 
SBP 
SBP, DBP 
SBP 
SBP after salt 
SBP after salt 
SBP, DBP after salt 
SBP after salt 
SBP after salt 
pp 
SBP 
SBP 
SBP 
SBP after salt 
SBP 
MAP 
SBP, DBP, MAP 
SBP after salt 
SBP 
SBP, DBP after salt 
SBP after salt 
SBP after salt 
SBP after salt 
DBP 
SBP, DBP 
SBP 
SBP after salt 
SBP 
SBP 
SBP 
SBP 
SBP 
Central Marker/ gene LOD score 
Sa 
DIMcol, Cytp450 
Sa 
Sa 
Mtlpa 
DIMit2, Sa 
DIMitl, Cytp450 
D2Mit6, D2Mit 14 
Nakal 
Camk 
Cpb 
Mtlpb 
Gca 
R598 
D3Mghl6 
D3Mghl2 
116 
Npy, Spr 
Glutb, Et-2 
Mitrl678,, Anf, Bnf 
Ace 
Ace 
Nos2 
Ace 
Ren 
D13Mit2 
R220 
DI 7Mgh5 
Rr 1094 
D19Mit7 
Hsp70 
Per-ha2, Per-ha7 
N/A 
N/A 
3.5 
2.5 
4.5,3.8 
3.0 
4.9 
4.7 
3.3,3.1 
3.4 
2.6 
7.0 
3.0 
6.3 
3.0 
5.6 
6.2 
N/A 
N/A 
N/A 
4.2 
N/A 
5.1 
6.3 
4.8 
5.6 
5.7 
4.3 
3.4 
3.2 
N/A 
N/A 
N/A 
N/A 
congenic strategy was thought to allow QTL mapping to aI cM segment, small 
enough to allow sequencing. In reality, it seems that even greater resolution is 
possible with the report of a Dahl Sx Dahl R congenic having an introgressed 
segment < 177 kb in size on chromosome 7 (Garrett & Rapp, 2003). Many other 
congenic strains have confirmed QTL found by GWS on most rat chromosomes 
(St. Lezin et al, 1999; Jeffs et al, 2000; Frantz et al, 2001; Yagil et al, 2003). 
Locus-locus interactions have also been demonstrated by so-called 'double' 
congenics having two introgressed regions. Rapp et al (Rapp et al, 1998) 
showed an interactive effect on blood pressure of QTL on chromosomes 2 and 10 
in a Dahl RxS cross by this method. 
1.3.3.1.3: Comparative mapping: the application of animal data in humans: 
Observations in animal models are only useful if they can be translated to 
humans. There are limited examples of this, at present (Corvol et al, 1999), but 
the following two examples demonstrate the potential. 
1.3.3.1.3.1. - Comparative mapping of a rat bloodpressure QTL to human: 
The rat chromosome 10 blood pressure QTL has already been mentioned in the 
context of ACE and WNK4 studies. It is also the only example of prospective 
mapping of a common rat blood pressure QTL to human. The rat chromosome 
10 QTL was first reported in SHRSP x WKY experimental crosses (Hilbert et al, 
1991; Jacob et al, 1991), confirmed in other strains and proven by congenic 
strain production (Rapp, 2000). On the strength of the evidence in rat, Julier et al 
(Julier et al. 1997) investigated the syntenic region on human chromosome 17 
and showed linkage to hypertension in French and UK sib pairs. Baima et al 
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(Baima et al, 1999) offered some confirmation in a US sample. However. 
studies of Afro-Caribbeans (Knight et al, 2000) and African Americans (Baima 
et al, 1999) have proved negative as have studies in Caucasian populations 
excluding diabetics (Knight et al, 2001; Rutherford et al, 2001). The 
chromosome 17 locus may, therefore, be relevant only in a subset of 
hypertensives (Knight et al, 2003). However, the study by Julier et al illustrates 
the application of comparative mapping to complex disease. 
1.3.3.1.3.2. - a-Adducin. - 
Adducin is a heterodimeric protein consisting of combinations of a, 0 or 
subunits. It regulates cell-signal transduction by changes in the actin skeleton 
(Cusi et al, 1997). The membrane skeleton was implicated in membrane Na+ 
transport differences in Milan hypertensive (MHS) and norynotensive (NfNS) 
rats. Adducin was identified as a potential candidate and non-synonymous Tyr 
to Phe and Gln to Arg polymorphisms were found a and P subunits, respectively 
(Tripodi et al, 1991). These affected protein phosphorylation, and genotypes at 
the loci correlated with blood pressure in an NINS x MHS FI cross, accounting 
for 43% of SBP difference between strains (Bianchi et al, 1994). The same 
group translated these findings to humans, with case-control evidence of 
association of hypertension to markers around the a-adducin locus in Italians 
(Casari et al, 1995), and confirmation in independent Italian and French samples 
(Tripodi et al, 1991). Study of a Gly460Trp polymorphism showed that the Trp 
allele was associated with hypertension, greater sensitivity to body sodium 
levels, and greater response to diuretic treatment (Cusi et al, 1997). Association 
of the Trp allele to hypertension was supported by the US HyperGEN study in 
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whites. However, their findings in blacks suggested no effect of the a-adducin 
locus (Province et al, 2000). Ethnic differences may be important, given other 
negative case-control studies in Japanese (Kato et al, 1998; Ishikawa et al, 1998; 
Ranade et al, 2000) and mixed South East Asian samples (Ranade et al, 2000). 
The involvement in whites may also be complex since studies of blood pressure 
in white US populations report no association of Gly460Trp (Schork et al, 2000; 
Bray et al, 2000a). 
1.3.3.1.4: Mouse models in hypertension research: 
The ability to produce knock-in and knock-out mouse genetic models has 
enabled functional studies of genes in blood pressure regulation. The study of 
Kim et al (Kim et al, 1995) has already been mentioned in the context of 
angiotensinogen. This very elegant work demonstrated an almost linear 
relationship between blood pressure and 0 to 4 functional copies of the murine 
"gt gene expressing in mice. The interaction of renin and angiotensinogen has 
also been demonstrated in mice expressing the human homologues. Both human 
AGT and REN were required for an effect on blood pressure because murine 
renin is ineffective against human angiotensinogen (Murakami & Fukamizu, 
1999). Transgenic approaches have proved informative in the study of many 
components of blood pressure control including enzymes, vasoactive peptides, 
receptors and ion channels (Cvetkovic & Sigmund, 2000). 
The genome-wide approaches used in rat are not as widespread in mouse, partly 
due to difficulties of phenotyping such small animals (Fitzgerald et al, 2003). 
However, at least two GWS have now been reported using F2 crosses of different 
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hypertensive and normotensive mouse strains (Wright et al, 1999; Sugiyama et 
al. 2001). Both report a number of significant loci although none are present in 
both studies. However, the latter noted that, of six QTL, five were concordant 
with rat QTL, and four were concordant with human QTL (Sugiyama et al. 
2001). 
1.3.3.2. - EXPERIMENTAL MODELS FOR INTRACRANIAL ANEURYSMS: 
1.3.3.2.1: Rat models: 
The dearth of genetic rat models of aneurysm formation has been discussed in 
Section 1.2. As noted, with the exception of the work by Coutard and 
colleagues, there has been no genetic study of lAs in rats due, quite simply, to the 
fact that they do not occur spontaneously (Coutard et al, 2000). Induction of 
aneurysms by renal hypertension and carotid ligation is common, and has been 
used to show, for example, changes in vessel wall structure (Kondo et al, 1998). 
Aneurysms have been induced in animals by infusion of large doses of elastase 
which underlines the importance of the extracellular matrix, and elastase itself 
(Miskolczi et al, 1998; Short et al, 2001). However, these models are intended 
for evaluation of surgical devices and are not physiological. 
1.3.3.2.2: Mouse models: 
As with hypertension, mouse models can provide useful data on gene function. 
Knockout mice, which develop arterial aneurysms and ruptures, may suggest 
candidate genes for IA formation. For example, expression of truncated rat 
elastin genes in mice resulted in an emphysematous phenotype 
for genes lacking 
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exon 33, but aortic rupture in mice lacking exons 19-31 (Sechler et al, 1995). 
This suggests potential for considerable variety in effects of elastin mutations, 
including haemorrhagic arteriopathies. Mice null for the lysyl oxidase gene, 
which initiates crosslinking of collagen and elastin fibres, also develop aortic 
aneurysms (Maki et al, 2002). The Blotchy mouse, which has a defective lysyl 
oxidase gene, develops cerebral and peripheral aneurysms with greater ease than 
controls following carotid artery ligation (Coutard, 1999). In mice it has also 
been shown that knockout of matrix metalloproteinase 9 reduces aortic aneurysm 
formation by elastase infusion or application of CaC12 (Pyo et al, 2000; Longo et 
al, 2002). Conversely, disruption of TIMP I function increases aortic aneurysm 
formation in mice (Silence et al, 2002). As has been described, genetic studies to 
follow up such leads have been performed in humans. Unfortunately, this is the 
only option with the present lack of genetic models. 
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1.4: AIMS OF THE STUDY: 
The overall aim of this work was to apply current genetic thinking and strategies 
to the dissection of two complex disorders, essential hypertension and familial 
intracranial aneurysm, in human study samples. Linkage and association 
mapping methods were used to accomplish this, taking into account current 
opinions on best practice. There were three specific aims: 
1. To examine two-point and multipoint linkage of a discrete region on the distal 
arm of chromosome 5 to blood pressure and essential hypertension in the Silesian 
Hypertension Study resource, with confirmation in a Scottish population sample 
from the MIDSPAN Family Study. 
2. To follow up linkage evidence by studying cardiovascular candidate genes 
within the 5q linkage region. This was achieved by linkage and association study 
of known functional polymorphisms within the P2-adrenergic receptor gene, and 
sequencing and study of polymorphic loci in the fibroblast growth factor I gene. 
3. To perform a pilot study of candidate genes of familial intracranial aneurysm, 
concentrating on collagen type III, polycystin I, fibrillin I and serine protease 
inhibitor AI- Linkage and association analyses were applied to a small sample of 
Scottish families. Studies of the serine protease inhibitor Al locus were 
expanded to a combined group including a small number of 
families from the 
south of England. 
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CHAPTER 2 
MATERIALS & METHODS 
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2.1: GENERAL LABORATORY PRACTICE: 
The procedures detailed herein were conducted with appropriate regard for 
safety. Routinely, lab coat and powder-free latex gloves were used as a 
minimum. Laboratory spectacles, facemasks and fume hoods (Holliday, Fielding 
& Hocking, UK) were used as required when suggested by hazard labelling on 
reagents. 
Instrumentation was used following appropriate training. Instruments were 
maintained under contract and calibrated, in line with manufacturer's guidelines, 
where necessary. Software used for collecting and processing data was as 
supplied by manufacturers for the requisite instrument and application. 
Computing equipment was sourced from reputable manufacturers and data 
backed up to appropriate extemal storage media. 
Reagents were of the highest quality available and sourced from specialist 
suppliers. Aqueous solutions were made using autoclaved, deionised water. 
Plasticware was disposable and either sterilised by irradiation or autoclaving. 
Glassware was washed in Decon 75 detergent, rinsed with distilled water and 
dried in an oven at 37'C. Manual liquid handling of volumes from 0.1-5,000 ýtl 
was performed using calibrated Finnpipettes (Life Sciences International, UK) 
and autoclaved tips (Alpha Labs, UK). Automated liquid handling of 5-1,000 ýtl 
volumes was performed by a TECAN Genesis RSP 500 workstation 
JECAN., 
UK) using supplied conductive tips. 
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2.2: STUDY RECRUITMENT AND PHENOTYPING: 
The work detailed in Chapters 3 to 6 used DNA resources collected for three 
separate studies. The studies described were conducted with the approval of the 
appropriate local ethics committees. All recruitment to the studies was with the 
informed consent of the participants. All data collected were anonymised before 
being made available to laboratory staff. 
2.2.1: SILESIAN HYPERTENSION STUDY: 
The Silesian Hypertension Study was based on recruitment of probands with 
diagnosed essential hypertension and their available parents and siblings. 
Recruitment strategies for the study were designed by Dr Maciej Tomaszewski, 
clinical researcher at the Silesian School of Medicine, Poland. Participants were 
recruited through probands attending hypertension clinics in the Silesian region 
of southern Poland by Drs Tomaszewski and Lacka during 1999 to 2000. In 
2001, Dr Tomaszewski received the International Society of Hypertension 
Fellowship based in Professor Dominiczak's laboratory at the University of 
Glasgow in order to learn genetic techniques and apply these to the Silesian 
Hypertension Study. He brought with him to Glasgow all DNA samples. I have 
set up the relevant laboratory techniques and trained Dr Tomaszewski in all 
relevant genotyping methods. Subsequently, he and I analysed all samples. This 
involved 638 DNA samples tested for II microsatellite markers and 6 SNPs and 
required several months of set-up work and genotyping 
from both of us. it is 
routine, in our laboratory, that genotyping of large clinical studies 
is performed 
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by several research and technical personnel working together. The data have 
been analysed and written up (Tomaszewski et al, 2001; Charchar et al, 2002) as 
a joint effort under overall supervision of Professor Dominiczak. 
In the Silesian Hypertension Study, hypertension was defined as systolic blood 
pressure greater than 140 mmHg and/or diastolic blood pressure greater than 90 
mmHg on three separate occasions and/or anti-hypertensive treatment. Clinical 
history, anthropometric data and cardiovascular phenotypes were recorded. 
Subjects with secondary hypertension were excluded. All other individuals with 
essential hypertension and their relatives were included. Clinical histories 
indicated only two cases of type 11 diabetes in parents. 
Height and weight were measured under standard conditions to allow calculation 
of body mass index (BMI). Blood pressures were measured by mercury 
sphygmomanometer with subjects seated and rested for 20 minutes. Systolic 
blood pressure (SBP) was recorded at the return of arterial sounds (Korotkoff 
phase 1) and diastolic blood pressure (DBP) at the disappearance of arterial 
sounds (Korotkoff phase V). Three consecutive readings were averaged for both 
SBP and DBP. Blood samples were collected for DNA extraction and to provide 
serum samples for freezer storage. Biochemistry and electrolyte assays were not 
routinely performed. 
For subjects receiving hypertensive treatment, the recorded blood pressures are 
right-censored values. With such a high percentage of treated hypertensives 
in 
the sample, a correction for this was necessary. We employed a non-parametric 
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method developed by the Framingham Study (Levy et al, 2000). Separate 
adjustments were conducted for men and women. Cubic regression models were 
fitted to account for age effects. Residuals were then sorted from highest to 
lowest within age groups (<35,35 to 44,45 to 54,55 to 64,65 to 74, and 75+) 
and a correction applied within each age group. For treated individuals, the 
algorithm used the expected value of the untreated residual conditioned on the 
distribution of other residuals of greater or equal magnitude, as the adjusted 
residual for a treated measurement. The adjusted residual equals the average of 
that individual's residual and all larger residuals. Adjusted BP equals the 
measured BP plus the difference between the adjusted residual and the initial 
residual. This approach takes into account an individual's position within the 
distribution of BP for his age/ sex group. This is perhaps a more individualised 
approach than an adjustment using an estimated age-specific treatment effect 
derived from a regression on age and treatment. The latter would result in a 
standard adjustment for all treated persons. The Framingham approach tailors 
the adjustment to the individual by using residuals from untreated individuals of 
the same sex and similar age to derive an expected untreated blood pressure. 
Thus, patients who have had their blood pressure lowered considerably by 
intervention will be corrected upwards to a greater extent than individuals who 
are treated but still remain hypertensive. It should be noted, however, that all 
such adjustments are inexact since the magnitude of response of an individual to 
a specific treatment regime is impossible to detennine using the available data. 
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2.2.2: MIDSPAN FAMILY STUDY: 
The MIDSPAN Family Study was implemented and recruited by clinical staff of 
the Department of General Practice, University of Glasgow. Between 1972 and 
1976, all residents aged 45-64 living in the large burghs of Renfrew and Paisley 
situated in the west of Scotland were invited to participate. Those willing were 
asked to complete a questionnaire and invited to attend for screening 
examination at clinics set up nearby. At screening, detailed data were collected 
on seated blood pressures and other clinical, anthropometric and socio-economic 
characteristics. In 1993-1994, the offspring of the original cohort were traced 
and those aged 30-59 years were invited to join the study. A total of 2,338 
offspring participated consisting of 869 singletons and 1,469 individuals derived 
from 608 sibships ranging in size from 2 to 8 members. Data collected on the 
offspring cohort included blood pressures, history of cardiovascular events and 
diabetes, smoking history and details of medication. Blood samples were taken 
for DNA extraction and measurement of serum levels of potassium, sodium, urea 
and creatinine. Glucose and total cholesterol were also measured although most 
subjects were not fasted. All data were stored in a Microsoft Access database. 
2.2.3: FAMILIAL INTRACRANIAL ANEURYSM PILOT STUDY: 
Recruitment of the FIA pilot study was funded by the McFeat Bequest 
administered by North Glasgow University Hospitals NHS Trust. Recruitment 
was carried out during 1998 to 1999 by a research nurse, Sister Mairi McDade, 
in 
Glasgow. The study was originally conceived as an affected sib-pair study, a 
87 
design since used by genome-wide scans of FIA. All families were under the 
care of Mr Ken Lindsay, a neurosurgeon at Glasgow's Southern General 
Hospital. Initial contact was made with a proband by the nurse. Further 
recruitment within a family was via the proband. After 6 months of recruitment, 
it was clear that affected sib-pairs were not easily available. I then focused 
recruitment on obtaining as many affected relatives as possible and on 
recruitment of parents of affected individuals, or unaffected siblings if two 
parents were not available. Relatives not known to be affected were recruited 
when possible. This rationale was based on the requirements of the increasingly 
popular transmission-disequilibrium statistical approaches of the time (discussed 
further in Chapter 5), the classic approach for which required clinical phenotype 
to be known for an affected child only. This was an advantage given the 
difficulties of establishing a genuine unaffected status in individuals (discussed 
further in Chapter 5). 
No distinction was made between individuals with unruptured IA or those who 
had survived aneurysmal SAH. The scale of this single centre study combined 
with the relative paucity of IA/ SAH patients did not allow us the luxury of 
studying subgroups. For the same reason, phenotypes were not differentiated in 
analyses. Presently, the largest published studies of FIA genetics also face this 
problem. For example, a recently published genome-wide scan in 104 Japanese 
sib-pairs also combined ruptured with unruptured patients (Onda et al, 200 1). 
Autosomal dominant polycystic kidney disease (ADPKD) is a rare disorder 
which is firmly linked with occurrence of intracranial aneurysms. 
We therefore 
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wished to exclude cases of ADPKD from the study. To this end, renal 
ultrasound (RUS) can be used to detect the characteristic renal cysts. RUS was 
offered to all participants and accepted by 58 individuals. Family history and 
individual serum creatinine levels were also examined. Of 80 study participants, 
RUS and family history eliminated ADPKD in 58 individuals. RUS was refused 
by 22 individuals but family history and serum creatinine levels did not indicate 
ADPKD. 
Participating subjects visited the hospital where the nurse administered a 
standard questionnaire. This included history of hypertension, smoking, 
medication, personal and family history of intracranial aneurysms and 
subarachnoid haemorrhages, and angiography. Blood pressure was measured in 
a seated position and blood samples for DNA extraction and blood chemistry 
assays were collected. Affected status was confirmed by reference to case notes. 
Data were transcribed into a Microsoft Access database. Transcription of the 
data was checked by a second person to ensure accuracy. 
2.3: DNA EXTRACTION, QUANTITATION AND DILUTION: 
Extraction methods for obtaining genomic DNA from whole blood varied by 
study. Extraction of DNA from Silesian blood samples was performed by 
technical staff at the Silesian School of Medicine. Extractions were performed 
using MasterPure DNA purification kits (Epicentre Technologies, US) following 
the manufacturer's protocol. 
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MIDSPAN Study DNA samples were extracted by technical staff at the 
University of Glasgow under the direction of Dr. Gordon Inglis using a standard 
phenol-chloroform method adapted from Miller et al (Miller et al, 1988). 
Briefly, cells were lysed with buffer containing 0.32 M sucrose, 10 mM Tris, 5 
MM MgCl2, and 1% Triton X-100, pH 7.5. Samples were mixed by inverting 
and centrifuged at 1,500g for 10 min. Nuclei were lysed by suspension of pellets 
in 3 ml of buffer containing 10 mM Tris, 0.4 M NaCl, 2 mM EDTA, pH 8.2. 
Addition of 0.6% (v/v) SDS and 200 ýtl of Proteinase K (Sigma, UK) was 
followed by 18 hr incubation at 37'C. I ml of saturated NaCI and 5 ml of 
phenol/chloroform solution were added followed by centrifugation at 1,200g for 
10 min. The aqueous layer was washed with 99% ethanol. Precipitated DNA 
was resuspended in 400 ýd of autoclaved, deionised water. Samples were stored 
at -70'C until use. 
Extraction of DNA samples for the FIA study was performed by technical staff at 
the University of Glasgow using Wizard Genomic DNA Purification kits 
(Promega, UK). Extractions were performed using the manufacturer's 
recommended protocol. 
Quantitation of all Silesian and MIDSPAN DNA was by Picogreen dsDNA 
Quantitation kit (Molecular Probes, Netherlands). Genomic DNA was diluted 
1000 fold by two serial dilutions of 1: 10 followed by 1: 100. The manufacturer's 
protocol using a high concentration standard curve was 
followed. Samples were 
read in black 96-well plates on a Wallac Victor 
2 microplate reader (Perkin Elmerq 
UK). 
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Quantitation of DNA for the FIA study was performed using a Biotech Ultraspec 
2000 spectrophotometer (Amersham Biosciences, UK). 5 gl of genomic DNA 
was added to 995 [tI of deionised water in a quartz cell and mixed. Absorbance 
at 260 and 280 nm, and concentration in ng/ýtl, were recorded. The reading was 
then repeated and the results averaged. 
Following quantitation, genomic DNA samples were diluted into deep well 
plates (Beckman Coulter, UK) at the appropriate concentration for the 
downstream application. Water blanks and control DNA were included on all 
plates. Control DNA was obtained from Coriell Cell Repositories. 
2.4: MICROSATELLITE MARKER GENOTYPING: 
2.4.1: POLYMERASE CHAIN REACTION AMPLIFICATION: 
Primer sequences for PCR amplification of microsatellite markers were obtained 
from the Genome Database (GDB, http: //gdbwww. gdb. org/), National Centre for 
Biotechnology Information (NCBI, http: //www. ncbi. nlm. nih. gov/), Applied 
Biosystems Linkage Marker Set 2 (Applied Biosystems, UK) or the literature as 
specified. Primer sequences are given in Appendix 3. 
Primers were manufactured by either MWG Biotech or Applied Biosystems. To 
enable fluorescent genotyping, forward primers were synthesised with 
5' 
fluorescent dyes. To improve electrophoretic resolution and peak morphology 
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reverse primers were synthesised with a7 base tail at the 5' end, the sequence of 
which was GTTTCTT. This has been shown to improve peak morphology which 
gives cleaner data and more accurate genotyping (Magnuson et al, 1996). 
PCR was performed using HotStar Taq (Qiagen, UK) with 25 ng DNA; 2 ýtl of 
1 Ox buffer with I 5MM M9CI2; 200 mM of each dNTP; 20 pmol primers and 0.2 
U of enzyme in a total volume of 20 ýtl. Reactions were set up in 96-well 
microplates (ABgene, UK) and cycled on PCT-225 thermal cyclers (MJ 
Research, US). A PCR program was used which maximised addition of 'plus-A' 
bases at the 3' end of amplification products to facilitate genotyping. This was 
as follows: 
1) 95'C for 15 min 
2) 94'C for I min 
3) x'C for 1 min where x= annealing temperature 
4) 72'C for I min 
5) Steps 2-4 repeated 34 times 
6) 60'C for 30 min 
7) Cool to 12'C 
Cycled PCR reactions were stored at -20'C until used. 
2.4.2: MICROSATELLITE MARKER GENOTYPING: 
2.4.2.1. - AB1377 SEMI-AUTOMATED DNA ANALYSER. - 
Genotyping of microsatellites for the Silesian Study, the MIDSPAN Study and 
the FIA pilot study was performed on an ABI 377 (Applied Biosystems, 
UK). 
The process of genotyping on the ABI 377 is presented 
in schematic format in 
Figure 2.4.1. Electrophoresis was performed ' through 5% denaturing 
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polyacrylamide gels. Gels were cast by hand using 50 ml of Long Ranger 5% 
acrylamide gel solution (FMC Bioproducts, US) containing 6M urea, 250 gl of 
10% APS (Amresco, US) and 25 ýtl of TEMED (Arnresco, US). They were 
allowed to polymerise for a minimum of one hour and a maximum of overnight. 
Microsatellite PCR products were pooled together and combined with a loading 
cocktail containing ultrapure deionised formamide (Amresco, US), 
GS350TAMRA or GS350ROX size standard (Applied Biosystems, UK) and 
Dextran-EDTA loading buffer (Applied Biosystems, UK). Samples were 
denatured for 2 min at 95'C and resolved on the ABI 377 (AppliedBiosystems, 
UK) using the manufacturer's recommended protocol. On completion of 
electrophoresis, raw data were extracted with GeneScan v3.1 and genotyped with 
Genotyper v2.1 or v2.5 (Applied Biosystems, UK). All gentotypes were checked 
by two individuals who were unaware of phenotypes. Positive control DNA was 
included on all plates of samples to ensure consistency from run to run. This was 
obtained commercially (Coriell Cell Repositories, US) and derived from a stable 
cell line from an individual of the CEPH resource. 
For samples where one or more genotypes were not retrieved, due to failure or 
ambiguity, the entire pool containing the problem marker was re-amplified by 
PCR and re-genotyped. Potentially the greatest source of genotyping error 
comes from the compilation of plates of the various DNA samples to 
be re- 
genotyped. This has to be done manually and there is potential 
for human error. 
By following the rigorous approach of re-genotyping an entire pool of markers, 
rather than just those that were lacking, we were able to monitor 
two t ings. 
Firstly, we could confirm that the correct DNA sample was being re-genotyped . 
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Fig. 2.4.1: A schematic representation of the microsatellite marker genotyping 
process using the ABI 377 semi-automated DNA analyser. Steps requiring human 
intervention are shown. 
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Fig. 2.4.2: A schematic representation of the microsatellite marker genotyping 
process using the ABI 3730 automated DNA analyser. Considerably less intervention 
is required and run times are shorter. 
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by comparing genotypes obtained in the original run with those in the re-run. 
Secondly, I was able to estimate genotyping error rates based on disagreement 
between genotypes obtained in two or more runs. It is likely that this over- 
estimates error rates since, inevitably, estimates tend to be based on re-runs of 
poor quality samples where genotyping is perhaps more difficult, ambiguous and 
error-Prone. In all cases, estimates of error rates were approximately 0.3-0.5%. 
2.4.2.2. - ABI 3 73 0 CAPILLARY DNA ANAL YSER. - 
Genotyping of microsatellites for the Southampton FIA samples was performed 
on an ABI 3730 (Applied Biosystems, UK). This process is shown in schematic 
form in Figure 2.4.2. PCR products were pooled together and combined with a 
loading cocktail containing fluorescent size standard and Hi-Di formamide 
(Applied Biosystems, UK). Samples were denatured for 2 min at 95'C and 
resolved through POP-7 polymer on the ABI 3730 using the manufacturer's 
recommended microsatellite fragment analysis protocol. Data were genotyped 
using GeneMapper 0 (Applied Biosystems, UK). Genotypic data were then 
checked by a second independent person. Genotyping was blind to phenotypic 
status. Positive control DNA was included on all plates of samples to ensure 
consistency from run to run. Where data from 377 and 3730 runs were to be 
combined, parity between these data sets was confirmed by running some DNA 
samples on both platforms. Genotypes from both instruments were compared 
using an Excel spreadsheet macro to ensure that binning was identical. Samples 
that required re-running to obtain missing genotypes were handled in exactly the 
same Nvay as ABI 377 genotyping. Error rates were similarly low. 
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2.5: P2-ADRENERGIC RECEPTOR GENE SNP GENOTYPING: 
2.5.1: PCR OF P2-ADRENERGIC RECEPTOR SNPs: 
Three polymorphisms within the ADRB2 gene were chosen for genotyping due 
to their reported functional significance. These were Argl6GIy, Gln27GIu and 
Thr16411e. Amplification of fragments containing the single nucleotide 
polymorphisms (SNPs) of interest was accomplished by PCR with HotStar Taq 
(Qiagen, UK). Primer sequences are given in Appendix 3. Total reaction 
volume was 20 ýtl and included: 25 ng genomic DNA, 2 [tl lOx PCR buffer 
containing 15 MM MgC12,200 ýM each dNTP, 20 pmol of primers and 0.2 U of 
enzyme. Reactions were set up in 96-well microplates (ABgene, UK) and cycled 
on PCT-225 thermal cyclers (MJ Research, US). The following program was 
used: 
1) 95'C for 15 min 
2) 94'C for I min 
3) x'C for I min where x= annealing temperature 
4) 72'C for I min 
5) Steps 2-4 repeated 34 times 
6) 60'C for 30 min 
7) Cool to 12'C 
Cycled PCR reactions were stored at -20'C until used. 
2.5.2: GENOTYPING OFP2-ADRENERGIC RECEPTOR SNPs: 
Each of the three polymorphisms introduces a restriction site 
into the genomic 
sequence. Therefore, genotyping was performed 
by restriction digest and gel 
resolution. The Arg I 6Gly SNP was genotyped 
by digestion of the PCR products 
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with 2U of BsrDI enzyme (New England Biolabs, UK) at 60'C for 6 hours. The 
restriction products were resolved on 3% Agarose-1000 (Life Technologies, UK) 
gel containing ethidium bromide. Bands were visualised using a Fluor-S Multi- 
Imager (Biorad Laboratories, UK). Gels were scored, by eye, by two 
individuals. 
The Gln27GIu SNP was genotyped by digestion of PCR products with 1.5 U of 
Ital restriction enzyme (Roche, Switzerland) at 37'C for 20 hours. Digestion 
products were resolved on 2.5% Agarose-1000 gels containing ethidium 
bromide. Visualisation was performed on the Fluor-S Multi-Imager. Gels were 
scored, by eye, by two individuals. 
The PCR fragments containing the Thr1641le SNP were digested with 2U of 
Mn1l restriction enzyme (New England Biolabs, UK) at 37'C for 5 hours. 
Resolution on 2% Ultra Pure agarose (Life Technologies, UK) gels containing 
ethidiurn bromide was followed by visualisation on the Fluor-S Multi-Imager. 
Genotypes were scored by two individuals. 
Accuracy of genotyping and reliability of the restriction digests were verified by 
direct sequencing of 15 unrelated individuals performed on the ABI 377 using a 
standard BigDye Terminator protocol (Applied Biosystems). All genotypes were 
found to agree with the sequence data. 
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2-6: FIBROBLAST GROWTH FACTOR 1 SNP IDENTIFICATION AND 
GENOTYPING: 
Within the FGF I gene, no known coding region polymorphisms were found in 
the literature or on-line SNP databases such as NCBI (www. ncbi. nlm. nih. gov) 
and Ensembl (www. ensembl. org). To confirm the presence or absence of coding 
region polymorphisms, in the Silesian population, the coding exons, flanking 
intronic regions and 3' UTR of FGF I were amplified by PCR and sequenced. 
2.6.1: FIBROBLAST GROWTH FACTOR I PCR AMPLIFICATION: 
Twenty unrelated individuals from the Silesian Hypertension Study group were 
selected for sequencing. Our rationale was to select a heterogeneous group of 
male and female hypertensives and normotensives. Thus, of 20 selected, ten 
individuals were hypertensive and ten individuals were normotensive. Within 
these subgroups, half were male and half female. Sequencing of these 40 
chromosomes was expected to give 99% probability of detecting polymorphisms 
with minor allele frequency of 10% and nearly 90% power to detect 
polymorphisms with 5% minor frequency. 
PCR primers were designed to flanking intronic sequences to allow amplification 
of exons and exon/intron boundaries. Primers for amplification of the 
3' UTR 
were also designed. Sequences of these primers are given 
in Appendix 3. The 
target genomic sequence was taken from the National Centre for Biotechnology 
Information (NCBI, Accession no: NT_029289) and exon sequences were taken 
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from published cDNA sequences from NCBI and the literature (Payson et al, 
1993). PCR was performed using HotStar Taq (Qiagen, UK) to amplify template 
DNA for sequencing. Reaction volume was 20 ýtl and consisted of: 2 ýtl of I Ox 
PCR buffer containing 15 MM MgC12,200 mM of each dNTP, 20 pmol of 
primers, 25 ng genomic DNA and autoclaved deionised water to volume. 
Reactions were set up in 96-well microplates (ABgene, UK) and cycled on PCT- 
225 thermal cyclers (MJ Research, US). The following program was used: 
1) 95'C for 15 min 
2) 94'C for I min 
3) x'C for I min where x= annealing temperature 
4) 72'C for 1 min 
5) Steps 2-4 repeated 34 times 
6) 60'C for 30 min 
7) Cool to 12'C 
Cycled PCR reactions were stored at -20'C until used. 
2.6.2: FIBROBLAST GROWTH FACTOR I SEQUENCING: 
PCR products were purified prior to sequencing to remove unincorporated 
dNTPs and primers. Nucleofast-96 plates (Macherey-Nagel, Germany) were 
used which work on the principal of size exclusion. PCR products are retained 
but small primers and dNTPs pass through a porous membrane to waste. 
The 
manufacturer's protocol for centrifuge filtration was 
followed with products 
being re-suspended in 50 ýd of autoclaved water. 
Purified PCR products were sent to MWG Biotech for direct sequencing. 
Forward sequences were obtained using the forward PCR primers. 
Sequence 
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data obtained were aligned to a reference sequence using Vector NTI v8 
(Informax, US). Potential polymorphic sites were identified following alignment 
and confirmed by reference to electrophero grams from the MWG sequencing 
runs. 
2.6.3: FIBROBLAST GROWTH FACTOR I SNP GENOTYPING: 
Genotyping of polymorphisms within the FGFI gene was done by the MRC 
Gene Service (Cambridge, UK). Genomic DNA at 5 ng/ýtl was provided. PCR 
primers were identical to those used during sequencing of the FGF I gene. 
Genotyping was performed on an ABI 7900HT (TaqMan) instrument platform 
(Applied Biosystems, UK). Allelic recognition probes were labelled with the 
fluorescent dyes VIC or FAM. Their sequences are provided in Appendix 3. 
2.7: STATISTICAL ANALYSES: 
All genotypic data were checked with PEDCHECK (O'Connell & Weeks, 1998) 
to detect genotyping errors and misspecification of relationships. Inconsistencies 
were corrected, if possible, or individuals were removed from the dataset. 
2.7.1: LINKAGE ANALYSES: 
Linkage analyses were conducted on genotype data derived from the Silesian and 
MIDSPAN study groups. All genotyped samples, which were passed by 
PEDCHECK, were included in analyses. Whilst this, potentially, leads to 
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analysis of a more heterogeneous sample, neither resource was large enough to 
sensibly address hypertensive subgroups. Different statistical approaches were 
used in each study sample owing to the differing ascertainment criteria and 
family structures. 
Multiple methods were employed for analysis of the Silesian data as consistency 
between different methods provides confidence in the result. Haseman-Elston 
(H-E) regression as implemented in SIBPAIR was used for identity by descent 
(IBD) two-point linkage analyses of hypertension status and systolic and 
diastolic blood pressures (Duffy, 1999). The merit of this test lies in its 
applicability to both quantitative and qualitative traits. Analysis of both is 
preferable to give confidence in results and allows direct comparison of them. 
The H-E non-parametric method regresses a function of squared trait sums and 
differences between siblings on the proportion of alleles identical by descent. 
The test essentially determines whether siblings, who are phenotypically alike, 
are also more genotypically alike than would be expected at a given locus. The 
identity-by-de scent of siblings reflects the sharing of 0,1 or 2 alleles which 
derive from a common ancestral chromosome. IBD was estimated within SIB- 
PAIR based on sib pair and parental genotypes. Parental genotypes were not 
available in 30% of families and in these cases IBD was estimated using the sum 
of sharing for each possible set of parental genotypes weighted by their 
likelihood based on all children in the sibship. Allele frequencies were 
calculated within SIB-PAIR using founders of pedigrees. 
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SPLINK vl. 08 was used to run a second confirmatory IBD two-point analysis of 
hypertension status (Clayton, 2000). This is an affected sib pair analysis which 
uses a maxmimum likelihood approach to estimate the probability that two 
affected sibs share 0,1 or 2 autosomal marker alleles IBD. Allele frequencies 
are also estimated by a maximum likelihood method for use in IBD estimation in 
absence of informative parental genotypes. SPUNK has the advantage that it 
does not use the unaffected siblings other than to assist IBD estimation. Given 
that some of the normotensive siblings may, later, develop hypertension, and 
therefore are misclassified, an affected sib pair analysis provides useful 
confirmation in a sample with unambiguous disease status. 
A two-point X2 identity by state (IBS) affected sibpair method in SIB-PAIR was 
also used to test linkage to hypertension as confirmation of the H-E results. 
Whilst of lower power than IBD analyses, the IBS approach does not rely on 
estimation of IBD and therefore circumvents any bias arising from such 
estimation. Identity-by- state is determined by the number of alleles shared, 
regardless of their ancestral origin. Observed IBS statistics are compared, by y, 2 
test, with expected IBS which are derived from allele frequencies in the whole 
sample. Missing parental genotypes have no effect on the test. 
MAPMAKER/SIBS was used for non-parametric multipoint analyses of 
quantitative traits since these are expected to be more informative than analysis 
of arbitrarily defined qualitative traits such as hypertension. For this reason, 
multipoint SPLINK analysis was not performed. MAPMAKERJSIBS calculates 
the ftill IBD probability distribution by a maximum likelihood method. The non- 
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parametric test ranks sib pairs by their absolute value of phenotypic difference. 
For each location across the region under investigation, a statistic is defined to 
relate the rank to number of alleles shared IBD and thus linkage may be 
demonstrated or refuted. Of the available tests in MAPMAKER/SIBS, the non- 
parametric option was preferred since it may be more powerful than other 
available options such as multipoint Haseman-Elston. It also makes no 
assumptions about distribution of phenotypic noise and therefore provides a 
robust confirmation of two-point results (Kruglyak and Lander, 1995). Allele 
frequencies for use in the multipoint analysis were taken from SIB-PAIR which 
calculates frequencies based on founders of pedigrees only. 
Both two-point and multipoint analyses in the MIDSPAN Study used the 
variance components methodology of SOLAR (Almasy & Blangero, 1998). 
SOLAR was selected following the example of other studies in population 
samples, for example the Framingham Study genome-wide scan (Levy et al, 
2000). Unlike the Silesian Study sample, which consists of small family units of 
consistent size, the MIDSPAN sample contains sibships ranging between 2 and 8 
individuals. An advantage of the variance components approach is that it treats 
each family as a unit, explicitly allowing for non- independence among sibs. This 
pedigree approach is more powerful and less liable to type I error, when using 
larger sibships, than are statistics based on pairs of relatives (Levy et al, 2000; 
Marlow, 2002). This made SOLAR a more appropriate choice than the sib-pair 
approach of MAPMAKER/SIBS. Variance components methods assume 
normally distributed phenotypes and so logIO-based transformations of SBP. 
DBP and MAP, and the BMI covariate, were perfonned. Nonnal distribution 
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was confirmed by a Kolmogorov-Smimov test using Minitab v. 12 (Minitab 
Inc. ). In the absence of parents in the MIDSPAN sample, IBD was calculated by 
SOLAR using a maximum likelihood method. This was based on allele 
frequencies which were also calculated internally by the program, again using 
maximum likelihood. To improve these estimates, singletons from the 
MIDSPAN sample were genotyped and included in the input. Two-point 
analysis was also repeated with all treated individuals omitted from the data set 
to ensure that inclusion of treated blood pressures did not adversely skew the 
analysis. The correction used in the Silesian sample was not applied as this, of 
course, cannot accurately derive untreated BP. Since the percentage of treated 
individuals in the MIDSPAN sample was so small, exclusion of these was more 
appropriate, rather than replacing treated blood pressures with estimates. 
2.7.2: BLOOD PRESSURE CANDIDATE GENE ANALYSES: 
2.7.2.1. - fl2-ADRENERGIC RECEPTOR ANALYSES: 
Analysis of the ADRB2 SNPs was conducted in line with analyses by Bray et al, 
whose study provided the initial motivation to examine the chromosome 5q 
region and the ADRB2 gene (Bray et al, 2000). They used TDT analysis 
in their 
families, and logistic regression in the parental generation of their sample. 
We 
therefore did likewise to make our findings as comparable as possible. 
Transmission disequilibrium testing (TDT) was employed to test for linkage in 
the presence of association (Spielman et al, 1993) using two parent-one child 
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trios. TDT detects preferential transmission of an allele (greater than 50%) from 
parents to affected offspring compared with untransmitted alleles which 
effectively provide the control genotype. Thus, TDT examines both linkage and 
association at once. At least one heterozygous parent is required for a family trio 
to be informative. TDT and similar family-based tests were devised to avoid the 
problem of population stratification which may give false positive results in case- 
control association studies. 
The results of TDT were confirmed by the empirical variance family-based 
association test (EV-FBAT), a method which was unavailable to Bray et al. EV- 
FBAT tests the null hypothesis that linkage is present but there is no association 
(Lake et al, 2000). This was appropriate because we were testing SNPs within a 
region already showing evidence of linkage to the trait. Unlike TDT, EV-FBAT 
does not require parental genotypes as it is not based on treating non-transmitted 
alleles as controls. Rather, the distribution of offspring genotypes is important 
and this can be calculated from genotypic data for all offspring within the family, 
in the absence of parents. Thus, it does not suffer from the costly reduction in 
sample size caused by missing parental data that is inherent with approaches that 
condition on sibling IBD patterns. EV-FBAT determines the expected value of 
an association test statistic by conditioning on the minimal sufficient statistic 
under the null hypothesis and uses an empirical variance-covariance estimator 
which is unaffected by correlation of sibling genotypes. At the time of the 
ADR132 analyses, EV-FBAT was a relatively unknown method, and we therefore 
preferred the widely reported and validated TDT method as a primary approach, 
as used by Bray et al. However, in its favour EV-FBAT allowed us to make 
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better use of families which contained more than one genotyped child. FBAT 
was designed to handle more complex families, and decomposes such families 
into nuclear units for analysis. TDT, however, is completely restricted in its use 
of trios and makes no use of genotyping in extra siblings. 
In concordance with Bray et al, binary logistic regression analysis was performed 
in the parental generation to test for increased risk of hypertension associated 
with each tested genetic variant of ADRB2. Correction was made for age, sex 
and body mass index. Finally, SNP haplotypes were assessed using a modified 
TDT method implemented in TRANSMIT. This is a likelihood method which 
allows for missing parental data and haplotype phase uncertainty and uses 
genotype data from available parents and offspring to efficiently determine 
phase. A score vector is generated which is averaged for all possible 
configurations of haplotypes and transmissions from parents to offspring 
consistent with the observed data. Additional offspring who are of unaffected or 
unknown status are used to narrow the options for parental haplotypes. The 
method is robust against population stratification. Again, this was a 
methodology not available to Bray et al, but haplotype analyses are expected to 
be more informative than single locus anlyses. This is particularly true where the 
combined effect of functional loci can be considered rather than examining each 
without regard to positive or negative influences from others. We felt this would 
be a more categorical analysis to confirin or refute the previous findings of 
ADRB2 studies. 
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2.7.2.2. - FIBROBLAST GROWTHFACTOR I ANALYSES: 
Analysis of FGF I SNPs was conducted using EV-FBAT (Lake et al, 2000) and 
the recent extension of this methodology, Haplotype FBAT. TDT was not used 
for FGF I analyses since, by this point, EV-FBAT was more widely reported and 
considered reliable. EV-FBAT was felt to be a more useful analysis since it is 
appropriate for both qualitative and quantitiative traits, unlike classical TDT- In 
addition, as explained above, it extracts all possible information from complex 
families regardless of missing parents and multiple offspring. This was more 
appropriate for a study group that contained genotypes in additional siblings. As 
stated, classical TDT is totally restricted to trios and dichotomous traits. At the 
time of the ADRB2 analyses, Haplotype-FBAT had not been developed. 
However, its availability for analysis of FGFI allowed consistency between the 
single locus and haplotype analyses of this gene and made it the preferred 
approach rather than TRANSMIT. It allowed analysis of the three locus 
haplotype across all SNPs gemotyped in FGFL This is discussed further in 
Chapter 4. 
2.7.3: FAMILIAL INTRACRANIAL ANEURYSM CANDIDATE GENE 
ANALYSES: 
The variable structure of the families recruited to the FIA pilot study and 
difficulties of defining individuals as unaffected meant that no single analysis 
method used the study sample to its full extent. 
I therefore applied multiple 
methods in an effort to detect linkage and/or association, with 
the aim of using as 
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many of the families as possible. Given the small size of the study, my primary 
aim of analysis was to identify trends across different analytical methods. 
IBS linkage between disease status and markers was assessed by the Affected 
Pedigree Member (APM) method (Weeks & Lange, 1988). IBS methods test for 
sharing of alleles between relatives. However, this is done in such a way as to 
disregard whether these shared alleles originated from the same ancestral 
chromosome. This makes IBS methods less powerful than IBD methods which 
are based on estimation of allele sharing where such alleles are derived from the 
same founder chromosome. Not all parents were available in families suitable 
for the affected pedigree member analysis. In the absence of parents, IBD 
statistics are estimated by a likelihood approach. However, the very small 
number of individuals suitable for the APM analysis would have made such 
estimates highly speculative and unreliable. The more simplistic IBS approach is 
therefore more appropriate, although a larger study would have benefited from 
IBD analysis. 
Linkage and association were assessed using the combined Transmission 
Disequilibrium Test JDT) (Spielman et al, 1993) and sibling TDT (S-TDT) 
(Spielman & Ewens, 1998) which was described in Section 2.7.2.1. Tests of 
association and linkage within extended families were done with FBAT and EV- 
FBAT (Horvath et al, 2001). FBAT tests the null hypothesis of no linkage and 
no association. It is also based on calculation of the expected value of an 
association test statistic conditioned on the minimal sufficient statistic, and again 
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was designed to handle complex pedigrees and information from additional 
siblings. EV-FBAT was previously described in Section 2.7.2.1. 
A case-control paradigm was also used. The existence of Hardy-Weinberg 
equilibrium in controls was first confirmed by Fisher's exact test using GDA 
vl. O (Lewis, P. 0., and Zaykin, D. 2001; http: //lewis. eeb. uconn. edu/lewishome 
/software. html). Frequencies of genotype in case and control groups were 
compared by an exact X2 test using STATXACT-TURBO v2.1 (Cytel Software 
Corporation, USA). Genotype frequencies were compared since they do not 
make the assumption of an additive affect, which underlies the commonly used 
comparison of allele frequencies. 
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CHAPTER 3 
LINKAGE OF BLOOD PRESSURE AND HYPERTENSION TO 
HUMAN CHROMOSOME 5q3l. l-q33 IN TWO POPULATIONS 
3-1: INTRODUCTION: 
Essential hypertension is an important risk factor for cardiovascular disease 
(Lifton et al, 2001). It is a multifactorial, complex polygenic or oligogenic trait 
and, as such, has seen the application of various complementary genetic 
strategies to clarify the underlying genes. Work has been conducted along three 
lines. Firstly, study of Mendelian hypertensive diseases has resulted in 
elucidation of a number of disorders, such as Liddle syndrome (Shimkets et al, 
1994), glucocorticoid-remediable aldosteronism (GRA) (Lifton et al, 1992a) and 
syndrome of apparent mineralocorticoid excess (AME) (Mune et al, 1995). Such 
advances have clarified the role of various pathways in blood pressure regulation 
but not contributed greatly to the public health impact of hypertensive disease. 
Secondly, genome-wide scan (GWS) linkage approaches have implicated 
quantitative trait loci (QTL) in essential hypertension, but have not definitively 
implicated a common QTL or, therefore, causative genes (Samani, 2003). 
Thirdly, candidate gene approaches have been used to examine genes implicated 
by Mendelian disorders, genes in QTL and other plausible biological candidate 
genes. Whilst a potentially powerful approach, results have been conflicting and, 
as such, difficult to interpret (Risch, 2000; Tabor et al, 2002). 
A targeted chromosomal region approach to complex genetics, essentially 
amalgamating the genome-wide and candidate gene rationales, 
has also been 
postulated (Krushkal et al, 1998). A small chromosomal region, selection of 
which is based on genome-wide evidence and the presence of suitable 
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physiological candidate genes, allows denser saturation with markers and 
evidence of linkage can be followed by positional analysis. The 5q3 I -qter region 
of human chromosome 5 is an excellent target region for such a study. A number 
of genes, known to be important regulators of blood pressure or implicated in 
cardiovascular phenotypes, cluster here (Fig. 3.1.1). These include the P2- and 
(XIB-adrenergic receptors; the dopamine receptor type I A; glucocorticoid receptor 
and glutathione peroxidase. Owing to the presence of such genes, the 5q3 I -qter 
region has been focused on before. 
Evidence of linkage in the 5q3 I -qter region to systolic blood pressure (SBP) was 
reported in young, discordant US sib pairs (Krushkal et al, 1998). Multipoint 
linkage was maximal at 172 cM from the pter, following genotyping of 8 
microsatellite markers across the region at an average density of 4.5 cM. 
Transmission disequilibrium testing (TDT) also showed greatest linkage and 
association at this locus. Maximal linkage at this same marker was later reported 
in a genome-wide scan of the same sibships using a 10 cM marker set (Krushkal 
et al. 1999). More recent genome-wide scans have also reported multipoint 
linkage peaks in the region at 189 cM (Hunt et al, 2002) and 160 cM 
(Kristjansson et al, 2002) when investigating hypertension, and proximal to the 
ADRB2 locus for exercise-induced change in diastolic blood pressure (Rankinen 
et al,, 2001). These have all been in Caucasian populations. 
With the exception of Krushkal's studies, the evidence of 5q linkage in the 
genome-wide scans has largely been overlooked. In all cases, greater logarithm 
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Fig. 3.1.1: An ideogram of chromosome 5 showing the region of 
interest, 5q3l-qter. There are multiple candidate genes for 
cardiovascular disease, some of which are noted. 
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of odds (LOD) scores were obtained on other chromosomes and emphasis was 
placed on these. This is due, to a large extent, to the importance placed on 
1.41 absolute magnitude of LOD scores by Lander and Kruglyak (Lander & 
Kruglyak, 1995). However, the majority of genome-wide scans for complex 
traits have failed to satisfy these standards leading to calls for less stringent 
levels of significance (Rao & Province, 2000). Lander and Kruglyak did, 
however, stress that linkage falling short of their genome-wide threshold may, 
nonetheless, be genuine. 
Such ambiguity has led to the suggestion that combination of evidence from 
several studies may be needed to localise genes with modest effect (Altmuller et 
al, 2001). To this end, linkage studies in two independently ascertained human 
populations are described here. The Silesian Hypertension Study is a sample of 
Polish nuclear families with aggregation of hypertension. Linkage of 
quantitative and qualitative blood pressure traits to the 5q3l-qter region was 
assessed in this resource. The MIDSPAN Family Study, a large, general 
population sample from Scotland, was used to determine whether findings in the 
Silesian Study were applicable outwith this hypertensive sample. 
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3.2: METHODS: 
3.2.1: STUDY DESIGN AND RECRUITMENT: 
3.2.1.1. - SILESIAN HYPERTENSION STUDY. - 
The Silesian Hypertension Study recruited hypertensive nuclear families from 
the region of Silesia in southern Poland as detailed in Section 2.2.1 using 
probands in hypertension clinics as a first contact. Subjects with secondary 
hypertension were excluded. A total of 638 individuals was recruited from 212 
families with clustering of essential hypertension. Hypertension was defined as 
systolic and/or diastolic blood pressure over 140/90 mmHg, respectively, on 3 
separate occasions and/or treatment for hypertension. Clinical history, 
anthropomorphic data and cardiovascular phenotypes were recorded for a total of 
635 individuals from 210 families. Blood samples for DNA extraction were 
taken. 
3.2.1.2. - MIDSPAN FAMILY STUDY. - 
The MIDSPAN Family study represents a sample of the general population from 
the west of Scotland consisting of sibships ranging, in size, from singletons to 
octets. These individuals were recruited in a second phase of the MIDSPAN 
Study as detailed in Section 2.2.2. A total of 2,338 individuals were recruited 
from 1,477 pedigrees. This comprised 869 singletons and 1,469 individuals from 
608 sibships. These individuals completed questionnaires on diverse lifestyle 
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and clinical parameters and were phenotyped for blood pressure as well as 
anthropornetric and other data. Blood samples for DNA extraction and serum 
assays were taken. 
3.2.2: MICROSATELLITE, MARKER STUDIES: 
3.2.2.1: SELECTION OFMICROSATELLITEMARKERS. - 
Initially, 8 microsatellite markers spanning the 36 cM from 5q31.1 to qter were 
genotyped. These were taken from the original study of this region (Krushkal et 
al, 1998). Following initial analyses, 3 additional markers spanning 19 cM 
proximal to the original markers were added to further define the linkage region. 
These were selected for their high reported heterozygosity and inter-marker 
spacing. Thus a total of 55 cM was investigated with II markers at an average 
distance of 5 cM (2.67 to 7.94 cM). Map distances were taken from the 
Marshfield sex-averaged genetic map as quoted by the National Center for 
Biotechnology Information (NCBI, www. ncbi. nlm. nih. gov). The Marshfield 
genetic map was compared with the physical genomic sequence map to confirm 
that marker order was correct. 
3.2.2.2. - MICROSA TELLITE MARKER GENOTYPING. - 
Genomic DNA was extracted from whole blood samples as described in Section 
2.3. DNA for both Silesian and MIDSPAN studies was diluted to 5 ng/[tl in 
sterile deep well microplates (Beckman Coulter UK Ltd, UK). 25 ng DNA per 
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PCR reaction was used. PCR was performed as detailed in Section 2.4.1 using 
Qiagen HotStar Taq (Qiagen Ltd, UK). Forward primers used were 5'-Iabelled 
with either the fluorescer 6-carboxyfluorescein (FAM) or its analogues TET or 
HEX. The size range of marker alleles and pooling considerations dictated the 
specific label used. PCR products for an individual's II markers were combined 
into 3 pre-determined pools for resolution on the ABI 377 DNA Analyser. 
Resolution and genotyping proceeded as per Section 2.4.2.1. Genotypes were 
scored by two independent observers blinded to phenotype. 
3.2.3: STATISTICAL ANALYSES: 
Genotypes from both Silesian and MIDSPAN studies were checked for 
Mendelian inconsistencies using the PEDCHECK program (OConnell & Weeks, 
1998). Genotypes were confirmed for individuals flagged by the software, 
corrected if appropriate or individuals removed from the dataset. 
Blood pressures of the Silesian Hypertension Study sample were corrected for 
anti -hypertensive treatment effect as described in Section 2.2.1. Multiple 
methods were then used for linkage analyses of the Silesian Hypertension Study 
clataset. Haseman-Elston regression analysis was used to assess two-point 
identity by descent (IBD) linkage of markers to quantitative blood pressure 
phenotypes. A function of squared trait sums and differences between siblings' 
blood pressures was regressed on number of alleles shared IBD. Two-point 
linkage of markers to hypertension status was assessed by an IBD approach 
implemented in SPLINK vl. 08 (Clayton, 2000). Two-point linkage to 
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hypertension was confirmed by an identity by state (IBS) X2 test, with alleles 
shared IBS compared with a random distribution. Both the IBD Haseman-Elston 
test and IBS Z test were implemented in the SIB-PAIR software package (Duffy, 
1999). Multipoint non-parametric IBD linkage analysis was performed using 
MAPMAKER/SIBS for quantitative blood pressure phenotypes. Analyses are 
discussed in detail in Section 2.7.1. 
The MIDSPAN dataset was analysed for both two-point and multipoint IBD 
linkage to quantitative blood pressure phenotypes using the variance-components 
methodology of SOLAR (Almasy & Blangero, 1998). SOLAR is particularly 
suitable given the variable size of sibships within the MIDSPAN cohort, as it 
intrinsically corrects for dependence of multiple sib pairs derived from the same 
pedigree (Marlow, 2002). This pedigree-based approach of SOLAR is also more 
powerful than sib pair analysis when data on larger sibships are available. For 
this reason it has been the method of choice for other large linkage studies of 
general population samples (Levy et al, 2000). Traits were transformed to a 
normal distribution by a log 10 transformation, and this distribution cofirmed by 
Kolmogorov-Smimov test. With only 5% of individuals treated, a correction 
was not done since this would only estimate untreated pressures. However, a 
second twopoint analysis was also performed with all treated individuals omitted 
from the dataset to confirm that these did not skew the result. Analytical 
methods are discussed in detail in Section 2.7.1. 
Since IBD estimation in the absence of parental genotypes is reliant upon 
estimated allele frequencies, the 868 singletons were 
included in analysis. This 
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improves both allele frequency and phenotypic distribution estimates. Allele 
frequencies were calculated internally by SOLAR using an maximum likelihood 
estimation. SOLAR also modelled the contribution of age, sex and normalised 
BMI within the MIDSPAN cohort. These were retained by the model and thus 
included as covariates. 
3.3: RESULTS: 
3.3.1: STUDY SAMPLES: 
In the Silesian Hypertension Study, 629 individuals from 207 families were 
included in analyses. These included 207 hypertensive probands (57% male; 
43% female), 174 parents (130 fathers; 144 mothers) of whom 53% had essential 
hypertension and 148 siblings (43% male; 57% female) of whom 32% had 
essential hypertension. Demographic and clinical characteristics are shown in 
Table 3.3.1. 
The MIDSPAN Family cohort included 869 singletons and 1,469 siblings from a 
total of 1,477 families of whom 45% were male. Of the 2,338 individuals, 
22.3% were hypertensive at time of recruitment and 26% of the hypertensives 
(5.8% of the cohort) reported being on anti-hypertensive treatment. Mean blood 
pressures were normotensive and body mass index was within normal limits, 
specifically: SBP was 127 ± 15.9 mmHg; DBP was 74.6 ± 11.2 mmHg and BMI 
was 26.1 ± 4.53 kg M-2 . Demographic and phenotypic characteristics are 
described in Table 3.3.2, sub-categorised by size of sibship. 
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Table 3.3.3: Map positions, number of alleles and observed heterozygosities 
of 5q3l. l-qter microsatellite markers in the study populations. 
Silesian Hypertension Study 
Marker Position (cM) Alleles (N) H 
MIDSPAN Study 
Alleles (N) H 
D5s494 127.93 15 0.75 16 0.76 
D5s642 134.72 11 0.72 11 0.72 
D5s5OO 140.72 11 0.81 14 0.84 
D5sI480 147.49 9 0.82 9 0.82 
D5s636 153.17 12 0.76 15 0.80 
D5s820 159.77 8 0.77 9 0.80 
D5s2O93 164.19 9 0.66 10 0.69 
D5sI471 172.13 14 0.77 15 0.75 
D5sl456 174.80 9 0.78 11 0.80 
D5s462 178.75 8 0.58 8 0.62 
D5s2ll 182.89 8 0.74 13 0.75 
Map positions are taken from the Marshfield sex-averaged genetic map and are 
quoted as distance from the pter. H= observed heterozygosity. 
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3.3.2: LINKAGE STUDIES OF 5q31.1-qter: 
Eight microsatellite markers were genotyped, initially, with the subsequent 
addition of three markers. Thus, 11 markers across 55 cM of the distal portion of 
chromosome 5q were ultimately genotyped. All markers had high observed 
heterozygosity in both populations studied. Marshfield map positions, numbers 
of alleles and observed heterozygosities are shown for both Silesian and 
MIDSPAN study populations in Table 3.3.3. 
Linkage analysis was conducted, initially, in the Silesian study sample. Two- 
point linkage results are shown in Table 3.3.4. Two-point analysis of the 8 distal 
microsatellite markers by Haseman-Elston regression showed significant linkage 
of D5sI480 to hypertension (P=0.001). This result was corroborated by SPLINK 
1131) and SIB-PAIR IBS two-point analyses. No other microsatellite marker 
demonstrated significant linkage. Results of linkage to hypertension status were 
supported by analyses of quantitative phenotypes, with systolic (SBP) and 
diastolic blood pressure (DBP) both adjusted for anti-hypertensive treatment 
effect. D5sI480 again showed significant linkage to both phenotypes as shown 
in Table 3.3.4. 
Multipoint linkage testing followed two-point analyses. Results of two-point 
analyses were apparently confirmed by the multipoint Z scores, maximal at 
D5sl480, with the Z statistic still increasing as the limit of the marker map was 
reached. D5sl480 marked the proximal margin of the marker map and it is 
possible that artefactual multipoint linkage may arise at the edges of marker sets. 
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To eliminate this possibility, the marker set was extended proximally with three 
additional microsatellites which were genotyped and analysed. Two-point 
Haseman-Elston analysis of linkage to essential hypertension implicated the two 
markers closest to D5sl480. Of the two, D5s5OO was closest and most 
significant with t=2.45 (P=0.008) whilst for D5s642 t=1.96 (P=0.03). Two-point 
linkage of D5s5OO also reached borderline significance for SBP (P=0.09) and 
DBP (P=0.06). 
Multipoint linkage results of SBP using the extended marker map are shown in 
Fig. 3.3.1. Multipoint analysis showed that linkage to SBP was maximal 
proximal to D5sI480 (Z = 2.3; P=0.01). This implicated a7 cM region between 
D5sl480 and D5s5OO, and confirmed that the previously observed multipoint 
linkage had not been an artefactual effect due to the marker map. Analysis of 
DBP showed an equivalent linkage peak with a maximal Z score of 1.8 (P = 
0.03) proximal to the D5sI480 locus. 
Further genotyping and linkage analysis were subsequently conducted in the 
MIDSPAN cohort with a view to following up the results in the Silesian sample. 
All analyses were conducted using SOLAR with age, sex and BMI as covariates. 
Two-point linkage analysis again implicated D5sI480, with linkage to all 
quantitative phenotypes greatest at this locus. The highest two-point LOD score 
was obtained for mean arterial pressure (MAP) (Table 3.3-5). Furthermore, 
when multipoint analyses were performed, a linkage peak maximal at the 
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Table 3.3.5: Results of two-point linkage of systolic, diastolic and 
mean arterial blood pressures to microsatellite markers spanning 
the 5q31.1 to 5qter region of human chromosome 5 in the 
MIDSPAN study group. 
Marker 
SBP 
LOD 
DBP 
LOD 
MAP 
LOD 
D5s494 0.00 0.13 0.03 
D5s642 0.90 1.05 0.90 
D5s5OO 0.71 0.63 1.02 
D5s1480 1.19 1.18 1.57 
D5s636 0.06 0.00 0.00 
D5s820 0.61 0.63 1.12 
D5s2O93 0.00 0.00 0.00 
D5sl471 0.28 0.05 0.13 
D5sl456 0.42 0.00 0.05 
D5s462 0.02 0.00 0.05 
D5s2lI 0.06 0.32 0.09 
SBP = systolic blood pressure; DBP diastolic 
blood pressure; MAP = mean arterial pressure; LOD 
logarithm of odds score. 
128 
C> rf) - 110 110 C) Cý kr) N - en C14 C) 
110 00 C'4 
CA CA 
k (A f) kr) kr) V) tn 
1.0 
FGF1 NR3CI ADRB2 
2.0 
MIDSPAN 
SBP 
LOD score 0.5 
0 
I 
117.93 147.49 172.73 
Chromosome 5q (cM) 
I (11 
Cý 00 "o rn - 'D r- kn C14 cn , I- "t ý, o 
C 00 N -- , 1, (14 V) cn Ln V) En CIO CA kr) tf') kf') W') kf) kti W') W) W) kr) kf) 
2.0 -, 
DBP 
LOD 1.0 
score 
0 
Silesian 
SBP 
Z score 
1.5 
1.0 
193.4 
It r, 4 C) 00 1ý0 (7ý r- W-) "- 
Cý 'IT C) t rl) C) I- "t \C - 
tr) 1.0 00 " - -'t C-4 CA (n rA 'A EA 'A U) V) 
V% wl tn kr) tn W% W') kn W% 
c M M Cý c 1: ý in C) C) 
2.0 1 
MAP 
LOD 
1.0 
score 
0 
117.93 147.49 172.73 193.4 117.93 147.49 172.73 193.4 
Chromosome 5q (cM) Chromosome 5q (cM) 
Fig. 3.3-2: Results of multipoint linkage analysis of quantitative blood pressure 
phenotypes to 11 microsatellite markers across the 5q3l. l-qter region in the 
MIDSPAN study group. Covariates of age, sex and BMI were included in the 
analyses performed with SOLAR. (A) Comparison of multipoint results from the 
MIDSPAN and Silesian study groups shows the close agreement of linkage in the 
two populations. Location of the genes FGFI, NR3CI and ADRB2 are shown. 
(B) Maximal linkage to DBP and (C) MAP was also seen at the same locus. LOD 
= logarithm of odds 
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D5sl480 locus was present whether SBP, DBP or MAP was assessed. Maximal 
multipoint LOD was 1.65 for MAP. Both location and morphology of the 
linkage peaks were highly comparable between the Silesian and MIDSPAN 
study groups. Results of these multipoint analyses are shown in Fig. 3.3.2. To 
confirm that inclusion of treated MIDSPAN individuals did not materially affect 
the result, a second two-point analysis was performed with treated individuals 
removed from the dataset. Two-point LOD scores were maximal at D5sI480 for 
MAP and DBP (1.68 and 1.11, respectively). LOD scores for SBP were 1.26 at 
the D5sl480 locus but maximal at the flanking D5s5OO locus (LOD = 1.29). 
This mirrors the broader multipoint peak seen for SBP (Fig. 3.3.2 A). 
3.4: DISCUSSION: 
A targeted approach has been used, focusing on the 5q3 1.1 to qter chromosomal 
segment, to examine linkage to blood pressure phenotypes in Caucasian study 
samples. The decision to focus on this small chromosomal region was based on 
previous linkage studies, which have implicated this chromosome segment 
(Krushkal et al, 1998; Krushkal et al, 1999), and the presence of putative 
cardiovascular candidate genes which provide scope for subsequent positional 
analysis if appropriate. Suggestive linkage of a7 cM region to blood pressure 
and hypertension status was found in the Silesian Hypertension Study 
(Tomaszewski et al, 2002). A peak of suggestive linkage to quantitative BP 
traits was also seen at the same locus in the MIDSPAN Family Study cohort. 
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The Silesian Hypertension Study comprised nuclear families that were recruited 
based on their family history of essential hypertension from the Silesian region 
of Poland. Consequently, nearly 64% of individuals were hypertensive and 
many were being treated for their hypertension. Therefore, an adjustment for 
treatment was applied to blood pressures (Tomaszewski et al, 2002). The 
MIDSPAN Family Study comprised unselected sibships from the general 
population in the west of Scotland. Just over one fifth of participants were 
hypertensive at recruitment. This agrees with prevalence of hypertension 
reported by large epidemiological studies in Western populations (Burt et al, 
1995). 
Linkage to the same locus, proximal to D5sI480, was demonstrated for both 
quantitative blood pressure traits and hypertension status in the study groups. 
The idea that the same genes underlie both normal population distribution of 
blood pressure and the pathological development of high blood pressure and 
hypertension is often tacitly assumed (Altmuller et al, 2001). Indeed, it is rare 
for linkage studies to analyse linkage to hypertension status and blood pressure. 
This is probably driven by two factors. Firstly, general population samples 
suitable for blood pressure linkage analysis often lack sufficient hypertensives to 
contribute power to such an endeavour; secondly, there is a widely held opinion 
that quantitative traits provide more power than qualitative traits which, as with 
hypertension, may be somewhat arbitrary in their definition. Interestingly, a 
recent review of 101 genome-wide scans across 31 different complex diseases 
found no difference in rate of linkage detection between quantitative and 
qualitative trait scans (Altmuller et al, 2001). However, statistical studies using 
11) 1 
simulated clatasets have suggested that quantitative traits are more informative 
(Duggirala et al, 1997). 
The ideal approach to analysis of complex disorders may be to analyse both 
qualitative and quantitative traits jointly, if study samples lend themselves to this, 
since this may increase power to detect effects (Williams et al, 1999). Since the 
Silesian study sample consists of a high percentage of hypertensive individuals, 
this provided the opportunity to analyse both blood pressure and hypertensive 
status. The results from these analyses suggest that, at least in the QTL proximal 
to D5sI480, the same genes may be involved in blood pressure control and 
hypertension development. However, this may not necessarily be the case for all 
QTL. Linkage to both hypertension and blood pressure has been examined in the 
same sample in at least one genome-wide scan. In this case the separate analyses 
gave very different results (Hunt et al, 2002). 
The major strength of this study is that the two study groups are very different 
yet the linkage to blood pressure at D5sl480 is present in both. Consistency of 
linkage evidence to blood pressure or hypertension is rare across the many 
studies now published (Samani, 2003; Harrap, 2003). A few studies have 
replicated their initial findings in an independent sample (Xu et al, 1999; Zhu et 
al, 2001) but this is the exception rather than the rule. As such this has caused 
concern and raised the question of the feasibility of finding blood pressure and 
hypertension genes by such methods (Harrap, 2003). 
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Much of the conjecture surrounding the successfulness of linkage approaches in 
complex diseases has been based around the lack of genome-wide significant 
results. This concept, first proposed by Lander and Kruglyak (Lander & 
Kruglyak, 1995), was based on their realisation that testing of hundreds of 
markers would certainly result in false positive results. However, in their 
argument for stringency these authors also left room for smaller scale studies 
which, unlike genome-wide scans, are partly hypothesis -driven. Given that such 
a targeted approach, as employed here, does not necessitate the use of many 
markers, it also does not require such stringent levels of significance. 
Since Lander and Kruglyak's guidelines were published, the practicality of their 
suggestions has been tested empirically. Logarithm of odds (LOD) scores of 3.6 
or over in complex disease studies are now felt by many to be too stringent (Rao 
& Province, 2000). Thus the thin red line of significance has given way to a 
broader, interpretative approach. Often this involves simulation methods to 
empirically derive significance levels (Cheng et al, 200 1; Angius et al, 2002; 
Caulfield et al,, 2003). Other studies use lower fixed thresholds of significance 
(Rankinen et al, 200 1; Rice et al, 2002; Cooper et al, 2002). No approach to 
significance determination represents a panacea, and interpretation of linkage 
results, particularly genome-wide data, is still very much a grey area. Indeed, it 
was acknowledged from the outset that such interpretation was not trivial and 
that high LOD scores could be false just as low LOD scores could be genuine 
(Lander & Kruglyak, 1995). 
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In light of the difficulties with interpreting linkage evidence, combination of 
evidence from multiple samples remains essential (Altmuller et al, 2001). 
Replication is one of the few ways to increase confidence in a linkage result, in 
the absence of a method for definitively proving the existence of a QTL. It also 
provides some evidence for broader applicability of the QTL than simply to the 
original sample studied. With respect to the identification of genes relevant to 
hypertension development at the population or global level, this is obviously 
important. Replication of our 5q QTL thus provides confidence in the result and 
may indicate a broader relevance to Caucasian populations. 
The expectation from simulation studies is that study samples with more extreme 
phenotypes provide greater power to detect genetic effects (Risch & Zhang, 
1995; Gu et al, 1997). This philosophy has been applied in some hypertension 
scans which have recruited individuals at the extremes of blood pressure 
distribution (Xu et al, 1999; Caulfield et al, 2003). From this, the expectation 
with our study samples is that the Silesian group should provide more power to 
detect blood pressure linkage given the majority of hypertensive individuals. 
That the same QTL with comparable linkage has also been detected in the 
normal, healthy MIDSPAN group is probably a consequence of the much greater 
size of this population. Certainly sample size has been 
identified as a major 
factor for success in linkage studies (Altmuller et al, 2001). 
The QTL described in our two populations is approximately 30 cM from that of 
Krushkal et al (Krushkal et al, 1999). QTL separated by such a distance would 
normally be considered to 
indicate different linkage effects. It is interesting, 
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however, that further work by the US group could only implicate the ADR132 
gene, which is within the linkage region identified in our study (Bray et al, 
2000b). Subsequent studies have reported linkage in the region proximal to 
ADRB2. A US genome-wide scan of 344 healthy, white sib pairs assessed the 
effect of a 20 week exercise program on ADBP. A multipoint LOD score of 1.38 
at the ADRI32 locus was reported (Rankinen et al, 2001). A GWS in Icelandic 
families reported a LOD score of 0.95 for hypertension close to the ADRB2 
locus (Kristjansson et al, 2002). A population-based study in the US reported 
linkage to hypertension but not to SBP or DBP at the qter in Caucasian families 
(Hunt et al, 2002). Between these previously published studies, the entire 5q3 1.1 
to qter region has been implicated. However, with the reproducible linkage 
found in our populations, and in light of the findings by others proximal to the 
ADRB2 locus, the region around 5q3l. 1 to q33 is now highlighted as a 
promising region (Tomaszewski et al, 2002). 
Classically, QTL may be tightened by addition of additional microsatellite 
markers to increase map density. We chose not to do this since our study is an 
amalgamation of linkage study and candidate gene study rationales. Our prior 
hypothesis is that any linkage detected within the 5q region may be related to 
variants of the ADRB2 gene encoding the P2-adrenergic receptor given the 
findings of the US studies (Bray et al, 2000b). At a5 cM resolution, we are 
already working with a map which is at least twice as dense as 
GWS studies. 
The observations of Krushkal et al and Bray et al (Krushkal et al, 1999; 
Bray et 
al, 2000b) also indicate that linkage maxima may not coincide with the gene 
locus in this region. Finally, the linkage region has a lower gene density than the 
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genomic average, with only a few sensible cardiovascular candidates. A 
candidate gene approach from this point therefore seems reasonable although 
grid tightening is a future option. 
Evidence from experimental models further strengthens the case for the linkage 
region found in our populations. A region of human chromosome 5q of 
approximately 13 Mbp is syntenic with rat and mouse chromosome 18. This 
syntenic block extends from the centromeric flank of D5s494 to the distal flank 
of D5s636, thus encompassing our entire linkage region. Genome-wide scanning 
of a stroke-prone spontaneously hypertensive (SHRSP) x Wistar-Kyoto (WKY) 
F2 cross detected a QTL for baseline and salt-loaded DBP on rat chromosome 18 
(Jacob et al, 1991). This QTL, denoted BP2, extended distally to the rat 
glucocorticoid receptor gene, Grl, the human homologue of which (NR3CI) is 
located under our peak of linRage on human chromosome 5q (see Fig. 3.3.2A). 
Linkage in this region of rat chromosome 18 has since been reported by other 
genome-wide scans in rat models; specifically, SBP in a cross of spontaneously 
hypertensive rat (SHR) x BioBreeding OK substrain (BB/OK) (Kovacs et al, 
1997) and salt-loaded blood pressures in Brown Norway (BN) x Dahl salt- 
sensitive (SS) (Cowley et al, 2000). This QTL is absent in other strains, notably 
our own Glasgow WKY x SHRSP cross (Clark et al, 1996). In mice, a QTL for 
SBP in a cross of hypotensive BP/I mice with normotensive M spretus was also 
reported on mouse chromosome 18, at the proximal limit of the region syntenic 
to human chromosome 5q (Wright et al, 1999). 
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Our QTL in the 5q31.1-q33 region contains several promising candidate genes. 
The previous work implicating the ADRB2 gene (Bray et al, 2000b), has 
implicated this as a prime positional candidate and physiological candidate with 
its involvement in regulation of vascular tone and dilatation (Wood, 2003). With 
regard to the wider cardiovascular picture, theP2-adrenergic receptor is known to 
mediate thermogenesis and lipolysis (Lowell & Bachman, 2003). It can be 
hypothesised to connect the vascular and metabolic abnormalities often 
cosegregating in hypertensive patients (Reaven, 2003). Functional relevance of 
ADRB2 polymorphisms is relatively well understood due, in part, to the interest 
of asthma researchers in ADRB2-mediated bronchial dilatation (Drysdale et al, 
2000). The ADRB2 locus has been studied, quite extensively, as a candidate 
gene in blood pressure and hypertension. Some studies imply an effect in 
Caucasian (Gratze et al, 1999; Busjahn et al, 2000; Bengtsson et al, 2001) and 
black populations (Kotanko et al, 1997), whilst others show no association (Jia et 
al, 2000). Our own findings with regard to ADRB2 (Tomaszewski et al, 2002) 
are described in Chapter 4. 
A novel cardiovascular candidate gene, which is located within the middle of the 
linkage region, is the acidic fibroblast growth factor gene, FGFI. Following 
comparative mapping of QTL between rat and the human 5q3l-qter region, 
FGF I was suggested as a positional candidate for blood pressure (Stoll et al, 
2000). Despite this, relatively few studies have assessed the potential of this 
gene as a factor in blood pressure control and hypertension. 
However, as a 
potent endothelial cell proliferator (Powers et al, 
2000), with proven effects on 
blood pressure in animal models (Cuevas et al, 1991; Wu et al, 1996) and a 
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possible role in defence against oxidative stress (Yang & deBono, 1997), FGF I 
suggests itself as a biological candidate whose involvement in the pathogenesis 
of hypertension could be explained by a number of mechanisms. 
The glucocorticoid receptor (GR), encoded by the NR3CI gene, is also located 
within the linkage region. As a regulator of gene transcription, GR affects 
immune, metabolic, behavioural, cell-growth and vascular processes (De Rijk et 
al, 2002). Mutations affecting ligand binding or receptor regulation cause 
corticosteroid resistance,, one feature of which is hypertension (Ruiz et al, 2001). 
The locus has been implicated in hypertension by some (Watt et al, 1992) but 
excluded by others (Lin et al, 1999; Takami et al, 1999; Dobson et al, 2001) 
using both association and linkage methods. 
The work described here, then, has suggested evidence of linkage of a7 cM 
region of human chromosome 5q3l. l-q33 to blood pressure and hypertension. 
The linkage evidence to blood pressure phenotypes has been seen in two 
Caucasian study populations despite different ascertainment criteria. Previous 
targeted studies and genome-wide scans had, between them, implicated a broad 
region of the distal 5q arm. The QTL described here provides a more focused 
area for further efforts. The implication of the proximal segment of the 5 q3 1.1 - 
qter region is also reasonable in the context of work in rat and mouse models. 
Physiological positional candidates for cardiovascular disease exist within the 
QTL and will provide a focus for further work to dissect this locus. 
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CHAPTER 4 
GENETIC STUDIES OF THE POSITIONAL AND 
PHYSIOLOGICAL CANDIDATE GENES ADRB2 AND FGF1 IN 
THE HUMAN 5q3l. l- q 33 BLOOD PRESSURE QTL 
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4.1: INTRODUCTION: 
The role of essential hypertension as a risk factor for stroke and coronary heart 
disease, and its 30-60% genetic determination (Ward, 1990), have made it the 
focus of Herculean efforts by the research community (Kannel, 2000). 
However, its complex, multifactorial, oligo- or polygenic nature (Lander & 
Schork, 1994; Caulfield et al, 2003) combined with small individual gene 
effects (Stoll et al, 2000) has consistently hampered advances in understanding. 
There are, inevitably, inherent difficulties in studying heterogeneous human 
populations with their variation in environment and genetic factors (Lander & 
Schork, 1994). 
Dissection of the complex genetics of essential hypertension necessitates 
combination of complementary approaches (Risch, 2000). Thus we began with 
a targeted linkage study concentrating on the human 5q3l. l to q33 
chromosomal region. We confirmed the presence of linkage to blood pressure 
in this region in two independent study samples (Tomaszewski et al, 2002). Part 
of the rationale for focusing on the distal segment of chromosome 5q was the 
presence of a number of good candidate genes for blood pressure control and 
cardiovascular disease. In addition, this region had been implicated by other 
linkage studies of blood pressure (Krushkal et al, 1999). By identifying linkage 
to a7 cM region we were able to narrow the field of candidate genes to those 
which were both physiological and positional candidates. 
The natural 
progression of this work, then, is the application of candidate gene strategies 
to 
assess the contribution of such genes to the 
blood pressure linkage. 
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Simulation studies suggest that association approaches should be more powerful 
in detecting small to moderate gene effects than linkage approaches (Risch & 
Merikangas, 1996). Such approaches lend themselves to interrogation of 
candidate genes and are, potentially, very powerful but can also be problematic. 
Analysis of candidate genes has been criticised on two fronts: firstly, the 
significant findings of association in many candidate genes studies have not 
been replicated when followed by subsequent studies. Secondly, candidate gene 
studies are based on the ability to predict ftinctional genes and variants. Some 
commentators believe that current knowledge is insufficient to allow this (Tabor 
et al, 2002). 
Many of the pitfalls of candidate gene studies result from the methodologies 
used. The most commonly used paradigm, the case-control study, can give false 
positive and negative results due to population stratification (Cardon & Palmer, 
2003; Ziv & Burchard, 2003). This has led to the development of family-based 
methods in an effort to control for such population effects (Spielman & Ewens, 
1996; Rabinowitz & Laird, 2000). In addition, studies are commonly based on 
the genotyping of a single polymorphism within genes which may span 
hundreds of kilobases. The polymorphism genotyped may have no functional 
relevance itself in which case it must be in linkage disequilibrium with any 
functional polymorphisms for association with disease to be detected (Sharma & 
Jeunemaitre, 2000). 
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Current guidelines recommend a hierarchical selection policy for 
polymorphisms based on their potential for functional effects (Tabor et al, 
2002). In addition, it is recommended that multiple polymorphic sites within a 
gene are genotyped (Sharma & Jeunemaitre, 2000). Here these policies are 
applied, in conjunction with family-based analysis methods, to the investigation 
of two candidate genes which are both biological and positional candidates 
following the previously described linkage studies. These candidates are theP2- 
adrenergic receptor and the acidic fibroblast growth factor genes, located within 
the 5q3 1.1 -q33 blood pressure QTL. 
ADRB2, encoding theP2-adrenergic receptor, is well recognised as a potentially 
important cardiovascular candidate gene. The gene has a simple structure 
consisting of a promoter region of approximately 300-500 bp followed by a 
single coding exon (Emorine et al, 1987). The protein is a 413 residue peptide 
with 7 transmembrane domains (Fig 4.1.1). Expressed by multiple tissues 
including epithelial cells, adipose tissue, vascular endothelium and bronchial 
smooth muscle, ADRB2 is aG protein-coupled receptor (GPCR) which 
mediates signalling by catecholamines such as adrenaline (Liggett, 1997). 
Binding of ligand results in G, -dependent stimulation of adenylyl cyclase and 
production of cAMP. In the context of blood pressure regulation, this signalling 
pathway mediates vasodilatory responses through receptors expressed in the 
vessel wall, but the role of the ADRB2 receptor may be considerably more 
complex. Recent evidence has suggested that the ADRB2 receptor complexes 
with, and regulates signalling through, other GPCRs including the angiotensin 
11 
type I receptor (ATIR). Antagonism of ADRB2 in mice was recently shown to 
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also reduce signalling via the ATIR (Barki-Harrington et al, 2003). ADRB2 is 
also known to be integral to metabolic processes in vivo and the P-adrenergic 
receptors, generally, mediate sympathetically driven thermogenesis as well as 
lipolysis and glucose homeostasis (Lowell & Bachman, 2003). 
ADRB2 has received much interest from the asthma community owing to its 
role in dilatation of the bronchi and the known therapeutic benefits of P- 
agonists. Consequently, polymorphisms within the gene are well known and 
some have been functionally characterised (Liggett, 1997). This prior 
knowledge allows the selection of known functional polymorphisms. Family- 
based methods were used to investigate association of three functional gene 
polymorphisms as single loci and haplotypes to hypertension in the nuclear 
families of the Silesian Hypertension Study. 
FGFI, encoding the acidic fibroblast growth factor, is a member of the FGF 
gene family encoding at least 22 ligands. These mediate a variety of signalling 
events via four widely expressed fibroblast growth factor receptors (FGFRs). 
FGFI itself has kidney and brain-specific promoters, and additional promoters 
controlling expression in various tissues including vascular smooth muscle 
(VSM) (Fig. 4.1.2). It is unusual in that it binds with high affinity to all known 
FGFR isoforms, unlike other FGFs (Chiu et al, 2001). FGFI is released from 
cells to bind to cell-surface FGFRs which triggers a signalling cascade and 
stimulates gene expression. It has wide-ranging roles in development, wound 
healing, turnour development and progression, and angiogenesis. FGF I is also a 
potent proliferator of endothelial cells (Powers et al, 2000). Systemic 
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Fig. 4.1 - 1: 
A schematic of the ADRI32 gene and receptor. The ADRI32 receptor 
mediates signalling by catecholamines in various tissue types. Its roles in cardiac, 
vascular and metabolic regulation make it an important cardiovascular candidate gene. 
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Fig. 4.1.2: A schematic of the FGF I gene. Its diverse expression is regulated by at 
least four promoters. A number of tissue-specific roles of potential relevance to 
cardiovascular disease are noted. Untranslated regulatory exons are shown in blue. 
Translated exons are shown in red. 3' UTR is denoted by the red-boxed area. 
NO = nitric oxide; HPA = Hypothalamic-pituitary-adrenal. 
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administration of FGFI into rats causes a dose-dependent decrease in blood 
pressure, arteriolar dilatation and increased vascular flow. Nitric oxide synthase 
inhibitors or endothelial denudation abolish these effects (Cuevas et al, 1991; 
Wu et al, 1996). FGH may also increase the endothelium's resistance to 
oxidative stress by increase of intracellular reduced glutathione (Yang & 
deBono, 1997). Infusion into rats has also been shown to stimulate the 
hypothalamic pituitary adrenal (HPA) axis, leading to increased plasma 
corticosterone (Matsumoto et al, 1998b), and the sympathetic nervous system, 
increasing catecholamine secretion (Matsumoto et al, 1998a). 
FGH has received little attention from the cardiovascular community, and in 
this context is a novel candidate gene. To investigate this novel locus, FGH 
sequencing and SNP locus and haplotype studies are presented as first steps in 
assessing its contribution to blood pressure variation and hypertension risk in the 
Silesian families. 
4.2: METHODS: 
4.2.1: SILESIAN HYPERTENSION STUDY DESIGN AND RECRUITMENT: 
The Silesian Hypertension Study was used in linkage studies described in 
Chapter 3. A detailed description of the ascertainment strategy, recruitment and 
phenotyping can be found in Sections 2.2.1 and 3.2.1.1. 
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4.2.2: P2-ADRENERGIC RECEPTOR CANDIDATE LOCUS STUDY: 
4.2.2.1: GENOTYPING OFfi2-ADRENERGIC RECEPTOR SNPS. - 
Three non-synonymous functional SNPs were genotyped in the Silesian sample: 
Argl6Gly, Gln27GIu and Thr16411e. PCR for each was performed as detailed 
in Section 2.5.1 in a volume of 20 ýtl using HotStar Taq (Qiagen Ltd, UK). 
Each polymorphism introduces a restriction site into the sequence. Therefore, 
genotyping was done by restriction enzyme digest as described in Section 2.5.2. 
Argl6Gly was digested with BsrDl (New England Biolabs (UK) Ltd, UK); 
Gln27GIu was digested with Ital (Roche, Switzerland); Thrl6411e SNP was 
digested with Mn1l (New England Biolabs (UK) Ltd, UK). Digestion products 
were resolved on agarose gels and genotypes were scored visually by two 
individuals. Digestion products have been described previously (Large et al, 
1997). Examples are shown in Appendix 4. Arg I 6Gly resulted in fragments as 
follows: 14,56, and 131 bp for Arg homozygotes; 14,23,56 and 108 bp for Gly 
homozygotes. Heterozygotes were distinguished by the presence of 108 and 
131 bp fragments. Gln27GIu digestion gave the following fragments: 27,55,97 
and 174 bp for Gln homozygotes; 27,97 and 229 bp fragments 
for Glu 
homozygotes. Heterozygotes were distinguished by the presence of 174 and 
229 bp fragments. Thr1641le gave 38,114 and 206 bp fragments in Thr 
homozygotes; 38 and 320 bp fragments in Ile homozygotes and 38,114,206 and 
320 bp fragments in heterozygotes. 
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4.2.3: FIBROBLAST GROWTH FACTOR I CANDIDATE LOCUS STUDY: 
4.2.3.1: FIBROBLAST GROWTH FACTOR I SEQUENCING: 
Single nucleotide polymorphism (SNP) discovery within the FGFI locus was 
performed by sequencing coding, flanking intronic and 3' untranslated regions 
(3' UTR) of the gene as described in Sections 2.6.1 and 2.6.2. Three coding 
exons are known at present, as detailed in Fig. 4.1.2. PCR primers were 
designed to intronic sequences flanking each exon based on genornic sequences 
in the NCBI database (www. ncbi. nlm. nih. gov; Accession no: NT_029289) and 
FGF1 cDNA sequences from the same database and the literature (Payson et al, 
1993). Primer sequences are given in Appendix 3. 
Twenty unrelated Polish individuals were selected for sequencing. A 
deliberately heterogeneous group was used. Thus, ten individuals were male, 
ten female. Of these two subgroups, half were hypertensive and half 
normotensive. HotStar Taq (Qiagen Ltd, UK) was used to amplify intron/exon 
and 3' UTR sequences as described in Section 2.6.1. PCR products were 
purified by Nucleofast-96 plates (Macherey-Nagel, Germany). Direct 
sequencing of the purified PCR products from the 20 individuals was done by 
MWG Biotech using the forward PCR primers. Data from MWG were aligned 
to a reference sequence using Vector NTI A (Informax Inc, US). 
Putative 
polymorphic sites were confinned by visual inspection of the 
electrophero grams. 
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4.2.3.2: FIBR OBLA ST GR 0 WTH FA C TOR I SNP GENO TYPING 
.- 
Genotyping of polymorphisms within the FGFI gene was done by the MRC 
Gene Service (Cambridge, UK). Genomic DNA at 5 ng/ýtl was provided. PCR 
primers were identical to those used during sequencing of the FGF I gene. 
Genotyping was performed on an ABI 7900HT (TaqMan) instrument platform 
(Applied Biosystems, UK). Allelic recognition probes were labelled with the 
fluorescent dyes VIC or FAM. Probe sequences are provided in Appendix 3. 
4.2.4: STATISTICAL ANALYSES: 
Genotypic data were checked for Mendelian inconsistencies using the 
PEDCHECK program (O'Connell & Weeks, 1998). Genotypes were confirmed 
for individuals flagged by the software, corrected if appropriate or individuals 
removed from the dataset. 
Blood pressure measurements were corrected for the effect of anti-hypertensive 
treatment using a method developed by the Framingham Study (Levy et al, 
2000) and described in Section 3.2. 
4.2.4.1. - ANALYSIS OF THEP2-ADRENERGIC RECEPTOR LOCUS: 
A detailed description of analytical methods used and reasons for their selection 
can be found in Section 2.7.2.1. Briefly, family-based tests of association and/or 
linkage were used to assess the SNPs genotyped in the ADRB2 gene and 
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hypertension status. Transmission disequilibrium testing (TDT) was employed 
to test for linkage and association (Spielman et al, 1993). This was originally 
devised as a test for linkage in the presence of association and uses simplex 
families consisting of parents and an affected child. Transmission of alleles 
from parent to child at a polymorphic locus is compared to non-transmitted 
alleles. This test is robust to the effects of population stratification since the 
non-transmitted alleles provide the control genotype. To test for association 
with hypertension, assuming linkage, the empirical variance option of FBAT 
(EV-FBAT) was used. The null hypothesis of linkage but no association is 
tested by this method (Lake et al, 2000). FBAT is robust with regard to 
pedigree structure, population admixture, phenotype distribution and 
ascertainment methods and uses all individuals in a pedigree unlike TDT. 
ADRB2 SNP haplotypes were assessed using a modified TDT method 
implemented in TRANSMIT (Clayton, 1999). This is a likelihood method 
which allows for missing parental data and haplotype phase uncertainty and uses 
genotype data from available parents and offspring to efficiently determine 
phase. The method is robust against population stratification. 
Binary logistic regression analysis was performed in the parental generation to 
test for increased risk of hypertension with genotype at the three polymorphic 
loci. Covariates of age, sex, and body mass index were included. 
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4.2.4.2. - A NA L YSIS OF THE FIBR OBLA ST GR 0 WTH FA C TOR IL0C US. - 
Genotypes derived from SNP genotyping of the FGFI locus in the Silesian 
Hypertension Study group were assessed for association to quantitative and 
qualitative blood pressure traits. The software package FBAT was used to 
perform a family-based association test of SNPs to phenotypes (Horvath et al, 
2001). The empirical variance option (EV-FBAT) was used to investigate the 
null hypothesis of linkage but no association (Lake et al, 2000). In addition, 
haplotype analyses were performed using Haplotype-FBAT (H-FBAT) in which 
genotypes at all polymorphic loci were assessed jointly. The method handles 
missing parental genotypes and unknown haplotype phase. 
4.3: RESULTS: 
4.3.1: STUDIES OF THE P2-ADRENERGIC RECEPTOR LOCUS: 
ADRB2 was examined as a positional and physiological candidate which has 
been implicated by other studies of blood pressure and hypertension. Three 
non-synonymous, functional single nucleotide polymorphisms within the 
ADRB2 gene were genotyped and analysed. These were Argl6Gly, Gln27GIu 
and Thr16411e. TDT analysis was used to assess linkage in the presence of 
linkage disequilibrium to essential hypertension. Analysis was performed in 
trios consisting of two parents, one child or trios of one parent, one affected 
child, one unaffected child. Argl6Gly and Gln27Glu were not significantly 
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Fig. 4.3.1: Odds ratios (OR) and 95% confidence intervals for binary 
regression modelling of essential hypertension risk. Confounders of age, sex 
and BMI were included. OR was calculated for heterozygous or homozygous 
variant individuals with respect to wild type homozygotes. 
ND = not done due to the rarity of the Ile allele. 
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012345 
linked to hypertension with P values greater than 0.05. The allele frequencies of 
1641le wer einsufficient to allow a vlid test of this locus (Table 4.3.1). 
The EV-FBAT method confirmed the TDT results. No test could be performed 
for the Thr1641le polymorphism due to the rarity of the Ile allele with only 17 
occurrences in the study group. However, tests for Argl6GIy and Gln27GIu 
agreed with the findings of the TDT analysis. Neither polymorphism was 
significantly associated with essential hypertension (Table 4.3.1). 
Of 8 possible haplotypes, 7 were observed in our population. These were 
designated A to G. Haplotypes B, D and F were most common and accounted 
for 97.4% of observations (Table 4.3.2). Transmissions of each haplotype were 
compared with expected number of transmissions using TRANSMIT. The 
observed transmissions from heterozygous parents to hypertensive offspring 
were not significantly different from the expected. Haplotype analysis therefore 
supported the single locus analyses, indicating no association of the 
polymorphisms to essential hypertension (Table 4.3.2). 
Binary regression modelling, including confounders of age, sex and BMI, also 
confirmed the single locus and haplotype TDT analyses. Presence of one or two 
variant alleles at any SNP locus did not significantly increase risk of 
hypertension when compared to common individuals. Odds ratios for 
heterozygotes and variant homozygotes were: 0.85 (95% Cl, 0.3 to 2.2); P=0.74) 
and 1.46 (95% Cl, 0.5 to 4.2; P=0.49) for Argl6GIy; 1.33 (95% Cl, 0.6 to 3.1; 
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P=0.5) and 1.54 (95% Cl, 0.5 to 4.4; P=0.43) for Gln27GIu; and 0.7 (95% Cl, 
0.1 to 4.9; P=0.72) for Thr1641le respectively (Fig. 4.3.1). 
4.3.2: STUDIES OF THE FIBROBLAST GROWTH FACTOR I LOCUS: 
FGF I was investigated next as a second putative physiological candidate which 
lay under the maximal multipoint linkage region. SNP hunting and association 
analyses were performed in the Silesian hypertensive family resource. 
4.3.2.1. - FIBROBLAST GROWTH FACTIOR I SEQUENCING AND SNP 
DETECTION: 
No SNPs within coding exons were listed in on-line databases such as NCBI 
(http: //www. ncbi. nlm. nih. gov/) so coding exons, flanking intronic regions and 
the 3' UTR of the gene were sequenced to allow identification of 
polymorphisms in the Silesian population. Sequencing was performed with 
genomic DNA from 20 unrelated individuals, half of whom were hypertensive. 
This sample of 40 chromosomes gave an 87% probability of finding 
polymorphisms with minor allele frequencies of 5% and 99% probability of 
finding polymorphisms with 10% minor allele frequency. 
Regions covered, and results obtained by sequencing, are shown in Fig. 
4.3.1. 
Sequence data obtained were aligned to reference sequences from the NCBI 
database. Polymorphic sites were identified which differed from the reference 
sequence. These xxere confirmed 
by a visual check of the sequencing 
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electrophero grams. The majority of polymorphisms were eliminated as 
sequencing errors. In agreement with available information, no SNPs or other 
polymorphisms in coding regions were found in the 20 Polish individuals 
sequenced. However, an intron 2 SNP (SNP 1, T->G) was found 19 basepairs 
from the start of exon 3 and three further SNPs were identified in the 3' UTR of 
the gene. These were located 284 bp (SNP 2, C->A), 323 bp (SNP 3, G->A) 
and 774 bp (SNP 4, G-+C) into the 3' UTR. In total, then, 4 SNPs were found 
spanning 987 bp. SNPs 2 and 4 were listed in public databases; dbSNP 
accession numbers were 34002 and 2278688, respectively. SNPs I and 3 were 
not listed. 
4.3.2.2. - FGFI SNP GENOTYPE ANALYSIS: 
Allele frequency estimates based on sequencing 40 chromosomes suggested that 
all four SNPs were common (Fig. 4.3.1). Given this, heterozygotes were 
expected to be common and each SNP was expected to be informative for 
family-based association studies. Therefore, all four SNPs were genotyped. 
SNP I in intron 2 proved intractable to the hybridisation method used, and so 
data were not obtained. However, genotypes were obtained for SNPs 2 to 4 in 
the 3' UTR. These were analysed by family-based association testing 
procedures implemented in the software FBAT. 
Association in the presence of linkage of each individual SNP and hypertension 
was tested using the empirical variance FBAT (EV-FBAT) test. This method 
was also used to test for association to SBP, DBP and pulse pressure (PP). EV- 
158 
FBAT was preferred over TDT for FGF I analyses since it makes more thorough 
use of available genotyped individuals, whilst TDT is restrictive in its use of 
simplex families. Use of TDT as the primary method for ADRB2 analyses had 
been prescribed by our desire to follow-up the ADRB2 studies of Bray et al 
(2000b). This decision meant we concentrated on analysis of hypertension 
status for ADRB2. However, because we subsequently adopted FBAT as our 
primary analysis for FGF 1, we were able to assess SBP, DBP and pulse pressure 
and compare them directly. In FGFI, SNP 2 proved to be associated with 
hypertensive status, pulse pressure and systolic blood pressure at the 95% 
confidence level. SNPs 3 and 4 showed no evidence of such association (P > 
0.05). No loci were associated with DBP. 
Association of haplotypes across the three SNP loci and hypertension status was 
considered using the haplotype extension of FBAT (H-FBAT). This 
methodology had not been developed when ADRB2 was studied. However, its 
availability for FGFI allowed us to examine single loci and haplotypes in a 
concerted manner. Of a possible 8 haplotypes, 7 were observed, denoted A to 
G. Three of these, haplotypes A, B and C, accounted for 96.9% of all 
observations (Table 4.3.4). These were common enough to be informative in 
the study group. Haplotype A, consisting of the alleles C, G and G at SNPs 2,3 
and 4, respectively, was significantly associated with hypertension status in the 
Silesian study sample. Neither haplotype B nor C was significantly associated. 
It appears that association of haplotype is dependent on the allele at SNP 2. All 
other haplotypes having allele C at SNP 2 had frequencies of 0.5% so were 
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uninformative. However, the particular importance of this SNP supports the 
findings of the single locus analyses. 
4.4: DISCUSSION: 
Previous linkage analyses focused our attention on positional and physiological 
candidate genes in a7 cM region of human chromosome 5q (Tomaszewski et al, 
2002). Association studies of two genes were performed in the Silesian 
Hypertension Study sample, using family-based analysis methods. Work by 
others had previously implicated the ADRB2 gene encoding the 02-adrenergic 
receptor, and this was investigated first. Single locus and haplotype analysis of 
three non-synonymous, functionally relevant SNPs within the ADRB2 gene did 
not support its involvement in the development of essential hypertension in our 
study sample (Tomaszewski et al, 2002). This was despite 86% power to detect 
association (P<0.05) with an odd ratio of 1.6 at the two common ADRB2 loci. 
Attention turned to the FGF I gene encoding the acidic fibroblast growth factor, a 
cardiovascular candidate gene which, to our knowledge, has not been studied 
previously. Single locus and haplotype analyses demonstrated association of 
polymorphisms within the 3' UTR of the gene. In particular, a single locus, 
denoted SNP 2 and located 284 bp into the 3' UTR, appears to determine 
presence or absence of association. 
The association analyses of both ADRB2 and FGH used family-based 
approaches. The compact nuclear family structure of the Silesian Hypertension 
Study sample lends itself to such methodologies. Concerns have been raised by 
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many regarding the possible effects of population stratification on results of 
association studies (Ziv & Burchard, 2003) and family-based studies have been 
developed to address this (Spielman & Ewens, 1996). In increasing robustness 
to stratification, however, there is generally a loss of power of family-based 
methods over the case-control method (Risch & Teng, 1998). Simulations have 
shown that this is particularly acute if parental genotyping is incomplete or 
absent (Risch & Teng, 1998). Power can be improved, however, by the inclusion 
of at least one affected parent and additional offspring, particularly if they are 
also affected (Whittaker & Lewis, 1998). In the Silesian sample, parents were 
present and genotyped. In addition, owing to the recruitment strategy, 
prevalence of essential hypertension was high in the group resulting in a high 
percentage of affected parents and siblings. Thus, whilst controlling for the 
effects of population stratification, the power of the family-based methods used 
is potentially maximised. In addition, use of multiple polymorphic loci and 
consideration of haplotypes results in a more robust analysis (Sharma & 
Jeunernaitre, 2000). These candidate genes were not studied in the MIDSPAN 
sample, partly due to unavailability of funding to accomplish this. However, it 
was also felt that such studies were more usefully pursued in samples with a 
significant disease burden, such as the Silesian sample, rather than a normal, 
nominally healthy population sample such as MIDSPAN since allele frequencies 
of genuine susceptibility loci would be greater. 
The ADRB2 gene, encoding the P2-adrenergic receptor has received much 
attention from cardiovascular researchers owing to its role in maintenance of 
vascular tone, heart rate, salt and water excretion and lipolysis 
(Bray & 
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Boerwinkle, 2000). Studies of this locus benefit from the existence of relatively 
well-characterised functional polymorphisms. This knowledge allowed us to 
select SNPs with known functional significance in line with current thinking 
(Risch, 2000; Tabor et al, 2002). These were Argl6GIy, Gln27GIu and 
Thr16411e. Argl6GIy and Gln27GIu affect receptor downregulation. The Gly16 
allele promotes agonist-induced receptor downregulation, decreasing numbers of 
receptors at the cell surface. The Glu27 allele has been shown to result in 
resistance to agonist-induced downregulation. Where both variant alleles are 
present, the receptor downregulates at an increased rate comparable to the 
presence of Gly16 alone (Green et al, 1994). The Thrl6411e variant receptor is 
less common but most functionally altered. The Ile allele causes a slight decease 
in agonist binding affinity but a substantial decrease in basal and agonist- 
stimulated adenylyl cyclase activity due to defective G, protein coupling (Green 
et al, 1993). 
Haplotype studies of ADRB2 gene polymorphisms are rare, despite the potential 
for interactions between the functional polymorphisms described. A case-control 
study including 707 French hypertensives found no evidence of increased risk of 
hypertension from haplotypes across four ADRB2 polymorphisms, including 
Arg I 6GIy and Gln27GIu (He=ann et al, 2002). This agrees with our findings 
in the hypertensive Silesian sample. Conversely, two reports of normotensive 
study groups from Europe reported association of haplotypes of Argl6GIy and 
Gln27GIu with SBP. A population sample from Italy showed association of SBP 
with the haplotype Argl6-Glu27 as well as association of the Arg16 allele alone 
(Castellano et al, 2003). A Norwegian case-control study compared 
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normotensive offspring of hypertensive parents with offspring of normotensive 
parents. It showed association of a4 locus haplotype with blood pressure. It was 
again found that Arg 16 was the critical allele (Timmermann et al, 1998). 
The vast majority of studies of the ADRB2 locus examine polymorphisms as 
single loci. European, American, Japanese and African Caribbean populations 
have been investigated. Ethnic differences may explain some of the variability in 
findings. For example, a case-control study in African Caribbean individuals 
demonstrated association of the pro-downregulatory Gly16 allele with 
hypertension (Kotanko et al, 1997). Association of the Gln27GIu polymorphism 
and hypertension was demonstrated in a Japanese case-control study with Gln27 
more common in hypertensives (Kato et al, 2001). However, in agreement with 
our findings and those of He=ann et al, studies in white European hypertensive 
samples from Sweden and the UK show no association of ADRB2 
polymorphisms to hypertension (Jia et al, 2000; Bengtsson et al, 2001). In 
contrast, positive association of ADRB2 polymorphisms with blood pressure has 
been reported in normotensive samples from Germany (Busjahn et al, 2000), 
Austria (Gratze et al, 1999) and Finland (Bengtsson et al, 2001). Association of 
SBP to ADRB2 has also been reported in white normotensive US sibs (Bray et 
al, 2000b). Studies of intermediate phenotypes in normotensives also suggest 
association of ADRB2. These include forearm blood flow, response to 
isoproterenol infusion in individuals from the UK (Cockcroft et al, 2000) and 
salbutamol-induced vasodilatation in Austrian men (Gratze et al, 1999). 
It is 
notable, then, that association of ADRB2 is negative 
in hypertensive European 
populations whereas studies in normotensive groups suggest association. 
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A possible explanation for the discrepancy in the contribution of ADRB2 to 
hypertension risk versus normal blood pressure distribution may lie in interaction 
of other metabolic and cardiovascular phenotypes. ADRB2 influences insulin 
resistance, obesity and heart failure (Bray & Boerwinkle, 2000). These in turn 
are known to have very different prevalence in hypertensive and nonnotensive 
individuals (Reaven, 2003). They cannot, therefore, be excluded as potential 
factors confounding the relationship between ADRB2 variants and blood 
pressure. This possibility is supported by studies of subsets of European 
hypertensives, for example those with type 11 diabetes, for whom positive 
association of ADRB2 to hypertension has been reported (Bengtsson et al, 200 1). 
Alternatively, the different contribution of ADRB2 in normotensive and 
hypertensive individuals may indicate differences in the genetic basis of high and 
low blood pressure. This remains to be clarified. However, in our hypertensive 
population there is no evidence to suggest that ADRB2 contributes to 
hypertension risk across the sample. 
The fibroblast growth factor I (FGFI) gene, unlike ADRB2, has received little 
attention from the cardiovascular research community making it an exciting and 
novel candidate. Studies in animal models have suggested a possible role in 
blood pressure regulation and, potentially, hypertensive disease. Direct effects of 
FGF I on blood pressure have been demonstrated. Infusion into rats causes a 
dose-dependent hypotensive effect which is blocked by nitric oxide synthase 
(NOS) inhibitors (Cuevas et al, 1991). FGFI has been shown to stimulate 
increase in intracellular Ca 2+ concentrations, and it is possible that FGH 
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regulates the calcium-dependent conversion of L-arginine to nitric oxide by NOS 
(Cuevas et al, 1991). Others showed that infusion of FGFI into rats at 
physiological concentrations resulted in vasodilatation of resistance arteries and 
arterioles. Vascular flow also increased and all effects were again blocked by 
NOS inhibition or endothelial denudation (Wu et al, 1996). Systemic infusion 
into rats has also been demonstrated to induce adrenomedullary secretion, raising 
plasma adrenaline and noradrenaline via a corticotropin releasing factor- 
dependent mechanism (Matsumoto et al, 1998a). Cerebroventricular or intra- 
atrial delivery of FGF I increased plasma corticosterone and adrenocorticotrophic 
hormone (ACTH) (Matsumoto et al, 1998b). This suggests possible roles in 
metabolic processes and energy expenditure for a molecule which is known to 
act as an appetite suppressant, via glucose-sensitive neurons in the hypothalamus 
(Matsumoto et al, 1998a). 
FGF I is important in development and causes proliferation of fibroblasts and 
endothelial cells (Powers et al, 2000) - hence its designation as a growth factor. 
However, on binding to FGF receptors, it also triggers expression of a variety of 
genes. Evidence from studies in cultured endothelial cells suggests that one 
effect of this may be to upregulate glutathione peroxidase-dependent oxidative 
stress defence. Studies in cultured human endothelial cells showed that 
application of FGF I or the closely related FGF2 increased intracellular reduced 
glutathione concentrations, and accelerated the removal of hydrogen peroxide 
applied to the cells (Yang & deBono, 1997). 
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Although the FGF I gene has been suggested as a cardiovascular candidate gene 
previously (Stoll et al, 2000), genetic studies have yet to be published. There are 
presently no known polymorphisms within the coding region of FGF. Consistent 
with this, we also did not find any coding polymorphisms despite good power to 
find alleles of 5% frequency or over. In the absence of polymorphic loci in 
coding regions it has been suggested that 5' and 3' regulatory regions take 
precedence since they may affect the timing, location or level of gene expression 
(Tabor et al, 2002). Our analysis of three polymorphic loci in the 3' UTR of the 
FGF I gene showed association of the locus to hypertension status and blood 
pressure phenotypes. This is consistent with our linkage studies which were 
positive for both disease status and quantitative trait in the Silesian group 
(Tomaszewski et al, 2002). Our results implicate SNP 2, primarily, since it was 
associated both as a single locus and within a haplotype across three loci. 
The frequencies of the haplotypes indicate linkage disequilibrium between the 
three loci. However, LD is not total since the allele at SNP 2 does not 
definitively predict the allele at SNPs 3 or 4. This may explain why SNPs 3 and 
4. as individual loci, are not associated. It is known that LD is not proportional 
to distance below 60 Kb separation (Wright et al, 1999). Complexity in LD over 
very short distances - in this case, 490 bp - may be expected and has been 
reported by others in studies of complex diseases such as asthma (Allen et al, 
2003). Equally, the possibility exists that strong LD may be present between 
polymorphic loci separated by quite large distances, perhaps as much as 100 Kb 
(Daly et al, 2001). Therefore, association of SNP 2 with hypertension and blood 
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pressure traits serves to implicate a smaller segment of the original 7 cM linkage 
region, essentially fine mapping an area of interest. 
SNP 2, itself, may be the functional locus but in the absence of functional 
characterisation it is not possible to conclude this. It may also be in LD with the 
causative locus. Determination of the strength of LD in the region requires a fine 
mapping strategy as used by others to describe haplotype block structures (Rioux 
et al, 200 1). At present, then, the association at the 3' end of the FGF 1 gene may 
implicate a region of perhaps 200 Kb. Fine mapping within this region will 
identify the critical haplotype tag associated with the phenotypes of interest. 
This may result in a number of genetically equivalent loci which cannot be 
separated based on strength of association, a limitation which has been reported 
by others (Rioux et al, 2001). In this case, study of the functional effects of 
polymorphisms may be required to determine their relative importance. 
Within the local region around the associated SNP loci, density of known genes 
is relatively low, compared to the genomic average of approximately 10 per 
million bases (Cartegni et al, 2002). The 100 Kb proximal of SNP 2 contains the 
FGF I gene including regulatory regions (Chiu et al, 200 1). In the distal 100 Kb, 
no other genes are known except for GRAF (GTPase regulator associated with 
focal adhesion kinase) which is located 85 Kb distal of the FGF I gene. GRAF is 
a GTPase-activating protein which interacts with focal adhesion kinase 
(FAK). 
FAK provides a link between integrins and the signalling cascades that are 
activated by them (Hildebrand et al, 1996). Integrin signalling plays a part in 
regulation of vascular tone, perhaps partly through regulation of 
ion channels. 
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Signalling through (xvP3 integrins results in NO production by endothelial cells 
and there is evidence to suggest that extracellular matrix deposition and integrin 
expression in hypertension are altered (Martinez-Lemus et al, 2003). The GRAF 
gene cannot be dismissed out of hand as a candidate, therefore. However, its 
distance from the locus of association weakens the case in favour whilst 
strengthening that of FGF I. Given that FGF I has plausible biological merit and 
is the only known gene within 180 Kb, FGFI is a logical focus for further 
mapping and functional studies. 
In summary, haplotype and single locus association analyses, using family-based 
methods, were applied to the investigation of two candidate genes, ADRB2 and 
FGF 1, in the 5q3 1.1 -q33 linkage region previously described. Analysis of three 
common, functional polymorphisms probably excludes an effect of these 
polymorphisms as hypertension susceptibility loci in our Silesian Hypertension 
Study group. However, such analyses are unlikely to describe all haplotype 
structure within the gene and must have lower power to exclude other loci, 
particularly those in low LD. Analysis of polymorphisms in the 3' UTR of 
FGFI, however, revealed association to both hypertension and blood pressure 
phenotypes and implicated, particularly, a SNP locus 284 bp into the 3' UTR. 
No other known genes exist within 85 Kb of the associated loci. Thus, FGF I has 
been confirmed as a positional candidate as well as being a physiological 
candidate. Further mapping and functional studies of this gene are required to 
confirm its contribution to hypertension risk. 
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CHAPTER 5 
CANDIDATE GENE ANALYSES OF FAMILIAL INTRACRANIAL 
ANEURYSMS 
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5.1: INTRODUCTION: 
Familial intracranial aneurysms (FIAs) form as a result of complex processes 
involving genetic and acquired risk factors (Alberts, 1999). Whilst as many as 
95% remain asymptomatic (Schievink et al, 1994), the minority that rupture do 
so with devastating effect. Aneurysmal subarachnoid haemorrhage is associated 
with 50% mortality and about a third of survivors have serious neurological 
deficits (Schievink, 1997). Prognosis for those patients who undergo elective 
surgery for intracranial aneurysms (lAs) is considerably better. Mortality of 1% 
and morbidity of 4% underline the benefit of detecting and treating intracranial 
aneurysms early (King et al, 1994). 
At present the aetiology of FlAs is poorly understood. Mechanical factors such 
as haemodynamic stress are involved and may account for the common siting of 
aneurysms at arterial bifurcations, particularly around the circle of Willis. Other 
factors such as inflammatory responses are thought to act on regions of the 
arterial wall weakened by other processes. However, the underlying weakness 
may be genetically determined (Zhang et al, 2003). Presently, no biochemical 
markers of aneurysm formation are known and, without an understanding of the 
genetic basis, it is difficult to effectively identify at-risk individuals 
in families 
with a history of FIA (van Gijn & Rinkel, 2001). 
Studies of the pattern of inheritance in intracranial aneurysm 
families have 
identified autosomal dominant, autosomal recessive and multifactorial 
inheritance patterns (Bromberg et al, 1995) . 
This indicates the possibility of 
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major gene effects, but also the probability of genetic heterogeneity (Schievink, 
1997). However, in the event that major gene effects exist they may be 
detectable by linkage analysis or association-based methods. Such studies in FIA 
patients are presently rare (Zhang et al, 2003). Here a candidate gene approach 
is used to examine the contribution of four genes to the formation of intracranial 
aneurysms in families from the west of Scotland who have a history of FIA. 
A present hypothesis suggests that the underlying defect, which leads to 
intracranial aneurysm (IA) formation, involves an imbalance in extracellular 
matrix formation and/ or degradation (Zhang et al, 2003). It may be this that 
amplifies the long-term effects of ageing and haemodynamic stress. Rare 
Mendelian connective tissue disorders such as autosomal dominant polycystic 
kidney disease, Marfan syndrome and Ehlers-Danlos syndrome type IV arise 
from mutations in genes encoding structural proteins. Features of these 
pathologies include vascular catastrophes such as arterial dissections and 
ruptures as well as aneurysm formation on both systemic and cerebral arteries 
(Schievink, 1997). It is reasoned that mutations in genes underlying these 
Mendelian disorders or other components of matrix fon-nation and decomposition 
may lead to the formation of IAs seen in families. Selection of the candidate 
genes studied has been based on this hypothesis. Consequently, genes encoding 
collagen type 111, fibrillin 1, polycystin 1, and serine protease inhibitor Al have 
been studied. 
Collagen type III is a major component of the arterial wall and is encoded by the 
COL3AI gene on chromosome 2q32.2. Three collagen al(III) chains form the 
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finished homotrimeric collagen III fibre (Fig. 5.1.1) and provide tensile strength 
to the arterial wall (van Vlijmen-van Keulen et al, 2002). 
Mutations in COUAI are responsible for Ehlers Danlos syndrome type IV (EDS 
IV). The majority of deaths in EDS IV patients are due to spontaneous rupture, 
dissection and aneurysm formation of large to medium-sized arteries (Schievink, 
1997). The COUAI gene has therefore attracted considerable interest as a 
candidate for aneurysmal disorders. Studies of collagen type III levels in skin 
fibroblasts from abdominal aortic aneurysm (AAA) patients suggest that 10% of 
AAA patients may have reduced collagen III levels (van Keulen et al, 1999). 
Reduced collagen type III production has also been reported in IA patients (van 
den Berg et al, 1997). Some IA patients may have impaired secretion of collagen 
type 111, as low as 50%, in the absence of differences in initial production. This 
may be due to structural defects affecting thermal stability (Majamaa & Myllyla, 
1993). Crosslinking of collagen fibres, essential to the integrity of the tissue, 
may also be reduced (Gaetani et al, 1996). 
Despite the biochemical data, sequencing or single strand conformational 
analyses (SSCP) of the coding regions of COUAI have failed to reveal relevant 
mutations in IA patients (Kuivaniemi et al, 1993; van den Berg et al, 1999). 
However, such mutations affecting the triple helical domain of the gene have 
been reported in AAA families (Tromp et al, 1993). Linkage studies 
have not 
been performed in IA families. However, a single case-control study of 
19 IA 
patients and 15 controls showed a significant association of an 
Avall restriction 
polymorphism to IA (Brega et al, 1996). 
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FBNI on chromosome 15q2l. l encodes fibrillin 1, the principal structural 
component of elastic- fibre-associated microfibrils (Fig. 5.1.1). It is crucial to the 
elasticity and resilience of blood vessels (Kielty et al, 2002). The consequences 
of disruption of this role are seen in Marfan syndrome where mutations in FBNl 
cause aortic ruptures and dissections. Case reports of intracranial aneurysms in 
Marfan patients also exist (Schievink, 1997). Its significance in at least a subset 
of AAA families has been suggested by linkage of intragenic markers (Vaughan 
et al, 2001), and mutations have been described in thoracic aortic aneurysm 
patients (Milewicz et al, 1996) and AAA patients (Francke et al, 1995). Studies 
of FBNI in IA patients have yet to be published. However, some groups are at 
present studying this gene in families having isolated features of Marfan 
syndrome including arteriopathies and, specifically, intracranial aneurysms 
(Zhang et al, 2003). 
The PKDI gene encodes polycystin I and is located on chromosome 16pI3.3. 
The putative functions of polycystin I include cell-cell adhesion and cell 
signalling, but its function is not precisely known at present (Weston et al, 2003). 
Mutations in the gene result in autosomal dominant polycystic kidney disease 
(ADPKD). A primary characteristic of this disorder is the formation of renal 
cysts which affect nephrons and collecting ducts. However, aortic aneurysms 
and dissections are also common and there is a firm link with increased risk of 
lAs (Schievink, 1997). As might be expected from the vascular aspect of 
ADPKD, polycystin I is expressed in medial layers of arterial walls (Griffin et 
al, 1997) (Fig. 5.1.1). 
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Studies to correlate site of mutation with phenotype suggest that more 5' PKD I 
mutations result in a more cerebrovascular phenotype (Rossetti et al, 2003). 
Families with more marked cerebrovascular but less severe renal manifestations 
are known (McConnell et al, 2001). However, despite the arterial expression of 
polycystin 1, the vascular defects in ADPKD and the confirmed risk of IA from 
this disorder, no studies of PKD I in IA families or aortic aneurysm families have 
been reported. It is, nevertheless, considered a candidate gene worthy of study 
(Zhang et al, 2003). 
The fourth gene studied is SERPINAI which encodes a serine or cysteine 
protease inhibitor known variously as 'protease inhibitor' (PI) or 'a I -antitrypsin' 
(Fig. 5.1.1). The gene is located on chromosome 14q32.13. Its product, PI, is 
the most abundant and important inhibitor of elastase which, itself, is a key 
enzyme in processing of elastic tissues (Zhang et al, 2003). The balance between 
PI and elastase determines elastin catabolism (Baker et al, 1995). Deficiency 
phenotypes of Protease Inhibitor (PI) exist within the general population. The 
wild type phenotype is denoted PiMM and has a 95% frequency. Of the 
deficiency phenotypes, the most severe is PiZZ which has only 10- 15% activity, 
but is also the most rare at 2-3% (Cohen et al, 1990). Homozygosity for the 'T 
phenotype leads to pulmonary emphysema and liver disease (Zhang et al, 2003). 
However, the effect of less severe deficiencies is unclear. 
Deficiency phenotypes of PI have been reported as more common in aortic 
aneurysm patients (Cohen et al, 1990) and small studies of IA patients have 
reported similar observations. Schievink et al (Schievink et al, 1996) showed a 
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2-fold prevalence of such deficiency phenotypes in 100 consecutive IA patients 
compared with the general population and others have reported as high as 8-fold 
over-representation in London IA patients, although this was not significant after 
multiple testing correction (StJean et al, 1996). PI activity may also be reduced 
in intracranial (Tartara et al, 1996) and aortic aneurysm patients (Cohen et al, 
1987). 
Investigation of the candidate genes described was conducted in Scottish families 
with history of FIA and SAH. Further analysis of PI was performed using DNA 
samples obtained from FIA families recruited in the south of England. To assess 
the association and linkage of IA formation to these candidate genes, an 
intragenic or proximal microsatellite was genotyped for each gene. 
5.2: METHODS: 
5.2.1: STUDY RECRUITMENT: 
Recruitment of Scottish individuals to this pilot study took place during 1998 to 
1999 following the strategy described in Section 2.2.1. It was conducted by a 
single research nurse from the case files of one neurosurgeon, Mr K. W. Lindsay, 
who has a special interest in FIA. The original study design specified 
recruitment of affected sibling pairs, a design since used by others in recently 
published FIA genome-wide scans. However, in the absence of suitable families 
or due to unwillingness on the part of individuals to participate, focus turned to 
recruiting with the following priority: 1) any affected family members; 2) parents 
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of affected persons; 3) any other family members. Affected status was based on 
history of aneurysmal SAH or angiographic screening for IA by Mr Lindsay's 
team. Data on IA and SAH risk factors such as age, sex, hypertension and 
smoking history were recorded. Eighty individuals from 21 families were 
recruited, including 28 affected by IA. 
DNA from Southampton FIA families was the generous gift of Prof. 1. N. M. 
Day at the University of Southampton. DNA was derived from 12 extended 
pedigrees with history of FIA and/or SAH. A total of 143 individuals was 
available of which 16 individuals were known to be affected. 
5.2.2: CANDIDATE MARKER GENOTYPING: 
For each candidate gene, a search of on-line databases and the literature was 
made to find an intragenic microsatellite marker, if known, or a marker as 
proximal to the gene as possible. From the Genome Database (GDB, 
http: //gdbwww. gdb. orgo, intragenic markers were available within intron 26 of 
COUAI and the 3' UTR of PKDI, and 7 Kb upstream from SERPINAL 
Primer sequences for these were taken directly from GDB. A literature search 
revealed a microsatellite in intron 43 of FBNI (Miller et al, 1996). 
5.2.2.1. - GENOTYPING OF SCOTTISH FIA SAMPLES: 
Fluorescently labelled PCR of the four microsatellite markers was conducted as 
detailed in Section 2.4.1 using HotStar Taq (Qiagen Ltd, UK). Primer sequences 
and annealing temperatures are given in Appendix 3. Following PCR, markers 
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were pooled together and diluted to enable resolution on the ABI 377 semi- 
automated DNA analyser (Applied Biosystems, UK). PCR products were 
resolved on the ABI 377 as detailed in Section 2.4.2.1. Data were extracted and 
analysed with GeneScan v3.1. Genotypes were assigned and checked using 
Genotyper Q. I. Data were checked by two independent individuals who were 
blind to phenotype. 
5.2.2.2: GENOTYPING OF SOUTHAMPTON FIA SAMPLES: 
Only the marker for SERPINAI was genotyped in the Southampton families. 
PCR for this marker was performed exactly as for Scottish samples. Resolution 
and genotyping was accomplished with an ABI 3730 DNA analyser as detailed 
in Section 2.4.2.2. Data were analysed and genotyped using GeneMapper v3.0. 
Parity of binning between Genotyper software and GeneMapper software was 
assured by the use of identical control DNA samples in all runs and genotyping 
of a subset of Southampton samples on an ABI 377. Genotypic data from 377 
and 3730 platforms were compared in this subset using an Excel spreadsheet to 
ensure agreement. 
5.2.3: STATISTICAL ANALYSES: 
Genotypic data were held in an anonymised Access database to aid analysis. 
PEDCHECK (O'Connell & Weeks, 1998) was used to check for and resolve 
Mendelian errors within families. 
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Initial analyses of the Glasgow data are described in detail in Section 2.7.3 and 
were as follows: two-point linkage between each microsatellite marker and the 
trait was assessed using Affected Pedigree Member (APM) linkage analysis 
(Weeks & Lange, 1988). This tests for an excess of identity-by-state (IBS) allele 
sharing between affected relatives, conditional on the degree of relatedness and 
allele frequencies at the marker locus. Although the IBS method is not as 
powerful as IBD methods, the small numbers suitable for the APM analysis and 
lack of parents meant that IBD estimations would have likely been unreliable. 
This IBS method compromised power for pragmatism. Empirical P values were 
determined by simulation, over 1000 replicates, using SIM and HIST (Weeks & 
Lange, 1988). 
Linkage was also assessed using the combined Transmission Disequilibrium Test 
JDT) (Spielman et al, 1993) and sibling TDT (S-TDT) (Spielman & Ewens, 
1998) in multiplex families. In this context, TDT/S-TDT is valid as a test for 
linkage only. Transmission of alleles from heterozygous parents to affected 
offspring is assessed by TDT. In families having only one parent, the S-TDT 
uses the unaffected offspring to provide an untransmitted genotype to replace the 
missing parent. Analyses were performed twice, specifying those with unknown 
affection status as unknown and then as unaffected. 
Linkage in the presence of linkage disequilibrium was tested by use of TDT and 
S-TDT in simplex families. Two analyses specifying unknown and unaffected 
status were performed, as for the multiplex family analyses. 
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The Family-Based Association Test (FBAT) (Horvath et al, 2001) tests the null 
hypothesis of no linkage and no association It allows the analysis of complex 
pedigree data by decomposing complex structures into individual nuclear 
families. This was used to test for linkage and association within the complete 
pedigrees, allowing inclusion of all genotyped individuals. The null hypothesis 
of no association can also be tested using the empirical variance option within 
FBAT (EV-FBAT). Markers were therefore analysed for association to the trait 
with this method. 
Finally, a case-control design was used to test for association between markers 
and trait. Eighteen affected, unrelated individuals were ethnicity, age and sex- 
matched to 18 controls. Obviously, these are very small groups for the study of a 
complex trait. Realistically, the power of such small samples is negligible, 
particularly in the face of probably heterogeneity. It is unlikely that a single gene 
disorder could be detected, particularly if allelic heterogeneity were present. 
Such heterogeneity has been reported for Mendelian disorders caused by some of 
the genes selected. To use the available patients as efficiently as possible, 
controls were carefully selected from families originating from the same locality 
as the FIA families, having no known history of cerebrovascular catastrophes, 
nor connective tissue disorders. The existence of Hardy-Weinberg equilibrium 
(HWE) was confirmed in controls using Fisher's exact test with 1000 simulations 
as implemented in GDA vl. O (Lewis, P. 0. and Zaykin, D. 2001; 
http: //lewis. eeb. uconn. edu/lewishome/software. html). Genotype frequencies in 
case and control groups were compared by an exact X2 test using STATXACT- 
TURBO v2.1 (Cytel Software Corporation, USA). 
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Genotypes obtained for the SERPINAI marker in Southampton families were 
combined with data from Glasgow families. This combined data set was 
analysed with APM, TDT/S-TDT, FBAT and EV-FBAT. 
5.3: RESULTS: 
A total of 80 individuals, including 28 known to have lAs, were recruited from 
21 families in the Glasgow area of Scotland. Demographic data are shown in 
Table 5.3.1. In five of the 21 families, only one family member was willing to 
participate. Of these five singletons, two were not known to be affected. 
Individuals recruited from the other 16 families are shown in Fig. 5.3.1. Family 
18 contained a single affected individual for whom no genotypes could be 
obtained due to PCR failure. This family and the two unaffected singletons were 
not used in analyses. In addition, PCR failed for the affected child in family 5 
restricting the usefulness of this pedigree. Thus, 76 individuals from 18 families 
were included in the final Scottish study group. Of these, 26 were known to be 
affected. 
Individuals from Southampton were derived from 12 families. Of 143 
individuals, 16 were known to be affected. Mendelian errors in a branch of one 
family resulted in 28 individuals being excluded from analysis. None of these 
were known to be affected nor had affected siblings, parents or children. Thus, 
the combined data set consisted of 191 individuals including 42 known affected 
subjects from 30 pedigrees of variable structure. 
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Table 5.3.1: Demographic and phenotypic data for Scottish FIA study 
participants. 
Affection 
Affected 
status 
Unknown 
N 28 52 
Screened for IAs (N) 28 5 
% multiple aneurysms 39 - 
% SAH 60.7 
% sex (m: f) 21 : 79 46 : 54 
Mean age ± SE / yrs 51.1± 2.0 42.4 ± 2.3 
Mean SBP SE mmHg 136.8 ± 4.3 131.0 ± 2.5 
Mean DBP SE mmHg 84.5 ± 2.4 79.4 ± 1.7 
% on HTN treatment 35.7 11.5 
% history of smoking 68 52 
Details are shown for patients with a positive affection status for IA 
and/or SAH versus individuals not known to be affected. 
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Genotypes for four markers were obtained in Scottish individuals. Locations of 
these markers relative to candidate genes are shown in Figure 5.3.2. Names, 
published and observed heterozygosities are shown in Table 5.3.2. Each 
candidate marker was assessed using linkage and association methods. Results 
of these analyses are presented in Table 5.3.3. 
Linkage of each candidate marker to presence of intracranial aneurysms in the 
Scottish cohort was assessed by both APM linkage analysis and TDT/S-TDT 
multiplex-family analysis. No marker was significantly linked to intracranial 
aneurysm status as assessed by APM. This was the case for the TDT/S-TDT 
analyses also, whether unknowns were treated as 'unknown' (Analysis 1) or 
'unaffected' (Analysis II). The lowest P value obtained for each multi-allelic 
marker is presented. In such small numbers of individuals, trends of significance 
may be of relevance. Given this, it is noted that the COUAI VNTR had the 
lowest P value in all three linkage analyses. However, it was not affected by the 
status of unknowns/unaffecteds in the TDT/S-TDT analyses. 
P values obtained for TDT/S-TDT in simplex families are also presented. No 
significant linkage in the presence of association was seen in these analyses but, 
again, COUAI produced the lowest P value. In analyses of both multiplex and 
simplex families, the specification of status of unknowns had the greatest impact 
on the P value of the SERPINA I locus. 
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COUA1 
VNTF, intron 26 
FBNI 
234 Kb 
Microsatellite, intron 43 
PKD1 
46 Kb 
Microsatellite, 3' UTR 
SERPINAl 10 Kb 
Microsatellite, 7.3 Kb upstream 
Fig. 5.3.2: A schematic representation of marker positions relative to genes. An 
intragenic or proximal microsatellite or 'variable number of tandem repeats' 
(VNTR) marker was genotyped for each candidate gene. Positions of markers 
relative to gene coding regions are represented schematically. Size of regions 
spanned by genes are presented. 
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Results from multi-allelic FBAT, multi-allelic EV-FBAT and ý analyses showed 
a different trend. In all of these analyses, SERPINAI produced the lowest P 
values. The case-control )? test for SERPINAI gave the strongest indication of 
association (P=0.028). This was not significant if corrected for multiple testing. 
Tests of association are more powerful than linkage analyses, requiring fewer 
individuals to detect the same magnitude of genotype risk (Risch & Merikangas, 
1996). Thus, they may be more useful in studies containing small numbers of 
individuals as in this case. In this study, use of FBAT also allowed inclusion of a 
greater number of participants in analysis than IBD linkage or TDT approaches. 
The Z analysis has, in its favour, the correct specification of affection status of 
both cases and controls, with little or no ambiguity. Total number of people 
included in the Xý analysis also exceeded that of the APM or TDT/S-TDT 
analyses. Since the SERPINAI marker gave the greatest suggestion of 
significance in these analyses, it was further genotyped in the Southampton 
family samples and the data combined with the Glasgow genotypes to assess the 
effect of increased numbers on significance. 
Results for analyses of the combined data set are presented in Table 5.3.3. Since 
matched controls were not available for the Southampton samples, aX2 analysis 
could not be done. Poorly-matched controls may result in type I error in case- 
control studies due to population stratification (Rabinowitz & Laird, 2000). This 
is particularly important given the small numbers of individuals studied here. All 
other analyses were performed using the combined data. AP value of 0.024 was 
obtained for the 157 bp allele ftom TDT/S-TDT analysis in multiplex 
families 
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when unknowns were set as unaffected. TDT/S-TDT in simplex families 
resulted in P=0.077 for the 157 bp allele, again with unaffected status specified. 
P values bordering on 0.05 were obtained for the multi-allelic FBAT and EV- 
FBAT analyses (Table 5.3.3). Bi-allelic FBAT analysis was also run on the 
combined dataset. This gave P=0.02 from 10 informative families for allele 
157. This reflects findings of the TDT tests. 
5.4: DISCUSSION: 
This study provides case-control study evidence to suggest that association of a 
marker proximal to the SERPINAl gene and intracranial aneurysm status may 
exist in Scottish individuals from FIA families. In a larger cohort consisting of 
families from Scotland and the south of England, combined TDT and S-TDT 
analyses suggested that the SERPINAI marker may be both linked to and 
associated with intracranial aneurysm status. A case-control design was not 
possible in this larger data set. However, P values from other family-based 
analyses support this trend. Linkage and association analyses of markers within 
the COUAI, FBNI and PKDI genes did not provide any suggestion that these 
markers are linked to or associated with intracranial aneurysm status. 
Clearly, it is not possible to draw firm conclusions from this pilot study 
including, as it does, small numbers of individuals from families with highly 
variable structures. P values obtained are not significant if corrected for multiple 
testing. Any suggestions of linkage or association require investigation in a 
much larger study. However, it is notable that a number of different analytical 
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methods, all using the data in different ways, display the same trend towards 
significance. It is interesting to note that most P values decreased on adding the 
additional Southampton families. The largest effect was seen for TDT/S-TDT 
tests when unknowns were specified as unaffected. It is almost inevitable that 
some of those unknowns will either be harbouring lAs now or will develop them 
later. This therefore introduces misclassification and must weaken the power of 
the S-TDT tests. However, the bias in this case would be towards type 11 error 
since some affected individuals would be misclassified as unaffected. It would 
be expected that this should decrease significance as a result. The fact that 
significance increases is therefore interesting. 
No other studies specifically examining linkage or association of the SERPINA I 
locus to aneurysmal disease in families have been published. Two recently 
published genome-wide scans of FIA patients both report linkage on 
chromosome l4q. Onda et al (Onda et al, 2001) showed linkage to marker 
D14s74,20 cM centromeric of the SERPINAI locus in Japanese affected sib 
pairs. Olson et al (Olson et al, 2002) demonstrated linkage in Finnish affected 
sib pairs at DI 4s 1426,12 cM telomeric of SERPINA 1. Prevalence of deficiency 
phenotypes has been reported to be increased in series of IA patients (Schievink 
et al, 1996). However, a causative role has not been confirmed. 
Since SERPINAI expresses protease inhibitor (PI), the most important inhibitor 
of elastase, the prevailing hypothesis is that a reduction in PI may result in an 
offset of the balance governing vessel wall turnover. Damaged or absent elastic 
skeleton is a common feature observed by histological studies of experimental 
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aneurysms (Yamazoe et al, 1990; Kondo et al, 1997). Generalised elastic fibre 
abnormalities have been described in skin biopsies from IA patients, raising the 
possibility that not only increased degradative proteins but increased 
suscepti ility to their action may exist in some IA patients (Grond-Ginsbach et 
al, 2002). However, the possibility also exists that increased levels of 
SERPINAI may result in FIA formation. It has been shown that elastase also 
fulfils a protective role, cleaving other proteases such as plasmin (Moir et al, 
2002). If elastase is inhibited, the net result will be increased degradation of 
glycoprotein elements of the extracellular matrix (ECM) by plasmin. This in 
turn leaves the fibrillar components of the ECM more vulnerable to matrix 
metalloproteinases (MMPs) (DeClerck & Laug, 1996). Plasmin also activates 
various members of the MMP family and is expressed at higher levels in 
aneurysmal tissue compared with normal cerebral arteries, although whether this 
is cause or effect is not clear (Bruno et al, 1998). 
This study serves to highlight some of the obstacles which have seen genetic 
studies of FIA published so rarely. The inability to detennine the affection status 
of anyone not known to be affected is clearly a major difficulty. Linkage 
analyses solely using affected individuals are one way to minimise 
misclassification. Such strategies have been used recently in the genome-wide 
scans mentioned above (Onda et al, 2001; Olson et al, 2002). However, linkage 
analyses are inherently less powerful than association strategies (Risch & 
Merikangas, 1996) and, of course, rely on the availability of affected individuals 
willing to participate. Herein lies another difficulty in a disorder which affects 
only 1% to 4% of the population (Rinkel et al, 1998) and may carry 50% 
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mortality and 30% morbidity from SAH (Schievink, 1997). This combined with 
the difficulty in identifying affected patients by screening (van Gijn & Rinkel, 
2001) means recruiting affected individuals is not trivial. This is reflected in the 
relatively small number of individuals included in the recent GWS studies. 
Association studies are more powerful but often rely on the presence of 
unaffected controls. The case-control paradigm largely avoids the problem of 
misclassification. Families with a risk for a disorder with consequences as 
catastrophic as SAH will be aware of this. Thus, controls can be picked with 
some confidence. However, the problems of admixture and population structure 
in case-control studies have resulted in their criticism (Tabor et al, 2002). 
Methods such as TDT (Spielman & Ewens, 1996) have been developed to negate 
these problems by using relatives to derive control genotypes. However, a 
reliance on the availability of parental data is a drawback in a late onset disorder. 
This has been partially addressed by S-TDT (Spielman & Ewens, 1998) but one 
parent is still required and both TDT tests can only use nuclear family data. This 
presumes that suitable family structures can be recruited and, further, that parents 
are heterozygous and so informative. This was not the case with the present 
study in which TDT or S-TDT trios were unusual. FBAT and the general class 
of family-based association tests allow the use of complex pedigrees. However, 
they again also use data from unaffected individuals. It is, then, a problem of 
circular logic: identifying patients is difficult and to recruit and correctly 
phenotype sufficient for robust genetic studies requires an effective screening 
protocol; but to develop screening we must 
have a better understanding of 
aetiologY, which requires genetic studies. 
Prospective recruitment may soll,,,, e 
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some difficulties, but requires long-term follow-up of participants to establish 
affection status. 
This pilot study has provided preliminary evidence that association and linkage 
of IA status and a marker proximal to SERPINAI may exist in UK families. 
Study of this locus in a much larger resource is necessary to determine if 
SERPfNAl is involved in FIA aetiology. However, as this pilot study has also 
demonstrated, such a large resource will require a collaborative, multi-centre 
recruitment program due to the paucity of suitable families at the single centre 
level and the resulting lack of power. There is also potential for classical linkage 
studies in extended pedigrees having simple modes of inheritance of IA and/or 
SAH. However, the high mortality makes it unlikely that such families will be 
easily obtained. Recruitment for this pilot study is, at present, complete. 
Considerable funding would be required to expand recruitment to other centres, 
and to allow a realistic chance of achieving sufficient power given that multiple 
families must be approached to find one that is suitable. 
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CHAPTER 6 
GENERAL DISCUSSION 
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In 1990 the World Health Organisation (WHO) stated that coronary heart disease 
(CHD) and cerebrovascular disease would rank first and fourth, respectively, as 
causes of global disease by the year 2020 (Murray & Lopez, 1990). Despite 
significant technological advances in the intervening 14 years, complex disease 
genetics still represent a considerable challenge. 
Essential hypertension and familial intracranial aneurysms are complex disorders 
sharing common features such as genetic heterogeneity, gene-gene and gene- 
envirom-nent interactions, small individual gene effects, pleiotropy and low 
penetrance. These features reduce the statistical power of genetic studies of all 
complex disorders (Glazier et al, 2002). Hypertension and intracranial 
aneurysms also differ in fundamental respects including the quantitative nature of 
blood pressure versus the dichotomous IA trait; the relative ease of phenotyping 
for hypertension versus the difficulties of identifying occult, dynamic aneurysmal 
lesions; and the prevalence in the general population. Genetic study of 
intracranial aneurysms is at least ten years behind that of essential hypertension 
and is made more difficult by the lack of confirmed Mendelian disorders, animal 
models and measurable phenotypes. 
6.1: ESSENTIAL HYPERTENSION: 
Essential hypertension is a classic example of a complex oligogenic or polygenic 
disorder, with an estimated 30% to 60% of inter- individual variation due to 
genetic factors (Ward. 1990). There is wide scope for interaction of multiple 
physiological systems and environmental factors (Soubrier, 1998). In the realm 
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of genetics, greatest success has been had in the dissection of Mendelian traits 
with the application of classical linkage approaches (Lifton et al, 2001). 
However, the application of these strategies in essential hypertension has met 
with far less success, and has necessitated the evolution and adoption of other 
complementary approaches (Lander & Schork, 1994). 
We examined the distal region of human chromosome 5q by a combination of 
complementary strategies. The selection of this specific chromosomal segment 
was based on the presence of good cardiovascular candidate genes and genetic 
evidence including previous work in humans (Krushkal et al, 1998; Krushkal et 
al, 1999), rat models (Jacob et al, 1991) and mice (Wright et al, 1999). 
Beginning with a linkage study, we detected a7 cM blood pressure/ hypertension 
QTL in a Polish hypertensive family resource (Tomaszewski et al, 2002), and 
confirmed the blood pressure linkage in a normotensive Scottish population 
sample. The use of independent study groups to confirm linkage has been used 
before (Zhu et al, 2001), but relatively rarely in hypertension linkage studies. 
Such independent confirmation goes some way toward negating the concerns 
regarding significance of linkage. The focus on a small chromosomal region also 
reduces marker number and type I error (Lander & Kruglyak, 1995). The use of 
both dichotomous trait and quantitative trait analyses again is not unique (Hunt et 
al, 2002), but is not often employed. However, such dual analysis is believed to 
be more informative (Williams et al, 1999). 
Evidence of linkage in the 5q3l. l-q33 region was followed by candidate gene 
studies. ADRB2 was selected, again based on the existence of previous evidence 
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(Bray et al, 2000; Bengtsson et al, 2001), the plausible physiological role of the 
P2-adrenergic receptor in hypertension (Bray & Boerwinkle, 2000) and its 
positional candidacy within our linkage region. This selection policy was driven 
by concerns that have been voiced regarding candidate gene selection and, 
specifically, the lack of reproducibility in candidate gene studies (Tabor et al, 
2002). 
Selection of ADRB2 polymorphisms for study was based on desire to test loci 
known to affect receptor function. We aimed to directly assess the role of these 
in hypertension as has been recommended (Risch, 2000). The consideration of 
haplotypes therefore allowed us to examine the interaction of these functional 
effects and provided a more meaningful analysis (Sharma & Jeunemaitre, 2000). 
Further to this, we employed family-based approaches to test for association of 
gene and phenotype (Tomaszewski et al, 2002). This allowed us to side-step 
some of the pitfalls which are believed to affect the more popular, and 
genotypically efficient, case-control paradigm (Spielman & Ewens, 1996). By 
also recruiting carefully selected families with a confirmed history of essential 
hypertension, we maximised our power to detect association (Whittaker & 
Lewis, 1998). Exclusion of the ADRB2 locus in our Silesian population does 
not, of course, imply any exclusion in black or Asian populations. However, 
taken in context with other studies in white Europeans (Jia et al, 2000; Bengtsson 
et al, 2001; Herrmann et al, 2002), it does demonstrate that this locus does not 
have a detectable effect on hypertension risk in such populations (Tomaszewski 
et al, 2002). 
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Our subsequent selection and analysis of FGF I was based upon the same criteria 
of physiological and positional candidacy as ADRB2. Owing to a lack of coding 
region variants, selection of polymorphic loci for genotyping was necessarily less 
directed. However, in the absence of coding polymorphisms, those in the 
untranslated regions have been suggested to assume precedence (Tabor et al, 
2002). Our demonstration of association of a polymorphism in the 3' UTR of 
FGH represents the first known data suggesting that this locus might have 
relevance in human hypertension. Further work will concentrate on mapping the 
association more finely to localise the functional variant. In the absence of 
coding polymorphisms, 3' UTR and promoter regions are obvious targets. 
Intronic polymorphisms may also be relevant given their potential for affecting 
splicing and RNA stability (Cartegni et al, 2002). Intronic polymorphisms are 
known within FGF I and these must also remain under consideration. 
Genetic studies alone will not yield a definitive answer on the importance of 
FGF I or any other gene in essential hypertension. For example, the possibility 
exists that several associated polymorphic loci may be statistically equivalent. 
Examples of this already exist in a study of Crohn's disease (Rioux et al, 2001). 
Dense mapping with SNPs across a region of 5q3l resulted in strong association 
of a 250 kb haplotype with Crohn's disease. However, eleven of 301 
polymorphic loci were unique to the risk haplotype and their relative importance 
could not be dissected by genetic methods. Recently, working criteria have been 
proposed for gene discovery in complex traits, taking into account the need for 
functional studies (Glazier et al, 2002). The need for such rigour has been 
demonstrated by studies such as that implicating phosphodiesterase 4D (PDE4D) 
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in ischaemic stroke (Gretarsdottir et al, 2003). Detailed genetic and gene 
expression studies have suggested PDE4D as a putative candidate. However, 
with no association to either of two coding polymorphisms found, in vitro 
functional testing of regulatory regions has yet to be done to support the 
association data. This is essential if the role of PDE4D is to be confirmed 
(Dominiczak & McBride, 2003). Similarly, successful haplotype tagging of the 
FGH gene would need to be followed by expression and, most importantly, 
functional studies to confirm its role. The lack of coding polymorphisms, which 
we have already demonstrated, suggests that we too would need to examine 
regulatory regions. 
Several pathways could mediate a contribution by FGH to development of 
hypertension. These could involve the endothelium and nitric oxide, oxidative 
stress, the sympathetic nervous system or the hypothalamic -pituitary adrenal 
axis, based on observations in animal models. Thus, there are many potential 
gene-gene interactions. There is an increasing acknowledgement that 
interactions between genes may need to be incorporated into analysis before 
complex disease genes can be detected (Cordell, 2002). Statistical methods are 
under development to model QTL interactions in genome-wide linkage (Cordell 
et al. 2000; Cordell, 2002) and linkage disequilibrium analysis (Ott & Hoh, 
2001). Such approaches have been explored, for example, in type 11 diabetes 
(Cox et al, 1999) and asthma (Zandi et al, 2001). At the level of candidate 
genes, analysis of interactions has suggested that gene-gene synergy is 
detectable. Staessen et al (Staessen et al, 2001) studied hypertension gene-gene 
interactions by genotyping polymorphisms in the a-adducin (ADDL 
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Gly460Trp), angiotensin I converting enzyme (ACE, I/D) and aldosterone 
synthase (AS, -344C/T) genes. Prospective analysis of 678 initially 
normotensive Caucasian individuals, who were followed up for a median 9.1 
years, showed that the ACE/DD genotype was associated with 31% increased 
incidence of hypertension. Incidence increased by 59% if in combination with 
the ADDl/Trp allele, and 122% in AS/CC subjects. Among subjects having 
ADD/Trp, AS/CC and ACE/DD there was 252% higher incidence of 
hypertension. AS/CC genotype was associated with decreased aldosterone 
secretion in the same population. It was suggested that this could result in over- 
compensation, by the renin-angiotensin system, in patients already more prone to 
sodium retention due to ACE and ADDI variants (Staessen et al, 2001). The 
synergistic effect between the ACE/DD genotype and ADD/Trp allele had been 
shown previously (Barlassina et al, 2000). Hypertensive individuals having both 
DD and Trp were most responsive to sodium loading and both alleles were 
associated with reduced plasma renin activity. 
Interaction of the M235T locus in angiotensinogen (AGT) and I/D in ACE has 
been examined in a Caucasian case-control study (Vasku et al, 1998). Of interest 
is the fact that neither AGT nor ACE, alone, was associated with hypertension. 
However, in 202 normotensives compared with 163 hypertensives, consideration 
of double homozygotes showed an increased frequency of DD/MM subjects in 
the hypertensive group (Vasku et al, 1998). The implication of the M235 allele 
is contrary to meta-analyses of AGT (Staessen et al, 1999). This suggests that 
data from gene-gene interaction studies may be as difficult to interpret as single 
gene candidate studies. However, many lessons have already 
been learnt with 
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regard to this. For example, the potential effects of population stratification are 
now appreciated although a recent review suggests that there are, in fact, few 
clear examples where population structure has compromised case-control studies; 
lack of power is perhaps a far greater problem (Cardon & Palmer, 2003). Power 
will be as important an issue with gene-gene interaction studies as single gene 
studies. 
Available strategies in hypertension research have, to date, failed to consistently 
identify susceptibility genes for hypertension. Candidate gene studies have been 
confusing, whilst linkage studies have not lived up to expectations. In the 
context of the popular genome-wide linkage paradigm, the recent BRIGHT 
Study genome-wide scan represents the cutting-edge of study design (Caulfield 
et al, 2003). Despite this, it has not eased the concerns of many that GWS 
studies have failed to provide a consensus on hypertension QTL (Harrap, 2003). 
However, the recent description of haplotype blocks and the potential for linkage 
disequilibrium mapping of complex disease genes is now offering new hope for 
gene mapping in complex disorders such as essential hypertension (Kruglyak, 
1999). Already, some mapping success using LD approaches has been reported, 
for example, with Crohn's disease (Rioux et al, 2001), asthma (Allen et al, 2003) 
and ischaernic stroke (Gretarsdottir et al, 2003). The approach has yet to be 
extended to a genome-wide study, and already debate rages as to the number and 
nature of SNPs to use (Daly et al, 2001; Maniatis et al, 2002; Dawson et al, 
2002). However, characterisation of LD across the genome is underway and may 
provide some answers (Gibbs et al, 2003). In addition, there is unprecedented 
availability of data following immense advances in sequencing, genotyping 
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(Syvanen, 2001), and microarray technology (Lander, 1999). The availability of 
the human (Lander et al, 2001), mouse (Waterston et al, 2002) and ongoing rat 
genome sequences (http: //www. hgsc. bcm. tmc. edu /projects/rat/) is an invaluable 
asset. In combination, novel strategies, wealth of data and application of 
technology provide the best opportunity for future dissection of the genetic basis 
of essential hypertension. 
6.2: FAMILIAL INTRACRANIAL ANEURYSM: 
The work on candidate genes of familial intracranial aneurysms considers a 
disorder which has yet to see the sort of detailed investigation directed at 
hypertension. The aetiology of FIA formation, like hypertension, is complex, 
most likely involving genetic heterogeneity and certainly affected by 
enviromnental factors (Zhang et al, 2003). Therefore, the study of genetics of 
familial intracranial aneurysms is similarly challenging. However, our work here 
highlights a specific set of obstacles for this disorder. Primary among these is 
the difficulty experienced in trying to recruit sufficient numbers for study due to 
high mortality and morbidity. This is reflected in recent genome-wide scans of 
FIA (Onda et al, 2001; Olson et al, 2002) which are small in comparison with 
hypertension scans. To compound this problem, in the absence of biological 
markers and intermediate phenotypes, analysis can only consider a dichotomous 
affection status. The expected benefit of quantitative trait analyses is not an 
option (Duggirala et al, 1997). Finally, the occult nature of the lesions means 
that classification relies on complex screening, the efficiency of which is a matter 
of debate (Kirkpatrick & McConnell, 1999). In many instances, screening has 
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not been performed as there is an associated risk and apparently healthy 
individuals are understandably reticent. 
Choice of the FIA candidate genes studied relied solely on plausible physiology, 
particularly derived from Mendelian disorders (Schievink, 1997). In the absence 
of genetic animal models (Dobrin, 1999) and, until recently, human genome- 
wide studies, comparative and positional mapping data were unavailable. With 
the small size of this study, mapping of large numbers of polymorphisms across 
the genes would have increased chances of false positives. In light of this, 
genotyping of a single microsatellite was a sensible option, and one that has been 
used in many studies before (Caulfield et al, 1994). Microsatellite markers may 
also be more informative than single SNPs owing to their multiallelic nature 
(Xiong & Jin, 1999). 
The preliminary results, suggesting association of a marker near the SERPINAl 
locus and intracranial aneurysm, suggest the value of further analysis of this 
locus. The most pressing requirement is for increased numbers of families to 
allow a more detailed investigation. Non-synonymous polymorphisms resulting 
in deficiency phenotypes are known (Crystal, 1989) and these would provide a 
starting point for haplotype analyses, were sufficient individuals available. It is 
also possible that the microsatellite tested may be functional. Located in the 
upstream region, it may affect promoter elements of the SERPINAl gene. 
Others have demonstrated such functional effects of microsatellites. For 
example, a microsatellite in the promoter region of MMP9 was shown to be 
associated with intracranial aneurysm. Reporter gene assays also showed that it 
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affected expression, lying between two transcription factor binding sites and 
perhaps modifying their interaction (Peters et al, 1999). 
SERPINAI is of interest in terms of the potential interactions with other 
components of extracellular matrix remodelling. As has been discussed, recent 
genome-wide scans have been followed by candidate gene studies which 
implicated elastin and collagen type I a2 (Onda et al, 200 1; Yoneyama et al, 
2004). Some in vitro functional studies have been performed in the latter case. 
However, further work is required for both genes, including detailed functional 
studies and confirmation in other populations, if presently accepted standards are 
to be adhered to (Dominiczak & McBride, 2003). Regardless, SERPINAI fits 
neatly into the pathology suggested by these genes. With its inhibition of 
elastase (Zhang et al, 2003) there is potential for interaction with variants of 
elastin. Elastase also protects some components of the extracellular matrix by 
degrading MMPs (Moir et al, 2002). Thus, plausible interactions may be 
hypothesised with unstable collagen variants or high activity MMPs, both of 
which have been implicated (Peters et al, 1999; Yoneyama et al, 2004) as 
mentioned above. 
Studies of inheritance pattern of FIA have shown that some families exhibit an 
autosomal dominant mode. Others are recessive whilst still others are more 
complex (Bromberg et al, 1995). One conclusion from this may be that there are 
Mendelian IA disorders yet to be discovered which might shed light on the more 
complex fonns of IA formation. These should be accessible to linkage studies 
in 
large pedigrees if enough survivors can be found, and families phenotyped 
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precisely. Description of Mendelian forms could prove enlightening with regard 
to potential aetiology of more complex forms. It would also offer further 
confirmation of the role of genes, as has been the case with the report of 
NOTCH3 mutations in cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy (CADASIL) in ischaemic stroke 
(Joutel et al, 1997; Dominiczak & McBride, 2003). There may also be IA 
subtypes which are highly complex and offer as great a challenge to researchers 
as essential hypertension, or some that are oligogenic and tractable to genome- 
wide linkage study. However, no animal models are available to give a 
perspective on this. The recent genome-wide scans may be the first of many as 
this approach is tested empirically, although the lack of consensus between them 
is a familiar story (Harrap, 2003). Alternatively, LD mapping methods, as used 
recently in ischaemic stroke (Gretarsdottir et al, 2003), may prove of worth in 
aneurysmal haernorrhagic stroke. At a genome-wide level, this will require a 
major undertaking to recruit enough individuals to provide power. Alternatively, 
QTL suggested by GWS linkage studies could provide more focused targets for 
LD mapping. However, a far clearer picture of pathophysiology, subtypes of IA 
and potential mechanisms is needed before full advantage can be taken of 
developments in genetic strategies. 
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APPENDIX 1: 
Suppliers of chemicals and reagents used: 
Reagent Supplier 
Agarose- 1000 Life Technologies 
Ammonium persulphate BDH 
BigDye Terminator Sequencing kit Applied Biosystems 
Bromophenol blue Sigma 
BsrDI restriction enzyme New England Biolabs 
Chloroform Fisher Scientific 
Decon 75 Decon Laboratories Ltd. 
Dextran-EDTA loading buffer Applied Biosystems 
dNTPs/deoxynucleoside triphosphates Promega 
EDTA Fisher Scientific 
Ethanol Sigma 
Ethidium bromide Sigma 
Formamide Amresco 
GENESCAN-500 Rox Applied Biosystems 
GENESCAN-500 Tamra Applied Biosystems 
Hi-Di formamide Applied Biosystems 
HotStarTaq DNA polymerase Qiagen 
Ital restriction enzyme Roche 
Long Ranger 5% acrylamide solution FMC 
MasturePure DNA Purification kt Epicentre Technologies 
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MgC12 Fisher Scientific 
MnlI restriction enzyme New England Biolabs 
Nucleofast-96 PCR purification plates Macherey-Nagal 
PCR buffer (I OX) Qiagen 
Phenol Fisher Scientific 
Picogreen dsDNA Quantitation kit Molecular Probes 
Proteinase K Sigma 
SDS (sodium dodecyl suphate) BioRad 
Sodium Acetate Sigma 
Sodium chloride Fisher Scientific 
Sucrose Fisher Scientific 
TBE (1 OX) National Diagnostics 
TEMED Amresco 
Tris Fisher Scientific 
Triton X- 100 Sigma 
Ultra Pure agarose Life Technologies 
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APPENDIX 2: 
List of formulations for preparation of solutions. 
ABI 377 sample loading cocktail for genotyping (for 96 samples): 
106 ýtl formamide combined with 40 ýfl ROX or TAMRA standard, and 40 gl of 
Dextran-EDTA buffer (Applied Biosystems). 
ABI 377 genotyping sample: 
2 ýd of ABI 377 loading cocktail and 1.5 ýtl of pooled PCR products. 
ABI 377 sequencing loading cocktail (96 samples): 
435 ýtl of formamide combined with 115 ýfl of Dextran-EDTA buffer. 
ABI 377 sequencing sample: 
Precipitated sequencing products plus 5 ýtl of ABI 377 sequencing loading 
cocktail. 
ABI 3730 loading cocktail for genotyping (96 samples): 
1000 ýfl of Hi-Di formamide and 1.2 ýd of ROX or TAMRA standard. 
ABI 3730 genotyping sample: 
10 ýtl of 3 73 0 loading cocktail and 2 ýd pooled PCR products. 
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ABI 3730 sequencing sample: 
Precipitated sequencing products resuspended in 15 ýd Hi-Di formamide. 
10% ammonium persulphate (10 ml): 
Ig APS in 10 ml sterile deionised water. Store at 4'C. 
BigDye Terminator sequencing mastermixes: 
For the ABI 377 (1: 4 reaction, 20 ILI): 
2 ýtl of Ready Reaction Mix (Applied Biosystems), 3 ýtl 5X sequencing buffer 
(Applied Biosystems), 3.2 [tl sequencing primer (I [M), 2 ýtl template DNA, 9.8 
ýtl autoclaved deionised water. 
For the ABI 3730 (1: 16 reaction, 20 Ftl): 
0.5 ýfl of Ready Reaction Mix (Applied Biosystems), 3.75 ýtl 5X sequencing 
buffer (Applied Biosystems), 3.2 ýd sequencing primer (I ýM), 2 ýtl template 
DNA, 10.55 ýtl autoclaved deionised water. 
6X DNA loading buffer (50 ml): 
25 ml glycerol, 25 ml deionised water, 0.05 g xylene cyanol FF, 0.05 g 
bromophenol blue. 
dNTPs (40 ml, 1 mM): 
400 ýtl each of dGTP, dATP, dCTP and dTTP (provided as 100 mM stocks) 
added to 38.4 ml autoclaved deionised water. 
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70% ethanol (100 ml): 
70 ml of analar 100% ethanol combined with 30 ml of deionised water. 
95% ethanol (100 ml): 
95 ml of analar 100% ethanol combined with 5 ml of deionised water. 
PCR master mix for Qiagen HotStarTaq (20 pl): 
2 [tl Qiagen IOX PCR buffer, 4 ýtl dNTPs (I mM), I gl primers (20 gM), 5 gl 
genomic DNA template (5 ng/ýtl), 7.96 ýd autoclaved deionised water, 0.04 VI 
Qiagen HotStarTaq (5 U/ýtl). 
Primer stocks: 
Diluted to 100 ýM with appropriate volume of autoclaved deionised water. 
PCR primer working solutions (20 pM, 100 pl): 
10 ýd of forward and 10 ýtl of reverse primer stocks with 80 ýtl of autoclaved 
deionised water. 
10% SDS (500 ml): 
500 ml 20% SDS with 500 ml autoclaved deionised water. 
Sequencing primer working solutions (1 pM, 200 Itl): 
2 ý11 of primer working solution and 198 [il of autoclaved 
deionised water. 
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3M sodium acetate, pH 6.0 (11): 
408.1 g sodium acetate dissolved in II of sterile deionised water. pH adjusted 
with glacial acetic acid. 
1% sodium chloride (11): 
10 g sodium chloride dissolved in 11 of autoclaved deionised water. 
1X TBE buffer (11): 
100 ml of I OX TBE combined with 900 ml deionised water. 
IM Tris, pH 8.0 (11): 
121.1 g Tris base dissolved in II deionised water. pH adjusted with 
concentrated hydrochloric acid. 
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APPENDIX 3: 
Primer and probe sequences: 
1, forward; 2, reverse primer. 
# indicates presence of a 5' GTT TCTT tail to aid microsatellite genotyping. 
Primer sequence Fluor T. Mg 2+ 
Label ('C) (mM) 
Chr 5q linkage 
D5s494 
I -GCT TTC ACG AAG GTA GAT ATT GCT FAM 53.9 1.5 
2-#CCA GGC TAG GCA GAT TAC AGA T 54.8 1.5 
D5s642 
I -AGC TCT TTA CTT CTG GAC TTA CAA A HEX 5 2.7 1.5 
2-#CTA GAC CAT AGA TAA CCC TGT GAT 53.9 1.5 
D5s5OO 
1 -ACC TAT TCG ACC TAA TGA CTA AAG A FAM 52.7 1.5 
24ATC GGT GAA ATG CAA CTA CTT 48.5 1.5 
D5sI480 
I -TTG GGA AGA ATA GCT TTC CC FAM 49.7 1.5 
2-#TTC TAG CTT CCC CCT ATG CT 51.7 1.5 
D5s636 
1 -AAG GCA TAT GGG AAA TAT CTG T HEX 49.2 1.5 
24CCA CAC CAT TAT GAC ATT TTC T 49.2 1.5 
D5s820 
I -ATT GCA TGG CAA CTC TTC TC NED 49.7 1.5 
2-#GTT CTT CAG GGA AAC AGA ACC 52.4 1.5 
D5s2O93 
I -TTG CAG TGA GTC AAG TTC G FAM 48.9 1.5 
2-#CTC GGC ATC ATA TAG AGG C 51.0 1.5 
D5sl471 
I -TAT ACA 
TGT GAA ATT AGA AAG CAC C FAM 51.1 1.5 
2-#TGA GCT ATG TTT GTG GCA GA 49.7 1.5 
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D5sl456 
I -TAT CGA ATT GTA ACC CCG TT HEX 47.6 1.5 
2-#TCT GGA AAA CCC TAA TTC TCC 50.4 1.5 
D5s462 
1-TTC ATT CAT CCA CTC AAA CA NED 45.6 1.5 
2-#AGC TAA TAC AGT CTT TCA AGC AG 51.7 1.5 
D5s2ll 
I -ACT TTG AAA ACC ACT GGC CT FAM 49.7 1.5 
2-#ATG TAT CTA GCC ATG GTA GC 49.7 1.5 
ADRB2SNP 
genotyping 
Argl6GIy 
1-CTT CTT GCT GGC ACG CAA T 51.0 1.5 
2-CCA GTG AAG TGA TGA AGT AGT TGG 55.6 1.5 
Gln27GIu 
I -GGC CCA TGA CCA GAT CAG CA 55.8 1.5 
2-GAA TGA GGC TTC CAG GCG TC 55.8 1.5 
Thr1641le 
I -GGA CTT TTG GCA ACT TCT GG 51.7 1.5 
2-ACG AAG ACC ATG ATC ACC AG 51.7 1.5 
FGFI 
PCR and sequencing 
FGF1 exon I 
I -GGT CCA AAG CTG TGT CCA AT 51.7 1.5 
2-ACC TTC CTC CCA CCT TGA CT 53.8 1.5 
FGF1 exon 2 
I-CCG TGA AAT GAA TGA GCA GA 49.7 1.5 
2-CTG GAA ACC TCA AAC CTT GG 51.7 1.5 
FGF1 exon 3 
I-ACC ATG ACC CCA ATT TTC CT 49.7 1.5 
2-ATT TTT GGG TCA ACC AGG TG 49.7 1.5 
FGFI YUTR 
I -AAC AGA GGG ACC AAA 
TTG CTT 50.4 1.5 
2-CTC AGC CAG TTT CCC TTT CTT 52.4 1.5 
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FGFI SNP 
genotyping 
SNP 2 primers 
I -GAT CTC CAA TTG CCT CTT GCA 
2-GAC CCC TTA ACA CAC TTC ATT TAG C 
SNP 2 probes 
I -CCC TCC ATG CAA AA 
2-CCC TCA ATG CAA AAG 
SNP 3 primers 
I -GAT CTC CAA TTG CCT CTT GCA 
2-CTC AGT AGA GGG AAA TAG TGT GCA GTT 
SNP 3 probes 
I -CAC TTA GCT GAC CCC 
ACT TAG CCG ACC CC 
SNP 4 primers 
I -GAA GTG GTT TCC TGA TAA CAA GCA A 
2-TCT CTG CAC TCC CAC ACT CAG T 
SNP 4 probes 
I -TTC ATG TGC ATC TGG 
2-CAT GTG GAT CTG GGG 
FIA genes 
COL3A1 VNTR 
1 -CCA TTC TTA CCA GGA GAC CCC TAA AG 
2-9GGG GGG CAG AGG CTA CAG TGA G 
FBN1 MTS-4 
I -GAT GTC CCT ATT GCC ATC ACC AC 
2-#CCT GTG CAG GGT AAG ACA AG 
PKID1 BPI 
I -CAC AGC CAG CTC CGA GGG 
2-#TCC TCC TGG GGG CTG GCT C 
SERPINAl D14sll42 
I -TTG CAG GGA GTC AGG TGT ATG 
2-#GCA TCA CAC AGA GAC ACG GAT 
52.4 1.5 
56.0 1.5 
VIC 37.3 
FAM 3 9.2 
52.4 1.5 
58.2 1.5 
VIC 44.6 
FAM 43.2 
54.4 1.5 
56.7 1.5 
VIC 39.2 
FAM 44.6 
TET 5 9.5 1.5 
62.2 1.5 
HEX 5 7.0 1.5 
53.8 1.5 
TET 57.1 1.5 
59.7 1.5 
FAM 54.3 1.5 
54.3 1.5 
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APPENDIX 4 
Examples of resolved restriction digest products for ADRB2 SNP genotyping. 
Argl6GIy 
131 bp 
108 bp 
Gln27GIu 
229 bp 
174 bp 
218 
Arg/Arg Glv/Glv 
Gln/Gln Glu/Gln 
Thr1641le 
320 bp 
206 bp 
114 bp 
Expected band 
pattern for rare 
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Ile/Thr Thr/ Thr Ile/ Ile 
APPENDIX 5 
Fibroblast growth factor I sequence and positions of SNPs 1.2,3, and 4 found. 
Intron 2 (black), 
Exon 3 (blue) 
3' UTR (red) 
Underlined text denotes primer annealing sites. 
..... CCATGACCCCAATTTTCCTGAAAAGGAGACTGAGGCATGGAGAGC 
TTTAGTATTTTGCCCAATGTCACACAGCTAGTAAATGGGGACCCCCAT 
GTGAAACTACTCACTGATTGTCCTACTCTCTVTGGTTTTATCTTTTTA 
GCAGACACCAAATGAGGAATGTTTGTTCCTGGAAAGGCTGGAGGAGA 
ACCATTACAACACCTATATATCCAAGAAGCATGCAGAGAAGAATTGG 
TTTGTTGGCCTCAAGAAGAATGGGAGCTGCAAACGCGGTCCTCGGAC 
TCACTATGGCCAGAAAGCAATCTTGTTTCTCCCCCTGCCAGTCTCTTC 
TGATTAAAGAGATCTGTTCTGGGTGTTGACCACTCCAGAGAAGTTTCG 
AGGGGTCCTCACCTGGTTGACCCAAAAATGTTCCCTTGACCATTGGCT 
GCGCTAACCCCCAGCCCACAGAGCCTGAATTTGTAAGCAACTTGCTTC 
TAAATGCCCAGTTCACTTCTTTGCAGAGCCTTTTACCCCTGCACAGTT 
TAGAACAGAGGGACCAAATTGCTTCTAGGAGTCAACTGGCTGGCCAG 
TCTGGGTCTGGGTTTGGATCTCCAATTGCCTCTTGCAGGCTGAGTCCC 
'I'C§A'I'(j('AAAAGTGGGGCTAAATGAAGTGTGTTAAGGGGTCICj('TA, /\ 
Ci'I-CiGGACA'I"I'AGTAAC'FGCACACTATTTCCCTCTAC-f'GAGTAAACCC'I' 
ATCTGTGATTCCCCCAAACATCTGGCATGGCTCCCTTTTGTCCTTCCTG 
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TGCCCTGCAAATATTAGCAAAGAAGCTTCATGCCAGGTTAGGAAGGC 
AGCATTCCATGACCAGAAACAGGGACAAAGAAATCCCCCCTTCAGAA 
CAGAGGCATTTAAAATGGAAAAGAGAGATTGGATTTTGGTGGGTAAC 
TTAGAAGGATGGCATCTCCATGTAGAATAAATGAAGAAAGGGAGGCC 
CAGCCGCAGGAAGGCAGAATAAATCCTTGGGAGTCATTACCACGCCT 
TGACCTTCCCAAGGTTACTCAGCAGCAGAGAGCCCTGGGTGACTTCA 
GGTGGAGAGCACTAGAAGTGGTTTCCTGATAACAAGCAAGGATATCA 
GAGCTGGGAAATTCATGTGJATCTGGGGACTGAGTGTGGGAGTGCAG 
AGAAAGAAAGGGAAACTGGCTGAG 
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